var title_f25_58_26528="Heel pocket out method";
var content_f25_58_26528=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Heel-pocket-out method of putting on compression stockings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 611px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stockings can be applied by turning the leg portion of the stocking inside-out down to the heel(A). The foot is slipped into the stretched stocking and pulled onto the foot by its folded edge (B). Once the stocking is over the heel, the remainder of the stocking can be gathered and progressively turned right-side out and gently worked up the leg (C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_58_26528=[""].join("\n");
var outline_f25_58_26528=null;
var title_f25_58_26529="External rotation testing of shoulder";
var content_f25_58_26529=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1124px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/82882/Ext_rot_test_should_video.mp4?title=External+rotation+testing+of+shoulder\" style=\"width:480px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    External rotation testing of the shoulder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 298px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEqAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD56brRQ3U1YSxvZEV47G9dGGVZbaQgj1BxyK9NtLc40n0K9FTTWl1Am+e0uoUyBvlgdFyegyQBUNNNPYGrCr19+1SZwR/nFRelP4HUgZ4yaoTJPftTqaO3GPanCggUUopKUUIocvWikFKKYgpwPakpQKYx2KWnIkjo7xwzyJH990iZ1TjPJAwOPWm9uORSTTJaa1F705BRHFLKSIIJ5ivXyoWfHpnaDiiZJ7eJpJrO9SNeWdraRQPqSMCplUjHdlRhJ7IXdsG4KzEdhxUd1cxywkfvI/4gxXK/mOlRTSo8ALMAjYwByT+XWq8ssMchhJnRicZT+WK8qtXVR6HfSpOC1MxLySGeQ5Lbs5Pr2rpdCuIpbySIsCqKZF57+vv6VjSabGjfv5pYyeRkDP4qOaLcrZTRSw3UMjoSNhUrkd+tYtKRqro059TEV3K/WQ4CjPy545xW7outpEWmuJPkRSqLjl271wtyjNcSFFYAnIPXGabJMxWNc42DA9ql07ofNbc9Amnjj013t2VppJRk+mecL9KpSMWnVpVIZzgHFcva6jOrJHFjavADHjnuav3tpeyLDMrmR2ByVPyqD0AqoNwkKcVJGqVwP5ik71NpVjdSpGAkg+UEtJGVBU9G5xleDyMirerQxwJG0RBiPyZHdq9WGLi2ovc8+WGkk2ihmjvmkwcjPalHWu3RnN5CinCkoOAMk4HWgBR1p2OPrSYcKjtFOsbY2u8LqrZ6YYjBz255pRyyqqu7McKiKWZj7AZJoTTV7hZ7WHdKSk65GGBBwVYFSD6EHkH2pckRNKY5vJXOZfJcoO33sY68daLpdRWbFpQKQU8Dt3qhIUDvThxSLTmYKpZjhR1JoBIcBnFPApoyH2OksbgZ2yRshx0zhgOKeKSaeqHazFxSgUAUopjFpy9PekAzTwKAAU4UUtACgU4D+VIoqQUAAFOAoFOXqKBBinAZNAHNOXigLgO1PA60AUoGKACnCgD2pQKBDce1GKeBSgD0pMY0igpkVMq8dOacV4pWAzZoCwOOaK0dntRS5UylJo8guOI5Poa+0pb7xTYfs++Gp/A0DXGtiwsgiCJZDs2ru+VuOlfFtz92TGcYP8q+y9RsfFF/+zv4bt/A0k8WtmxsSjQzrC+wKu75mIA4rzsR0Ouj1PDfin4g+K174WFt49sJLbSJLiPDvaRxAyjJVdyknsfyrNtfhXeal8NJfGWgavbapBboWubGOBkmhK/6xTknLIDnGORyOozY+Ivhz4rWXhs3fjya/n0WGZCRcajHOqyE7VO1TnPOM9s12n7Pqz+APCOuePfEl3cWnh24jWG3sVALXr7sCVVPfqq46gkngClfljeL1Ltd2Z5v4n+HN34X8B6b4h13U7a1vdSG600gws07jrlmBwuFIY8cZA6mvQPhx8KNFvvhTrXiPWNa0xbq7tmihnZxJBpg4yzn/nr2P93OB3p/7TPhy41OXT/iBpN6+p+Hr22iiyDuW0BHyFfRGJ59G69RjY+DmmTeKP2cPFfh7SWhfVJLi4QQs4XlgjJn0BA4J4pSnKUL36gklK1jxXV/C/k+KrDQvDer2Pii4vVQQyafwnmMSNhJJAwBknOAOtdm/wAIbe11uDw9qPjzQ7bxVMF2acIJHTcwyqGXIAJ7DAJyMDkUnw5069+F3xh8MS+O7WPTEuopVUtMjiIODGruQSFG7jOeAc13XxR0LW9M+Ic+qaT8MdO19LidLy21OFrh3LgA/vAsmFYEegUjHvTlUknZMlQVrtHkOkeANXvPiQngm+aLTdVLurvIpkjAVC4ZcY3KwHB4689K7HRPgPrWo6xrtpPrFjZ2Gly+QL54WIuH2B22puGFUNgknr0743PDWqeIdY/ac8PXXi/SbbSdXFkytbW77vk8mVlZuThuTxngAVxf7Qup3l/8W9aiuJpFhsCkFtGjFVjUxqzEAd2LEk9/pTU6k5JJ9BOMYq7RX8CfC/VfG3hXWNb0W+tpDYTPBHaCJi90yqGG1iQF3ZGM9O9dDpvwM1HVdDvLrR/FOg6jqloMT2FoxkCOBnyzKDw3UcrjNdF8FHkh/Z6+IkkDvFIhuijodpXFsvQiqn7Hg2eLvECJ8sZ06EkDgZEjY/maJTqK7vsNRi7Kx5V4S8Nrr9ve3l5relaFptkUWe51Fzu3tnCJGOXbg5GeK6vUvhVJ/wAITd+KvCviXTvEWl2e5rhYYHhkQLgtgEnkA5IOOOlWfhD8ONO8aS+K9V1T7VcJo8sgj06zfy5blzvcAvglQcbQBgk554xXqXwzsdWvvgp40s/+EWh0Ke5juEs9NghaORw0AClt5LsxORufrjjjFEq0k7pgqatsc5+z+T/wp34k4PHlzf8ApLXz9bf8e0P+4P5V9A/ACOSL4P8AxLhmieKaITxSRuuGR1tcMpHYgjFfP1t/x7Q/7g/lWtF3lJmdXSKufSX7Hudni/r/AKy1/wDQZKtfCLxz8R9b+Jl7pPiPT5pvD264DTzaf5IgCk7MOAA2eBg5znPY1U/Y8+74w/66Wv8A6DJWZ8GvjDrN78S73wt4tvjeWF/cTW9pI6qjQSBm2puUAkMARzyDjBrkrfGzen8KPN/jfo+n6X8ZtU0/wtbqzS+UI7O3UFUupAMogHAOSDjsW7VvJ8BpdJjsk8WeN9C0TVr/AP1NrL87Ek9AxZcnJAJAxnoTTfFPh6z+En7QGiXN0JP+EdlvEvoJpWLlEbKuGY5LFGOcnJxg11n7Qvwy8U+MvHltq/hm1TVNM1CzigSZZ0CwYJ5OT9w7g2Rnv7VhY2T2PJviD4A1jwJ4jtrHWWtEF1gWt2km23lGQCSzfc2kjdu6DnJr1XxR8HPDuk/DfRBceK9H0+/u7lbmfWLoZjucxnEcRyP3YByPXGT7H7V1/ZLpXhXws11HdavZRma4bOWVRFsG70LnnHoM+lb3xG8L6p8Qfgd4EfwjBHqD2sNu7RrKqHHkeWSCxAyrcEZ9fShJK9h8zdrnguj+DV1TVNZgPiXRrPRtLcebqtzIVimUsVQxIOWLbSQM/j0rqJPg3DqHhPUPEHhHxRpviO1sAzXMUMLwSAKu4gbieccgEDPY1pfC74Wr4n8T+JLXxUzJP4fVY5dPs5V82eRlJ2iTsvy4yOcnqO/qHwXtNRm8BeM7U+FIvDqzRslnYpE6SvmFh87SHe5zgbmwCQccUlHTUcpdmeWfs7/DPSPGGuvqGs3NnNZacwcaar5luG7NIv8ADFn/AL6I9Bzz/jPw/p+gwudN8V6HrZllmV7ay3LJCoDNk/MQB/D0HtXpn7LUTaZ401S01CNrS+k09YfImXY++KTDrg9xuHHpXnPjH4Z+I/C1re3OpaakUE1xNEs/nowkJDuCqgk4KqTyBjpUvWOw38VrnTfFXRvEHh+Lw1J4l1e21UPp7QWhgt/J+zwxhGIYc785Xnr8tOt/hdejwvaaj4x17R/DNpdOHt0viWlORkBvmUKcc7Rkjvjmuu/aSJEfgZhGZALeVtg/i2+Q23HfIGPxrU+Nejaj46sfD/iLwbbnXLB7WWHy4JEDR+YVO7DED+EowzkY5HWrUE5XZm5NRsePfET4f6z4IS1u76a1v9JvOLe/s8+WzEZCsDnaSBkEEg4654rU/wCFRa5/wiuja9HqekLZahGk80lxugjsYmTdvkcnBA4XAAJJrsvioi+Ef2f/AA54O1iaCXxA3knyFfcY1Ry7N/uqPkz3J4qL4vF/+Gf/AIdx7m8tza71zw2LdiMjvzzXfGrUaikzllTgm3Y5Hxj8Lb3w74Tg8TWOt6drujMUEk1ohXYGO0Op3MGXdgHkEZ+tcB9a9p8Pkn9knxMuSQtxOFHoPPQ8frXi5HzHNdOHnKV1J3szGtFKzXU+gfhjIPiH8Dtb8HXEm7UtMQw27McnH37dsn0K7P8AgNY/7M+kQW39t+N9cC2lnpsLW0ckwwI2A3Tt/wABAVf++q474KeJf+EW+I+mzyvtsdQ/4l90ScABz+7Y/R8c+jGvUP2kNVs9A8MWfhDRoYrb+1Z5Ly7jjGB5Qfe2R/00kP5Bq5akJRm6UdpG0JKUVN9Dlf2iPC0i+NtN1fQ4xLF4lEcMRjGQbvAVT/wJCp/4Aa2/j3e23g/4f+HfAOmy7IjCsl2wyMwRY5b/AH5OT67WrpvgDrNl4p8DWun60kdxfeGLlfKeY5KIFbyZc+oQsmf9k14D8RvEbeLvGOra4gMtvJKEtIz3t4jhBj/awW/4HRTUpyUJbRCbjGLkupsD4fPp2h2OreMfEOm+GbfUAWtILmGSe4cYB3MiEbeCCeuMjODxWV428J6j4OmtPtslte2V9D59lfWZJiuV4OBno2GBxkgg5B649v8Ai5H/AMJbo/h/xR4Y8Laf4tsmhZG3SS+dAGII2pG655BDDlgQPevKviNqPii48I+HNH17wpZeHtFgufIsNxdXyEK4Ku5cIFbJYjtVQrzbu2KVKCVkLY+A7KXVodIv/Hfh211qV1iWyhSS4CyHpG0oIXdnjHrxWN4s8M6j4P8AFMWkav5JuUmtZkmgJKSo0y4Zc8jlSCD0I6mvRNZ8BN4B8T+ENP0Dw3Lr0k80U13rV6jPb2gWQbtkYxFEcfMGfJ6Yyeaq/tSadfr8T/DOp/Zp/wCzZI7a1E4H7syi5LbCfXGDis3iprrdMuNGL8jS/aUtbrUPiZ4csNOt2ur+7sDFbwLwXcy+vYAZJJ4ABNee/ELwnceB7yCxu9X07UNQaIzz29tC6/Z48EgsxJGWIwBgEgE8CvfPHHiWz8LfGXSb3U7SJ7GTSTBLeFcvZhpuH/3CcBu4GD0Bryz4peB5dE8TanPf3E1zYax5tzaai53bpCpJgkPTcB9w9CowOVNRDEumkuiLdFT16lO8+FeuWmjaPq0mqaOmm38Kzz3NwWgisUZAwLsWO7JIUAAEn0qLxj8O77wzoNnrsGq6frWi3LpH9ps1K7C/Ct1YMpPGQeCRXYfG4t/wrT4bwsW8oxxsyE/KWW1+Ukeo5x6VDAD/AMMpSjkKl6Qn+yPto6VvGtUsp36mUqcNY2OI0Pwddaj4bk8R6lqdhoPh5ZPKjvLxHka4bO393GvJGQRnOTg4GOab4g8J3Ok6LZ65ZajY634eu5PJS/s1ZPKkzgLJG2SuSCM568EDIz6fbBPFvwH0SDRNE0/XdR0QxR3Ol3Ero0borIxUIyneQdwBOGBPeuJ1i/8AFll8OtS0Y+BrbQPDk00bTzOsqMkjSJhkEshZmLBegPrQsRU5t+oezjYp2PgWQ+EbXxN4g1/TvD+k3rKln9oheaWbdnaSqkY3AEgDJxycdKxLXR7i+8TRaFot3p+sXU8iRwXFpIfIkDJvLEkErtAO4ckYxzXoXw0vfE15pOjeHdd8HSa94K1AqYJJY1f7LExOGEgJG1eThtrqOATwK5/xloMnhT4sDS/AklxLexSRXFmiSK0kErI7NGWc4cbF+6xyVbGelVGrPmab/wAhOnGydiv4q8JWnhqW9tLnxloMusWUfmTaeYZIiTt3BFkJK7yOgPJyOlc2hDKCOARnFe2SaSvxA8J67qvxA8MHw1rWnQ5TVghh88KhYEo3JVcAFW3Dn5T6eI2zNJbxO67WdFYr6EjOK1w1SU78z2M60FG1kSAU8Cm08CupGAoFOA9KAKUUCF7U4DijtThQACnAUAU5RTATFOUUAU8DikAqinY5pQOlOApDGAUU8Dk0Uxnjbj5iDV+HXNZghSGDWtWihjUKkaXsqqijoAA2APaqUv3zTK5LJ7m0W1sXLzVdUvrcwX+q6jdW7EExT3UkiEjoSpOKZc6hfXVvDb3V/eT20OPKhlnd0jwMDapOBgccVWooUY9iuZlpdS1BLA2KaherYFShtRcOIipOSNmduM89KdpuoX2mzmbS7+8sZyu0yWs7RMV9CVIz+NUx0qRenB/GnyrsJyZYu7m4vZ2mvrie7mfhpLiVpGI9CWJ4q9Za/rdjaC1stb1a2tQMCGG9kRAPQANgD6Vm8EHmlo5V2I5n3JYJ57e5Fzb3FxDdbi3npKyyZPBO8HPP1ollluJnluJpZ5nOXllkLux9SxyTUYpRTUUtkF3YnhvLuG2mt4Ly7htpv9bDHO6RycY+ZQcHjjkUtpeXdlK0lheXVnIw2s1tM0RYdcEqRkZqEUVXKuwXZZ06/vtNuTcaZfXdjOw2mS2neJmGc4JUjPPrU8Or6rBNdSwavqcUt3g3MiXcitOR0LndliPeqAp1Lkju0HM11J4Lq6ghmhtr28ggm/1sUVw6LJxg7gDhuOOaiAAAAHHSiihK2yFe+5Qk1rUdOupP7K1K9sgcB/ss7xbyOhO0jOKy1llSZZlkcTh/MEgYhg2c7s9c55zVjUo1W52r93HTNVT1YE9DXlVG3J3PQgrJWL19quo6mUOqahe33l5Kfap3l2Z643E4zWjYa1rul2r2una3qlnBg4it7uSNP++QcCuf61aMrFQ55bGAayaZrFrqS3RZpBM7s0sud7sSx3+pJ5OR3rQ03xBq2lwtb2Wp6jZQOcyR2108cchPchSOfeqdvKpVQRkE/MD+lMiUPCyt1DZH0pepWh0WlXNzZXv2uyvbq2umU5uYJ3SUk44Zgcn8a6rQ2v2u57g6lqIurj5Z50vJVedewZg2Wx2z0rltCiSSeBXUmMYyMV6b4e00CEE4LDGOOx7VzzbXU6KUebdGrpWnWwhtY5oBiGQtkEq2T/GGB3BueTnPWu2svD1jeZluI2uJWRo2a5mkmO0jBA3scZHHGKztHtI/ICE/PnjjkV0VmjBc5IzxxWKb7nZyrsc14j8JWMdlNcWsTtPbQsYRLPJIFAGdo3McdB0rxWfWLmCc3OkXd7prTjdKtpcPDub1IUgH619J3iNJazL3Mbj6/Ka+VPMJXBz6Y9K9bLoqbbl0PJzK0LKPUWR3lmknuJZJ55OXllcu7/VmJJqRpriSGGGa6u5YIf8AVQyzu8cfGPlUnA444FQ5AA9aeOlexyrsePzPuSiacWz2wuboWjnc1uJ3ETHOclM7TyAenam96Qd6WmklsJu+4rKGUg9KnvLu6vrk3GoXl1eXJUIZbmZpX2joNzEnAyePeoRzS1Vle7FfSxNbXV1amY2d3dWpnjMMv2eZo/Nj/uNtI3LyeDUSgKoCgBQMADsKSloSSd0JtvQs2F3eadI8mm317ZPJ982tw8W/3IUgE+9ZfiG+nm8x7ie4ublwFea4kaVyD/CCxJ/CrckixRPI3RRms3SF+26iZZzkoMgehrgx1VUo+6tWduDpOrL3noTQjxHqenx2F9q2oyacm3ZaT3cjxLjp8uccdvSuqXQ9S1ryn1nWL+/eM/J9puHk2Y7rknB9xzS2UXzjjBPeur0hWjj/AMa+dq1pdGfS0cNTW6DTvCzPcpc3Op3s8+wxlp53lJUnJXLE8H0reuPBOl3dgtpcy38lsu3bEbqQxjb93CFscduOKuWQIWPdxmugtMMQpxWCqzvudHsKf8p5x4o8LyaTpxuoHudQs4YmQwzzO7W4IADx5JAxgAgDpXAWs8lxZ+WZrlbffva389/K3ZznZnb156da+l57OKWArgbHG1s9MHrXit34Qax0++kiQiSG4ZVGchkGc49PWvUwWKcJKM9UeRj8NFrmhozm4Xkt7kXFrPPbXGMebbytE+PTcpBI9jT7qe4vJlmv7u7vJV+69zcPKV+m4nH4VH1GQacBivo+WN72Pn+Z2tcmsrq8sUZNPv7+zjflktruSJSf91WAqHykwRgnLby2479397dnO7/azmnAU8UKEV0Dmb6kt1c3d5CkN7fX93AhBWK4u5JUBHT5WYg/jTe/qTSU4DmnGKWiQOTe4o608dKaBxUg5pkCrTqTFOHrQAoHNOFIOtOAoGhQOKctGKcBQIUetOUGkxzTwPegLjgOKdQoxTiKQxuKKcBRQFzxmb/Wt9TTKluhi5mHo7D9airlR0BRRRQAU9Onc+1MHByKcv1600BMDnrS01T+lO7UXJFAp2MdaaKceRTAWiiiqEKBTqbnninA0AOozSUv4UwsY+pfLMScDdzWeDWnq6EOrkcNwD6e1ZoGTXkVY8s2j0IyvFGnoulvqTzkP5cECeZLIeiitS48PGOzSe2nWaPqV6MB64q/8Prf7RDf2jj5bxoIifRfM5ro/EstvZavbYtYoYLd8ea5OdnQqAK5ZSadj0adKPs7vc88mtiijapUDB5p1hbuZQFzy3p2rr9es45oS8MRRSMqrD8jVDwrbebqluHHCyfOD6daOfQx5LOx2HhTQkjKSzqSQBhff1rvLNY4ghUcAYz61HYWsflfKCTjilkhmt2JkRjGe4Fc/wAR2xXIjf08khdoFdBA5hC5GQfbvXBafrCzSmK0uoNynBU53A/T1p97rmswagLazMMg2B2eQHaecYUjrjvS5GDqo9DSVCyyMfkX5m+nWvk69kSS9uXiGI3mdl+hYkV7T498U3Wi+G4VCKL7Ud8YZTxGgHzMPU84FeHjAAA6CvYyym4xcnszx8zqqUlFdB/PFSDpjNRKSKcD05r1jyyUGlxTQfTpThTRIo6U6kHQUtNAFKOlApRQIqavIY7BsD7xC1F4a+acHruOTj0p+uxmTS5gvVcP+RpPBkbSW88oByMKv1rx8xXvq562X/DodrZkBlLkAHtXTaZdwncu4ZC5xmuBuXW2jdryeQNtztiXc+Pb0rE07V4/tSfZ/OETH5GZvmJ9xXjujzantxxCjoe8xToX2qQSkat7DNbel3EZ2guPrmuc8C6cL2zuDcOzNJGSX79K8+17WbrR9UaOCW5jhhkEe44POeMisYQ5tjpqVeRXZ9GRbTCCpzkYzXGeJEjt7TUJZG2AhzkHrxVTwRrd5c2484hiB86nIOPXFZXxE1COM3lo24MsrBMHqWAPT6VvRpOU4w8zz8TUXI2ecD7ozTlpBTh3r68+XFHSnLQBSgUAONOA4ptPFCAcKeoxTB1qQU2IXFL2pB1pwFIBR1FSDvimDr7U8UAOFOFNFOXpQA4CngflTV96eooEPApwHNItPpDEFFAHFFMR43f8X90PSZx/48agq1q426tfD0uJB/48aqZriT0R19RaKKKYgpaSimBKO3vTxzzioVI56+1SrnaB3piY8cUo6c02lpoQ8UUgpxp3ABS00U49KoBRzTs1F2pwPqMUgG3MIniKNxnofSsaS0mizvU4zjI71117oepWMBmvLV4YwAc43cEZBwM8VVsoVvDmNw6r3XpmuLEuk03fU6aEZ8yjbQ0vCsRtdkgDsowSBwce3v3r0WXTNM8XXEouYYy4jyJoyVdmI+9joCD19a5XSbdlGGABrSiN3pt0txZSbS3UEZB+orxnLmZ7tJ8is0TX+nTootLxxNNbqEEuzZvAHBI9cVT0vQ2trszLznuOlb0DTXbtNcyF5nbc7HvWlHAFUhFwOtK9tGOUU9US6ZcPHKBnIHau60yWG5i6A44rhbKHMuMYDVu6ekkH3TjJ7dKVjRNSVmXb7wnpUl59pMO2VjnKtjNJNZWkG9IiP3S7VHYetX7Vi7ANuPua5u3vzqerXEVmB5KsVLkfex3HtT5mT7NJ6HN/GGAT+EtDvQDut7h4D9GXP81ryQdK9z8dWZvfhzqysoEljIlyv/AWwf0NeF5r28vlelbseFmUeWtfuPpVOPpTKcK9BHnEqZxTxmmIT6nFPAqiWScY60tNFL60xB3pw6U3vS45qrATIPMaGBI1kEwbeCudw6ACrPhS2FpatFtwRKwIPUHPSm2m94ZUhOJgpEZPbIxV3SrcWTiABxgBsP1yeufx5r5rGcyrSjI+mwkYuhCSNZrCCQs7RqS3cjJrMbS4IphMFwQeOB/kVrxkluc46VU1KRoz5nltJGoPyr1J7VwKTvY9D2cLXSPTfhsQumYPJPFXtW8MWU2oC6miDiQ/NhQef9odxXNfD6+vI7NvJtVMjxBxFI23IzgkV3EVxI8rQygjByv0qfeg9C2o1C3Z6TYpIt3DAiThdjOvBYe9cl4xt44m1S4mhgkiuQUcumWVUhzlT2O7bXcxsI7bk+wrgvHMssXhrWnuVCrcToltkjJU4BPtnFa0E3UjruznnCMYSbWiR5Mudoz1p4FMPanCvsD5AeKcKaORThQCHfjThTadmgB4xTxUVSDpQxDh1p3rTBThSAeOlPX3pgp4oAeOtOHApg6Ypy96AHipFqNTmnrQIlWlpq04UhiiiiigLHkPiAbdd1JfS5k/9CNZ9aXinC+JdVHpdSfzrLzk5zXDHVI6x1LTRx70tMTHUU2nUxBnFSocY5FRU5T+lUMnzzSimDC9xTxTIsKKUUL3pVPrVCCigmlHSgdhKv6Ja/b9ZsbXkiWZVP0zk/oKo11/w6024fW7fU3t3Njb7sy+rYx8o6t74rOrNRi2aQXNJI9l02NGdYZEDRt0U9vp6U7VvhpZ3NvJPbweRMvzkwqA+O5K9GH5GrmgxLJfWkilXRnByvSvV57YECWPhgMgivDjDnvc9GUnF3R8yX+gX2j3CmdBLaNwlzHyh9j/AHT9asfZw8PTJX51/DqK97vdEivEeS2VEnbO+Ij5JPw7H9K4DV/CxikZrBPJmQ5Nu/C5/wBk9vp0rGVGUXdHRTxaekzkLa3XapXlSMgj0q/FESpII6fnTIE+z3ZtZY2jDElFcYKsPvIfp1HqPpWgqBTt49qDo5tCtCmGUnt0rbsiCnPFZbJsDEVNaylf4sDpSepUXY3YHRVyzAAnoa5rU/DFpeBxB5kaZMgETEbTySRg8VcvBKeIbjy8jqI1fJ981yHxCvdT0Pw0Wi11/Nu5BCqJGsZMZB3Yx/OtKMHOSSCrUUIOTOEvvHGq3mi3Glt5SQT/ACSuAS7qD0yT7DJrnFPtUI6cCpF6AV9DTpxpq0T5mrUlUd5MkFPFRgVIvBzWyMWKpqZM1CKlT9KtEslHSlBpo4pw61RIU4daaaUDpTGTQSvDIJIzhhWhDdNcTrIwCsAF46GstRz15q3YcSZ7dOa87MKUHDntqd+ArTU/Z30OmiYhCVGT6VXupIoJFF3MN2eIxyTU9owADk8AdKswxK05nRF3Hq4HP4mvnGlfU+mi7o6PQ9ZtmntnlsbuJ44/LDKjbXX16fpXbWN5aXDxrBcJLvGUPc/hXK+HtRuobkAmXyBgdDjNddJFbTyQziGNZVcOGVQCT61MrFtludvkKE4XHPt614p4t8U3fiIwxSrHFZ27N5ccf8R6B298fhXsOoOWtLkry3lSEfgpNfPMf+rQ+wr18qpRk3N7o8XNKsopQT0ZKKcOlMB59qcK908O45akFRCnrQIfmnLTRS0wHinioxUimhgSLzRSUtIEOBpwNMFOFAiQGnVGp5p4oGPWnqaYpxTgaBEy04VGOlL2pDJBRTKKAPKfGK48UawD/wA/L/zrGDYHPNbXjkEeL9XHb7QT+grD7V58PhR2j1Y4zTgT60xTjHI+lPB545qhMdS5HvTe1LTRLHUUdqKpMESKQP8A69SjpUCk1KpHamJofS9+tNBpaaEyQUCkGea2fCmg3HiHU1tocpCuGmmx9xfT6ntRKSirthGLloh/hTw7c+Ib8RRApaoR502Og/uj1Jr3/QtFitYY0RNqRqFVQMBR6Ck8PaLa6VYw2tpEI4YxgDrz3JPcn1rpYIvkwv0rxq9d1npsejTpqmvMfo2jq9xJcWrKrRYYow+Vz/Q+9d1pVwJYvLkBWRRyjdR/iPesXRI/s8LEfcZtpH9fzrcWMOAY32SLyj+h/qPUUQjZEydyZoNjFk71Xv7GPUIxnCTqPkc9/Y+1XLS4WcOrDZPGcSRnqp9fcHsae8Y6jrWhFrnnOv6DBqETwXivFKp+WVOJImHQg9/p0rz/AF+4m8O3EKa4FjikO2O6VT5Mh+v8J9VP8q951CyW8TIANwg4P98elcxqemW97Zz2l7AlxayjbJDKuQaylTTHCtKk/I81iuI5o8q6srDgqcg/Sm2zxujKeueTXK/EzTz4J+zWWi31vaxyA3EaTAmUr08sEcY784J9a4W28cazC2RJbv7NF/hRHBzmrxOpY6C3PcxHb21nLcTzgQQoZHZuygZNfOWp6hc6rfS3l7M8skjEgsfurnhQOwA7Vpa74t1fW7cW15chbUHJghXYjH/a9fxrCB5ruwmG9im5bnJi8SqzSjsP7VIlR9hTlruOBkoNPFRj6CpBVoljhUiccZqLvT1rRMlk2eKcppgp3SmQOHelpo6GndadwFU81o6XF5xlUg8AEYrNxyRWx4cOLpy2cEAVyY7+BJnZgda8S9buwjZW++vXPf3rS0+78llOQFyMiqt5Ftk3r19MU23wpyMAHrXzctVc+kjJwdj0HR9SjOo7FYeUVAwDXViaOVl2HgCvNdFtWlkV0LBiOcGvQ9ItCIwXzsAzz3rFq2xo5t6F0Rj7Jeyc7RBIFB/3TzXzpH/q1ye1fSyxiWKWIcb0ZePcEV81EbCUIOUJU/gcV7OTyupL0PIzaNnEevy/Wnhhg8VFnJpQfWvbPEHjmpBUYOGyBTg2WpoCQGlFMBp4oAeKeOlRg0/NAEgNKD60wGnUgHg8UoNMBpQaAHg08GogeadmgCUGnqaiB7d6epoAmDU7NQg08GkBJniimAnGaKAueY+PhjxjqvvLn/x0Vz9dF8QgB4x1Aj+LY3/jorna86m/dR2jhjHvSg9/0plLVgTLyKWokbHanI1AmiTNLTAc0oPIpkjqchI74popRz0qkwJRyeuRTx0qEHg1NbRy3E8cEEbSzSMEjRRksx6AU7hYv6Lpl1rGoxWNgm6eTnJ+6i92Y+gr6A8M6LaaBpMVracqOZJcfNK56msnwh4Xh8OactuxVr+fD3cw/RF/2R+p5rsrRVysjqOP9WnYe9eRisR7R8sdjuoUuRXe5p2UGEDycccCtC2DO4CDJzxVOKNiu6UnnoOlbthbiNXlI6/IvsO5rnii2W7XG5VUnYowM9fxrSibGADWdCoD555rQhU9RXTEyY65hlkZJ7dxHdRj5Hxww/usO6n9Ks6dqC3W6ORDDdR/6yJuo9we496EOKS7tPtaxsrmG4iOY5QMkeo9x7VdiS44+YMvX+dV76xW6QvHhZsZz2b6/wCNSRCZVAmEe4dWUnn8Kzo9XuLfUJLa+hQcZiMecMPUZ60cotJaHyT8fLg3vxY1CAkhrKCCAA/wnZuP/oVefspUlWGCK+sP2h/h1/wkuit4j0S3B1/T4yXVB813AOSh9WXqv4jvXyeJRcRrMuSCMA10YeTT5TOpBctxvenDik+tPHeuw52KOnNOH1puKBxVkkymnA0xegp4qkSx+adxmmUoNWiSUHinA1DmnA0xWJlPPtTwalsbC6vWHkRfJ/ebgV0mneGkXa1yTI3oeB+Vc1bG0qOknd9jpoYOrWfuqy7nPWtrNdPiBC3qew/Gum0nT/sfHViPmb1NbUdosSbUAA9AMVIIAR7ivDxWYTr+7ayPcw2AhQ9692VPs/mAjPOMYqsLd0YB/Xnitz7OVXcBV2CxF3GpAGa4lPodrjct+F7cYXK/n2rt4/liC9CeuK5nS7d7UDK9OtdFYN57gZFROQRWpo2oKspHUHNeO+PfBF7p2oXd/p0T3OnyO0rKgy8OTkgjuue4/GvarZQrHnOO1SSKu3I+961phcXPDT5o6mOJoRxEeWR8sKcjIINLXvPiHwdo2s7nnt/Iuj/y8W+EbPuOh/GvONd+Hurafvksduo245/d/LIB/unr+Br6LD5lRraXs/M8KvgKtLVao44E08HnrTWUpI0ciski8MjDDD6g0or0DhHipB04qIHmnDimIlHQ5p2STUeeKcD2pASqeOaXPHpUYNKDQIkBGadmo8mjPNAyUGlBqMNxTqAJAc4p4NQg4pwagCwDTgahDD1p2TgUASZ6UU0NRQB518Qx/wAVbdH+8kZ/8cFc3XS/EP8A5GiQ/wB6CI/+O1zeK8qm/dR3taiUUtBrS4rCUo+tJS4pphYerY4xS7uSeRUeKKLisTA8U7dUO7mng8incTiTdutet/B7w0LeA+I75BucFLNWHRe8n49B+NeSW8LXNxFbx/fmdYxj1Y4/rX1DHbiGC1sLZcpDGsYA9AMVx4yq4xUV1N8PC75iS0USyNLLkqO3949gK6Kw0+RiJZV+c/dTstXtD0aC2g+0XJ8yRQNqjgAnrT7y7SyuYjbrvQL82fWuFU7K7OiU9bIa2xbmON23MGy+OgA5rWnnUJFEnG0DJ7ZrFgLPaQggCSWUsTjk+1aeqzSJaxiMjcjhqpbNks0LY7lGMEitW3XcmfTrWNpspWJGIBGOtbtoyPypxntW0NrkMkCZFGSKkQYBHakYAKM81qiLj1Ib61nazA8rWsiRGRIpN52/eA74q8AVPtUoPpSAdbTxzr5kLZXofUH0I7Gvmv4mfB1/+EzvxoC+Xb6nbzX1jCo+X7SmGkg9gwJZffI7V9HeUol81Plk6Njo49/8addwC6jjyv7yJxJGe4Yf/WJH41SfK7oT1R+ehBUkOpVgSGVhgqRwQRSg4r3D9o3wCbK7Pi7SIMWV04XUY0H+pmPAkx6N0PofrXhwrvhJSVzmkraC7gKdTKUGtLk2Hg4qQGoc80ueaq5LROGpwIqAN611/g/RBcBbu5jLbv8AVAjgf7RrKtXVGPNIuhQlWnyop6T4dur/AGs/7iM85IycfSu20bwRagbpFaRuPnc5/Idq6LTbJYwMdB1966azhUKBwMDtxXz2IzGrV62R9FRwFGkr2uzAj0CCFTtjA4xx7VRu7VIH+UnPpXaToAh461zl9CDLyfyFcSm3udaVtjEhRpHbA49qtCydlBPGenNWYbTa7dRnkVK8ghC7vmYEim5dgsJaQZJVgM+la+mWnkyr8pKH1rOhZTIODuHUmt21lIA2jk9zUMtR0Ld7Gnl/uyKNFl+z7nmX6c1GHMseCRkdOMZo2kbeenBwOv0pX6E8nY1ftDsxKEbT04qO5ubhgEjyO3SoYO6qee5ParMzBIlck7j39+1UhNWIra3nlJbf2zhu1Wri1ZINxY8+nNQRXJ2lU5K/fI6H2q8kySoASuR2obsS2zlr/R7LUiU1C1iuMdGkXkfiOa5PXPhurhptDudhAz9nuGyD9H7fjXpE0I83cBx04pYkzgjp+daUcdWoP3HoZVsLRrL3o/5nzvfWVzp901tewSQXC9Ucc49R6j3FQA19C6/4bs9fsTb3sfI5jmX78Teo/qO9eD6zptzo+rXOn3igTwNtJXow7MPYivp8Dj44pW2aPnsXg3h3fdFTPNPBqMUqmu84kSijOBTAaXNAyQHmlz9aiB5pcjrQKxJmn55qHNKGoAmB65p2elQ7qA1IZYBpwbioN3vS7uKAJ91FQ7uKKVwOJ+IY/wCKgQ/3rWI/pXNV03xB/wCQzbH1tE/rXM15dP4Eeg1uFJS0lWJIMUtFFMLBSYpaKQWEpc0UU7isdT8MrT7b4201WGUhZrhs+ijP88V9K6NCZLhRj5nYEmvB/gfbB/EN7cScIsKwqT/edun5Cvo/w5bgXG89FFcNf3qljop+7A276UW1uFHGBXPSsZmAzyxqzrFzvkYZ4qlaH94DWFV8zsioKyubNqB9rt1xwnSp5CZpnTrniqtmcTK3NXrVMNuPUnNUlcTZo2KjyAnap4mMLDsM1XsCRIyH1q3cIGTjrWxma0LiRA2fajb1jbuOKoaTLmNkPVeavXJxGGHVWBq0xMSB96EH7ynBp4O089O1VwfLv2Xs4zVoimydhQaerKoJY4XHJ9KjHpTg2DSHcp6lY219b3FnewpPY3kZjljblXBGCPxFfDPjzw6/hPxjq2hs7SJaTYikYYLxkbkJ98EV9yPIbS4EbDFrKRsP/PN/T6H9K+af2rdLW18Z6Vqca4F/ZbHPq8TY/wDQWH5VtRbUrEVFdXPE80ZpppK7DEfkUoNR0oOKaEaOjWbajqdvaLnDt8x9FHJr2bTbURqqqqgYCgegHavP/hhZedd3t0w4jQRKfcnJ/lXqlpGAAPavFzGpzT5ex7GXQ5Y83c0LSPaFHXtWnEwVeTk+pqhAflwakeTBGfrXjPU9RMnnl3EjtWbIiyMQy9PU1IWbJC5GTnIpIwzKQ3zMeMj+dCViiOWMbCFcqp4yRzn2qlOEBHOea1hFlfmGD3IqCSJM8BQB7U0yl2KELOs2QCcdq1bWTb8rD5T0H9KrrDjJBH1qVFLqCFGAc88fhRcbdjSgw4G4Zz+lWPmVgqhiemfaq1lliCyNuxzVl3GMKrYHoe9IjmJUciUhVBUEckdD61ZlDFSd2ex4/wA4qtbfuTy3HpipZpnC/IpYn+EU76FLXcqeY4fCqScdKv22Sy7shj0INQlDklh82fp+FXIUKuAASMfXFJu4pFuFd6PkY69qYECYJ4BqxB8qHL9/WrJTePpzipsZOVhsP3QBnrXl/wAcdHXZp+sRLhlJtZiPQ8of/QhXqK9Ocg1gfEWzXUPA2rxdXSLz0z13Ic/yzXZgKvsq8ZHFiYc9No+dM0ZApobOD2NG7rivsT5skzS55qLd9KXd/kUwJM+lKDUYNG7ikBNmkBqLf1o3UAT7jntQDUAajcaBosbqN1V99IXNICz5mO9FVS/HvRQBznj/AJ1OyOc5tV/ma5mul8e/8fenn1t8f+PGuZBzxXlU/hR6D3YtFJR+NXcSFoooouAUUUUAFFFJTA9h+FsIt9A09lHz3Ny0rH1wdo/QV75pZEFjI54JFeD/AAwO/Q9IB52ySfluNe43Unk6UoHGRXFL4mzbokZVxOZJCT0NWbQ4IrJR98vtWnbtyBXMtS+hsWhzItaikADFY0TbCp961IPmmA4xWsSDYs4/n3evep2OTtHU1EZBDCPbiord2MgbNa3toRYsWAeK+2P0cEVpz827euM1CiByhZcMDkMKt7QQ6nuCKqImU5TmW3k/2cZq7VMD9xFnkp8pqxAwZc1RFyQ8Uh+9SnpSUDINUOLJ27grg+hyK8R/aqtDP4K0O+xlrS/MTH0EiH+qivc50861miOPmQj8ccfrXkvxzgbVPgzqkpQiW3aC6IPYpIA38zVQdpJhJaHyUWAOKZuFNfrzSV2mNrEm4AZzTgwwP51D2xSbtoJHpTuKx678LIdnh55SOZbhj+AwK72Drk+mK5fwRbfZvDthCeojDH6nk/zrqYgcY9q+fxMuabZ72GXLBIsK+0+1RPKSTg9+tVrybylGTTdOO6xhYnJZd2frXI4nSnYsxli4JIJ7+1WC7KQoXLemOtV1IXvjBxT1mViOcfzNZtWNosuNIdnoagYHkkgj1qsLsu7RqAQvBb+lORzhWZuDweelTYaJ4EZuDgnptFWwytEzHnb2xVOIHAK43Zz1xkVIDMYSApGCc+/qKEhMllmVgBv2ygnaw7cU6O4cKCQOeQR0qt5IDLK3CEbsHOfoahmvVjcq4/eHnbjOBTISNqGXjczMT6k4GfSpoJGJIhk3Z9DWLbneAQw56jOcVs2BSCMuqnOcHjkVDK2Ni1QeWM8np0qyoK4Axv8AeqS3vOAhx6jHNX4p8g+YuFx1Pap1IbJUXbwec9T3qyi4AwOKqrIuSVOferikbPrzVpGUn0I5MA8VR1ZRLpV6j9GgkB/74NTpIXlmQjBRyoqrrDbdIvj3FvIT/wB8GqpP30Zy2dz5cib9yn0FP3e9QRN+7T/dFP3V9yfLslzRuqLdSbqAJt2KTcM4qIycdKaX5ouBMW5FG/FQGSmGTrzQBZD8Um+qnmdaTzD60hlvzKY0vHWqhkpC9AFky+9FUmfrRRcCr47AMunH/piw/wDHq5ck5FdT45HGmnHPluP1rk8nPJyfevJpfAjve5JnPTrQBkZpobnoeuKViMjNaCHZpaZkgc0oNMB1FN/HmlHIoYC0UUlAz134OzCaxijPJt53XHscEfzNe1a1LttIU9s14F8FZcXuoITwDG4/UV7brc3+p9lriq6NmsdUirbPmStez+aSsG0k71u2Bzz71gi2aUhwB6Zq+kpil5FVQvmR+uK0LqEbY2AxlRWsUZssfbBLGyt3FSw3iRsMnisvIjAz1p0R3HHHtVNpCVzt7R0nhR4yORUz5VucYrL0VDDbKDnk5rXOGXkda0RMivKuEl9/mFNtGypxxUzj90w9qrWJySKojqWxS0UtFyhBw1cj4s0z+0fC/iPSCuTPZzoo+qFl/UV1jHDVTvwIdStJW+5KfKb+f+NHW4j89lOVXd97FJ0zWz4t0w6N4p1rTWXBtLyWID0Ac4/TFYrEGuxPQyE7ipreEz3MMI6yOqAfU1BkA81t+DovP8S2Knor7+fYZpTlZNjgrySPb9MjEcSR9AowAK14wdtZll+p74rTVjsBH5189Ud2fQ01ZGVrbYTI49ar+FLtbjTmQn5oJWiPrjqP0NO1x/3Tmua+H1xI+r62nPkiVCP94rzUQ8y5rsdtdHaucgehrPjuXEBds8fxZ5J9qt6hINm3PGPmGM4rHvrpZLP5FQoT39B3puIRkWbS48wc5VfQ9T7mtKyBkCkOFOeQegFY+luHDvjKoeCB941qK77tsKLkAEBupPvWLXQ0TNAyCKUbAXRhx2wR/Sr9gy3EeEJHoD/hWdbSKzZZQWHLIrfdNW9PuwgDswy3ygY6g980WJlIZeqRb7VEuXJ24bB4rBusRAANukJ+Yn0roruSOE4LmSQrkleefSuRvZGjnaU8IeSMZH0FNxuKMjU0+ZdjODnacZ9/aui0/ewBlkC54z6iuJsL1FkRcHHJyDhQPXNdTYuGZYkO2FvunOSfX6VDi0VzXR0sEqshRWZSB94DH4ZqxbTMy+W/yqBxjgms6KUKGR2Lj2OK0IQFUrc4IUcMDTUSGy3AhhjxHnLfjmtEyYjBPHH5VjWGopMGQ/JKG+U9iKyfF+uPbaYsUBxLdyeSD/dXGWP5cfjVctiGm3Y2dMulnmlkUjY8hIPt0/pVjV1D6Xer/egkH/jprC0CTbGoBwMVt3cm60kLfLmNsj8DSp/EhSjufKcbfu0+gp27rUAY4I9zQWOa+2Wx8nLRk+7mkLYHWoCaTNDFcmL00ufWo8+9Bz3ouO44t700k00nHSmljmkG47OKQtTC3FMLcUmxpEhao3fBqNnpjN61LY7EjPkUVXLYoouFibxsf9H05j2LjP5VygOBXVeNc/YbE9g7j9K5Ifn615tD4EehLdkmSRgHJ60vXk5zUQPy5A/MU5n6c9fStbCHseMjHHWmSEjnGM9abkbs9fY0jdDSYJHTJbQFV/cRk49KT7JbkHNvHkfUVasY/Plhj86KDdj95KcKvHen3UDW08sLurshwShyp9we9cTm72ubJIo+NLK207xRf2tigjtkKFEHRcxqSPzJrFrf8fEnxdfHOcrCf/IS1z/fpXZF6GJ2fwquPJ8QXCA48y3z/wB8sDXuurS7vJOTgxgivnXwLOLfxZp5Y4WRmhP/AAIEV75PIZLeA+kYH5Vy19zWnsOtH4610Gnvt2j1NcvatzXQWDZKZPANYdS2ddZR4gLetWncm3QnnAqKJ18kY9KZK220bnoa22RmUri43TquOhzWxpUHmT5PQHNcxExkusjqTXdaVEIyrHqRWUPed2OWiNIjYgwcYq5A2+Me1ZV1cfMEXvWrbLtgUHrXQnqZ20HsPkb6Vn2hxK1aLfdP0rNgIWZgatbGb3NFG3D3paihbrUpoLGHqapeI1dtEndP9ZBtnX6qc/yzVxjgmldBNA8TciRCh/EYpMEfGf7Q9otr8UdQuIx+61GCG9XHcsmG/Va8yr2T9pWALqHhW5x876fJCx/3JT/jXjBbgntXVB+6ZNaju9dR8OVDeJkJ6rC5FcoG4ycV2nwvi8zW7iXGRHFtz7k1nXlamzXDxvUR69ZvtQcHnsKvkkRjscetZ9vuAwACewq1McxZ6e3pXhN3Z9DGOhjaxNlG559Kz/BUHlWdxOOtxcM2QOw4/pVfxTci3tpnY8IpI+tafh6MQaPax8grGM49T1pRQMs3M+1ndTmQgjk9vasO4ZhEjMpBPC7eg9Kv3KOD8u7HP3ulZk1xMkbqTtwMDHb2rZWsYxfK7l6C5eC0LtkZOMdK0tLuSFYyYx97I7k1z8UnnFRID0HPXPrVlJdhRCckNhcdcH+lZuJXOdNayrJLk7iCPQDFakcMblsSKSRtwD075rnbQBmSKY543BAc4rXhkGdzyJx0x+lTYTdwvw4Tc2CyEcjHB7YrntRkKptMivO+VcdQvtXQTy4GWZHxnb2yfXFQQaetw4aFFVRyzEYOfWlcfQxLKyiR9spL7MNwOAf8K6izfZtUnBHYGs6axdZ9oO0dh7fT1rTs8+WMZDluD3NO1xc1kbVi6SeXuIDr0OccetWrt5Vm4AMargKPr61mSbkVjnk9BgYrQnLSqoRlGfmOeoFFrEXILWNLV5J2mbYx4jLdGrE8Yp52v6a24+Wlu5A6AneBn9K6OFHciMBCc46cCuc8ZyhfElvAOsVouee7MT/Shs0pvmmbWiSAAf0rZvpT9inJIx5bf+gmuZ0STO3mtvUm/wCJVdkckQSEZ/3TUwXvIc1oz5iU/KM0ZqNG/dp9BS7q+yWx8i1dseTmkzTC3rSE0CsPzimliaaDxSMeeaVx2FznNIxApmcd6aSKTYCls00k0hOBTWbFTcYE1G7c4oduwqJmpNlJCM1FRsaKnmLsaPjP/kG2Z9Jj/KuPJyfauv8AGPOkwH0m/pXHiuKh8B2S3FLZ/LFKDkjjpTaK1JDqTmlPQ0A8YoOcfhSY0dVbnKIRw2AR7VLI7vveVi8h6se9ZkOp26xoCzggDPy1IdStWBHmNz6qa4eV32NUWfHvHiq66/6uA/8AkJa5/P51qeKdRg1TXJ7u0LeU8cSjeMHKoqnj6g1kliCM8V2R2Mbali0nNrd29wp+aKRZPyINfRNvMJbdSpyp5H0PIr5uYAqfcYr3XwTdNdeHNNlLAs0Cqx914/pXPiFomaU+xuWzYfHoa6DTH+b8a5qJiszfWt7Sny/0rmZodnbyboV+lMupgLeQA9s0y0P7gE1n30hLYB61U3oSldj9KIN3Fnua9AkYJErLwK8+0n/j6Q+ldrJIZLI7ewp09gkPtf3t2M8gV0q8IPpXO6WAZFPWuhJ2xjgmtoGctBx5FZLHbK31rUjOay7rAmIrQyZbgbpVoHis+BsGriNlaRSEbqeafC3Cn0NRFqImGCPSgEeAftA+GjrMGlJbyeXc2j3Qj3DKtlwdp9PrXzTe209ndPb3kTxTocFXGPy9q+xvilGPtloxOAZZR+YU15h4qs9Lm0/bqNulwrcIh+9n1B6inGry6MrkctjwIV6Z8KrUx2NxcYA81wAT6CuWv/DDi4b7HIohz8okOSo9M45r07w7bx2Nnb28YG1FwTnGT3rHGVo8lo9TswVCXtLs6a2zsBxip5f9Uc9hVSO4VcMwZEz95hlfzFPvJQIWIPGOua8lO57DVkea/EG9AuLe2B4klUt9Aa7zRiGtI/TArxjxnfGfXSwJKxtxXrHhi482xgcHhkBroqU3GEZdzmp1OeUo9jauLZZlIwQfXHSs6fTlEDKiBznjPNbi/MBmkkjGc8A9qyUi3FHJNp21sCRwoABxxkVZtbZFO0HKHox6nHpW1JHwMgY7ihUCYO3J+lU5EchXit5IVHeRuCB296trjbukA4GACMAe9PjC7CW5Y9s/1pu9pC2MKPQr0NQ2PlK8gEkkexSE3cuT19SK2YSpXETAOFwOMKKyyA1yifI2BwoPymrMUVyjHzFDJu/hz+XNIUi/DGoY4BeU8Fmfv7VbigcSJGVAXGcZ4NR2jhHxjGeTk9K1VcKUIC46jnFFyWixZxo+VZNjJ0yOKufZo58lyDtHQcZplqASCTluvPerUQAl2EncuOp6j0oJYW9ukYGF+6MV5Rrt19r8ZavKDlYpBbr9EAH8817DtEfzEjGefp3rwTTZjcS3Vyes08knPuxppGtLc7fQ5ORk10tz8+nXC+sTj81Nchoz4Zc/WutgbfHg9CMH6VN7NFy1TPl5chQD1HFBOKn1WE2mp3tu3WKZ0/JjVTdX2EXdJnyM01JoeWoJ7VHk0bqdybjs460ham5ptS2A7PqeaaTxSE1GzcVLZQ5nqMtmkJNMLcUmUkBbnio2PFKTTCahsuwjOAMmikHOSevpRUNjsa3i4Z0ZPaYfyrjRXZ+K8HRfcTLXGVy4f4Dqe4UlLSCtxC9qUHGe4pKMUhDs8dvelDAds00HFLn6nnrQUODDuT604vnHPT1FRKcc0q9KQiUnBzn8q9Y+F1wZPDaoTzDM64+pz/WvJN2ODyK9D+FFxt/tKDdwGSXGPXIP9KzrL3S46M9Kf5bgY6EZra0V90oXPWsCVuEOeAcVq6NMI7pD2zXEzU7jcEjx3rMlfdMc9q0JWV49wI6VjSOVnI7GonK7sEUaum8OG966q0fdEVJ6iuUsOAldFavjBq4ESNbRDmQA9q6ccYHrXHWdx9mmWQqWXPIHXFdL9ohmxJ9oXB6BTXRBaGUnctcRP83H1rJvf+Pk49atyzxjaQrSE+p6VDqQAljZRxjmrTIlsQOSjcVZtpzuCsCAaqtJk1YtiC2TTbBbErtgnvUCS7ZR6GieTBYZqlLNhqQJnFfF5vLt7WYNjZONx7YKH/4mvDjqsepXksrHMedqeyivXPjw8sngu7kgYK+YiD6fMVP6NXzPb3MloFVWOQMFT1rGpqjqotJ6ncX9oEtnnVzszwx7mtqyB8tAOnH4mvO4Ncmv57SxfeFDjJ6jrXpVkFUIwBPGF471w1k1uenRavdGlbTqCUPOOozwKW+tsxMbXlSOY/T6VQQFAxwCBye241cs7i5cCOLGSeFIrnUXfQ6nNNHg/iQFdYuQ/AzxXrXw1sNRn0K2aS3eJOitKNu4eoHXFdPbeFdBj1N9VvLGKW+Yhi8nzKpHcL0/GuhttSFxuWziJRTtMuOAfQetdlfERlTUEtjkoYaUajm3oypHpd4BgRowH8QcYou7aW1kEcpQsVDZRtwq/cxRzRbJFuCp+8XkwP8AvkfyNUoNKv8AJNteW1wM8JIvlkD0yMiuLmO3k0KVxE6xFzG/lg4LYO0H61WBfaDu/Ou90pZLTSLmKZPlkRwykZ529PevNXZ4ocZ3AgZ+WnFtoykrOxbJdARGQzjsPT6VE7kRbZgVPXOKigmjwXlXBQjheSPwqxcXMbRAMoIZf/1cVRk2JZShLhC4XcckdsD1rXF5K+za/wAgyc8jd9K5ptplh2qxVPmZc/eB+tdFYLvzM5UE9jTaRDZLA22YM0RXH8QI7+tbVrIrFW2EtjPP+eKyVdjJsGAmeg5zWnAsixZWTjPBx0/OkK5r2zIrEq3B6+1aUYDur5yACM4rJt0zg5XOOT1q3FuDAKflJ6UXJY/WLoW+lX0uf9VbyPj/AICa8K0EFLOEHOdoJr1r4i3P2LwPq8mcNJEIR/wNgv8AjXlOmj5UAq0tDSkdZprFcc101pN8gPf0rkrdjEqgck1vabKGxyfwqZK6NLnj/wAUbL7H4xu2VcJcqs49ORg/qK5LPWvUfjVaYh0u8XPDPCc+/I/rXlhNfSYOfPRiz5rGU+StJC55ozTN1IzYzXRc5rDyaQtgUwv6Uw5PWk2VYezelRn3oJphbjrU3GkKxqM9KUmmmpuWlYKbnnn8KG6GkHAyTUtjQjNjqeaKilOT60VIzd8Tj/iSS+0imuMrtfEnOiTf7y/zriq5cP8AAdUtwooore5Ngoo7UUwsFGaSlHSgYvbFKT0xTaM0gFrvfhQmbjUmzn5UT+Zrgc16N8KEAttQk9ZFH6VnV+EqO53zMfKGeQcVpaWwaaMHPJxWY3RwPqKk0yfbcR9hmuLoWdebue2Qqw3L0FNRzNKpx1qCeRmxVzSYDPdKoGTjJrPdlbG/p0ZZRmty2gdgOOKfplgqQqWrVVUjQdDXXCmorU5pzb2IoLPoxwMdRVrfFbr8oBb3FVpJznC9KS2Rp7gKQauUktETGDe5rWSFv3s1WpniVXaTgMpwD34qvczxWdtvfkDhF/vtVK2dp453lJaZxtGP4Qf/AK1TsU1cZbKtwkTozBZACOK0HhNsg3Opyce+aI/LsVjXaGnIAVf7oqDUAZbyCBFywG9yPU9KAditcSnzGCgn6Csy8ldT8yOv1U110cQgUDAz3wKjufKLpDIN7P1AP3R602wSPGPio4uvBmqRA5YR7wM9wQf6V8u6xqUcjrBDKu2M5LAjk+3tX3Vr2k2jKYbyOG5tZQVaKWMPuB6gjuKq6f4Y8O6fFGmm6FY2gxx5Fug/mCamMkt0W79D4k06RWCzDcsi8O2CAff0r1Dw/qKXVmreYMhcEA9K+o4dMhVHLRK0ZGCjxoR+WKzZfC+j3DKx0yxY/wB77OoP6VlUpqZvSruDPCVUSEbF3OcYTP6VuWFt9nXcx/ekYPfA9K6DxjoNnolybmwt1gifAYL0Ge49Oa51JNqnHJrikuWVj0aU/aR5kXTFHcqYpWKqe6nBFQWumTWdtDbW9z58MZJ3fdY5OeRUTSkox3DIo0u+H9oJG7ZUnrWbVzqp3L11NLGUSXzGZh8qqpYn8qtWMkodVW3uQ3Y+UcVoTeSinDDnnmltm2qzRuy/7p60uV9CnLuVtb8RNYatbxXds32bygX42sCeCR65rgrm5gMzgltjElUxnA7ZrvNb03/hIbNZhOy3UCFY1IGG74P+NedjylBVV+bPOevuKcYWRjNtlyzuVyfLRJO59RUrzhQSz7hnnAHHtVSNhG2QCh9Av61MksmOQhXr0yTTsZNkDS7LtfJCuwOOegzWtb3Du4BDGIHnPH/66y550jvo1KYLfKMcKD3ratVYfKrIoPQ7cYFMg0o5sIFC8jnJ/p7Vo20hCoZSGiPoOlU4TEvl+WFLZ65JFXYz8xACBW9TxSsTc1bOQHI359q0IVGQeeKoWsYjQjYFI9Ktws2SCMdsVD0Dc4n453ZtvBcMa/8ALe+iU/QZauG0tgUVu9dP+0Dk+FNNK8gX3/shridCn8y0ibPVRXU4/uYy9RYeV6ko+h2EbB1UluB2rT059r/KeKwrR8jArUsmKuOuSRXI3c7uWxQ+LKC58GGQ5JhnjkB+uR/WvEy3Fe3/ABDc/wDCE38eB/CRnthhXhpOeTXu5ZL91Z9z5/Mo/vU/IA2BQTTGb0pCxr0Dz7Ds47Uhbimkn1pKRVhT1pDRmmk0gSCk6nFBprY9allJCg5FNfIHGaVcdaa568moYyButFB6UUDOi8QD/iS3P4fzriq7XXOdHu/90fzriq5MP8J0y3CiiitybBRRRQAlLRSUAFHWl/GkobGHevTvhauNIuD/AHpyPyArzEV6n8NF26Ch/vXD/wBKyq/CVDc7SQYZH9etVgDDc9gCcjNXSm6DFVLob4Q3cVyo0OlidmiVzjbgYrqPAkwTVwXAYEbcH0Nea2V3IIgm4kDsa6nw9NNHMHjIEi8jNEY2dxSd9D2SaOO3GYxgdqoyS7u/FZkOtrfWsYkVo5l4YGka7XHBGK1d2ZJJGkHA9K0NMIEc8ztsROGc9FHeuTn1Er8sQyamsEubrKyyP5THcUBwp/ChRsDlobHmvqV357ArCvywoew9T7mtSNks7dpmOCB+dQ2kKxx5YAKvU1n3c7X04VOIUPH+0fWrtbVkXvoieBpJ5DIS29j19K6S1jAYysMyNyTWRpUYZ8Dt1rXnlEUfUUvNlMbd3IjVmJ6Vl6dM/mPNKCS56+1OdGuXy5wg5+tT/KiBVGMVNm2GiIJLZrm782U/IPu1LNNDbbWbkEhRimTT7VwDWRfu0mMcgc1XLbUSlc6W7I+z4HfvVeLKBhnIPQ1HDOJ4It3GBzQ7A5xnA9O1JjTOU+I8Jm0S4U/eMbEfgM15LFc5gjkJG09817F4rbdBCj8hmYH3GK8BiZf3sIf92HO3n0NcdeN5XPRwdTRxN5ZwWyv3umOxrU0Szhu71QfkYc1x5tZMF4JmcdwDW54X06+kujJFcHB9etZOJ2Rn3O91/R3urDbZzrbXaj5ZJELIfqBiubtdF8UxAqbvTZkx1j3r/OjW77WbEKFinuYycNtbO361FY+K57aPFxbSALwSrA01dbk8yZPeT6/pNg7zQQiMna0yNu254BIrjJWEQ4A98cn6112ueJ7e80e4tYiZJZxt5GAg9T71xfmuHwFycYGTj8ahjepcWaZlUsNgHQmrMRTYCrAEH5ttVrPzHyQ5OPvKwH5irflSFGCQgxtz8xqSbFbMdxeptRCwJJLe3f2rorSFXt9kmMpjBPQ/Ws7T7SKOZ5WBYtgsOn51rOsjqvkx7Sp/iPBFMjqWcGMIA6BO5UcVo28qsRsUv/CSBkCq1km5QkxHP8LDA/KtCHagICnB6jGMUrjLizYQAthiOntVqLrgZPc1SQYQZBx9c1cXcwG1sd6h6iOI+OcBm8AmResF1E5+hJB/nXl3hWUNYoO4yK9f+LmH+HWsBuyIR9Q4rwzwpOFEkZI4ORXelzYb0ZjCXLiPVHoNm/Iz0FbtouSpHODk/SuYspgcZNdHZP8AcYEbcdjiuBo9KTK3xBUf8IdqL4yNo7c9RXhJIJr3P4gygeDL/HIdVA49xXhVe1li/dv1PCzH+IvQXPNJRSZr0TzhaQ0E+lJmi4xKKO9IcVLARj6H8qaPypeTkdqBgemelS9ihD3z0qFzk+gqV8g5x2xmoqkQlFIelFMqx0mr/wDIJvP9yuJ7V2+qf8gy8/65muIriofCdMtwooorcQUlLRRcAoooouAUUUUAHGa9W+HahfDduT3lZv1rykV614GG3wpZEdyT/wCPVlW+EqO52afdYehzVZV3GSM/UVYhI34/vLUE5MVysnbvXKtzRlWEm1ny4+UnkV3fhnT5rzEsCZiAwZDwB+NczNbiaPIAOa2fDfiG70y1GmytH9k3EoX4Kk9s1qkupm27WR2kkdvagguZX744FV2meQ4QBR6CsmXVI1f5lyx568VFJq7H7i4q2+xmo9zeia3hZWnbBPTNdXo0SzRh48FMdRXlrXEs7cnr0Fdv4X1f7ForWs0ciy7sq/YrQn3G46G9qU+T9niPH8WO9NhQRoOlZDaj8xaJRuP8TVH9rlkYh5RnHYUWuK9lZG9Dc/ZpvMjI56j1qeXV45DzGx+lc4jlsYYknpWjaQFVy361SRLZrx3QdBxjPao5pxGhZmFRRvEB8xGc1VumErldw255p7E7kjS7xkuB+NNOD90g/jWfeEOVSJOFHUU23gZWJORmoepSNu1kdflRc1YMjMg3xMfcVjhDuUozg/XFXVQBNpmlLjjluDQxo4b4r+IItEtI9zf6U8T+TBn52Y8Zx6Dua8N0u6QxhJc+Z1z61H+0VqjXfxRuYI5CF063itlYHBzjc36muI0/xFd2/wAtwi3SYyC5w4/EdfxqZ0HJXR0Uaqpnpu/CkxuysDniux8Fzakv72JIpVz1JINeMWfjO3WX/SbeePjjYQ+f5V23hH4mWUULWsaSRs33WlACg+9c0qUux2wrR3uel3niGASMl7bzRTr1jKjJri724kuL2afYI43YkAdQP60SzG6d5pG8xpTvLdc1UmL4VkZsD+Hrn8KzmuhcJa3HFTLIzKmVHAGcHPrT7dG835wML7dPbNVnlcNjBVT1JXpVqGRNg81iFJyB/nrWTjY35kaUDR5CtGjL7Hn61d8mMJm34OOoJP4VDplvaqSFO0nk7e9aGrWkVzplzbxzMkzxkK6PyOOCRUddRN30RTs0l3xhlw3U56fWtjyX2na2MjIIauG0bR5bCaNITKz/AMbM55HoBXc2+CgWUMHXnO7p9aTeugcvcsRQNhGDMWyOgrStZNi7gpLDhgP8apQSyIwRXBX+76fSrgAkYKSWB7KMAfWlZ3EyygLktgcZ7dvSrEBVSoAzgc1STCuA7uVHf1/z6VZVlClgQOMkk9PqavlM27HE/HDUUtfBMlsD893MkSjPUA7j+grwjS5zDeKc/ersvjF4hj1nWILa3fdb2gYA/wB5jwT+lefh9rK3TBzXs0aP+zNHl1K3+0KSPRtJut2PfqK7XSHXYuTlep9q8x0ibLp154r0TR8GFXjGf4WGf1rx5rU9yLuiP4lmNfB97jAY7OPq1eIk8V7B8UGZfCjoTlfMTGeo5rx2vYy/SmzxMwd6iFzRSE0ma72cI7qaSjNITxUgLnmmZBAJpC3NJ370DFJGOM9fzobjvikGMEnpmkLdO6+lSwuJIw6AjpUVOY5602pAG6c0UxjmimWjqdR50y7/AOuZrhh0Fdzff8g66/65muGH3R9K4aGzOme4tFApa3EJRRRQKwUUL1o7UBYKKKKAsFeveDhs8K2Q/wCmef1ryGvYfCf/ACK1l/1yFZVvhKjudOrfLC/of5068jDo2OvaoR/x7D6irTf6sVyvc0ZZ0GUTQ+U33lNWLm03SFSAcVl6GSL8gHFdQAPMY4GcVvHYyloc3cW80ALQs2F6jPFXdNdpIIpn+ZS+wg8Z4rSlVSjZA/KqVkANJtccf6U38jTFc1jfJaAYtzGP72M1LBqschyGLfhTb1QbBcgdPSsjTv8Aj4/GjYSdzqbW+81wiEZI4zxVsPJkAsgz361ihRvXgflVllAU4AFNCskbMCyCQOtyiEdMLWirSPy92T9ABXH7ju6mpbckk5JP1p3Fa516JDjLSlj7tUu+3UffFcsVUQkhRnPXFUXkcFcO350XBJHbC8gUYXaaQ3g7DFcnFI5HLt+dXY3YgZY/nUjN5Jw7DJAXuTUzOFUuFXCjdwc5rFhJ2NyelOV2S1uCjFSI2IIOMHFPcR8rfGhw3xM1rJBcsm8js2wZFcZEpdwqjJ6DnrRfTS3F7czXEjyzSTOzu7FmY5PJJ60xP4foa6VogGsu45GWI+9xVlI8qrDKOOjjnn3qJ+ChHB4q2OAR2rlZrHVG1oniW80wokpBiJxhjlG+h/hNd1p2t2upIVB2Snlo24Ye49R7ivLbQAz7TyrA5B6Gk0lmFtd4J/dnKc/dOe3pWc4J6mtOo07Hr7MHbYGfzO+TkH6UKMDBL8dT2/OsfTnZ7KJnYsTGpJJz3rR6xnNc/Lc7FI19PnLviAqnGCXOefb2q3e6iljHsjXzHf7z+tZkXFmxHUL1qvJwUYfeyefwrNxRpzNI2tLuQ4KvLhux6N+vpXRWuxgN0m4jODjp71x9r8ylm5b1PXoK2tNJ+yy8mo5UPnbOjynkqNy+aeAVOMfhU8c3lxgAkADBbnmsfTwCjEjnaOanmdxIcM3X19qaVyJM0L7UrWyhWW6mESBchFGWb3x/WvMPHnxBnuYprPTCLa1HEsvUn0Hu3oPxNZXjC4nOmrIZpDIzTFm3HJweMn2rhtU+/ZL/AA/Z1fHbcep+p9a64U1GPMcUqjnPlI43acTzyA/eCqCc4Hp7008gircAH9hg4GTIOfxqrXo4dtw1OGs/fNzRJ+IiTzXp3h2bygpHMbHnHWvJNH/9mr0/w1/x6H8K8SurSZ72Gd4i/FchvDAPIcTIOvBHpXj5OK9c+K3/ACLI/wCu6V5Ga9bL/wCEeTmH8UaSKTdQfvCox1au1nEh5PvTSRjFIe1IaBhQTkYP60L1/Gn/AMNQ2NjBjnHBApufwpW6L+NI/wB40MkaaazAcZp3ao5Pv0ikITwMGig9KKBn/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Isometric testing of the infraspinatus tendon is used to assess the strength and integrity of the tendon, as well as to elicit pain indicative of injury. This test can be performed by having the patient attempt to externally rotate their adducted arm while the clinician resists the movement with their hand",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Simons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_58_26529=[""].join("\n");
var outline_f25_58_26529=null;
var title_f25_58_26530="Angiolipoma";
var content_f25_58_26530=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Angiolipoma of the forearm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_58_26530=[""].join("\n");
var outline_f25_58_26530=null;
var title_f25_58_26531="Aspergillus silver stain";
var content_f25_58_26531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aspergillus fumigatus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Silver-stain of lung tissue (x400) shows septate hyphae with acute angle branching characteristic of Aspergillus fumigatus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_58_26531=[""].join("\n");
var outline_f25_58_26531=null;
var title_f25_58_26532="Dolasetron: Patient drug information";
var content_f25_58_26532=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dolasetron: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=see_link\">",
"     see \"Dolasetron: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/13/29909?source=see_link\">",
"     see \"Dolasetron: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F162413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anzemet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F162414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Anzemet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691522",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat upset stomach and throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dolasetron or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a heart problem called congenital QT syndrome, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697138",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a low potassium or magnesium level, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696427",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A faster, harmful heartbeat may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is given on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12392 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-2AD339225F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_58_26532=[""].join("\n");
var outline_f25_58_26532=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162413\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162414\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021165\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021167\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021166\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021171\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021172\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021174\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021169\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021170\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021175\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021176\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=related_link\">",
"      Dolasetron: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/13/29909?source=related_link\">",
"      Dolasetron: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_58_26533="Southern tick-associated rash illness (STARI)";
var content_f25_58_26533=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Southern tick-associated rash illness (STARI)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/58/26533/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26533/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/58/26533/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26533/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26533/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/58/26533/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26533/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/58/26533/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 17, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the 1980s, physicians in Missouri and the southeastern United States described a new illness characterized by the presence of a rash typical of erythema migrans (EM) and mild flu-like symptoms that was temporally associated with a bite by the Lone Star tick (Amblyomma americanum) (",
"    <a class=\"graphic graphic_picture graphicRef71086 \" href=\"UTD.htm?23/1/23582\">",
"     picture 1",
"    </a>",
"    ). EM-like skin lesions appeared at the site of these tick bites, but serologic tests in such patients consistently failed to show evidence of infection with Borrelia burgdorferi, a finding that fits with the fact that the vector for Lyme disease (Ixodes scapularis) (",
"    <a class=\"graphic graphic_picture graphicRef73802 \" href=\"UTD.htm?14/13/14558\">",
"     picture 2",
"    </a>",
"    ) was unknown or uncommon in these locations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26533/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Experimental studies subsequently revealed that A. americanum is an incompetent vector for B. burgdorferi sensu stricto, the sole cause of Lyme disease in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26533/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link\">",
"     \"Epidemiology of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Over the next 20 years, this illness was given a variety of names, including Southern Lyme disease and Masters' disease. The most widely used name, Southern tick-associated rash illness (STARI), may be misleading since this syndrome and its presumed vector is now known to occur in other regions such as the Midwest and the Mid-Atlantic States.",
"   </p>",
"   <p>",
"    The putative causative agent of this disease, Borrelia lonestari, has never been isolated from a human with STARI, and Koch's postulates have not yet been fulfilled in experimental studies. Nevertheless, STARI is widely presumed to be caused by B. lonestari and to be transmitted to humans by the Lone Star tick.",
"   </p>",
"   <p>",
"    Numerous questions remain unanswered about the spectrum of clinical features and the pathophysiology of human illness following exposure to B. lonestari. In addition, the nature of its intermediate vertebrate host(s), the geographic range of illness, and the most effective treatment for STARI are unknown or incompletely understood.",
"   </p>",
"   <p>",
"    At present, STARI should be considered to be a syndrome of unproven cause that is clinically diagnosed on the basis of its characteristic skin rash, mild clinical course, and occurrence in areas where Lyme disease is either uncommon or not present, but where A. americanum ticks are known to be present. Until there is a definitive diagnostic test for this illness and until the causative organism has been definitively isolated from humans, much of our understanding about epidemiology, clinical features, and treatment will remain speculative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSATIVE ORGANISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies using the polymerase chain reaction have led to the preliminary finding that STARI is caused by a spirochete tentatively named B. lonestari. Initial descriptions of this organism were based on PCR amplification of the flagellin B gene and 16S rRNA from ticks collected from patients with STARI or from ticks that were collected in regions where STARI was recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26533/abstract/3-7\">",
"     3-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2001, a patient with typical features of STARI was identified who had an embedded A. americanum tick in the center of an EM-like skin lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26533/abstract/3\">",
"     3",
"    </a>",
"    ]. Simultaneous PCR testing of a skin biopsy sample and the imbedded tick in two geographically separate laboratories yielded an identical amplification product. This PCR product had an identical sequence to PCR amplification products of the flagellin B gene and 16S rRNA recovered from Lone star ticks by other investigators in different locations where STARI was recognized. Attempts to culture Borrelia from a portion of the skin biopsy were unsuccessful and serial testing of the patient's serum failed to show evidence of infection with B. burgdorferi.",
"   </p>",
"   <p>",
"    This is the only published report of finding PCR products typical of B. lonestari in a sample taken from a human. No other investigators have been able to duplicate this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26533/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Borrelia lonestari has been grown in vitro from A. americanum ticks collected in Georgia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26533/abstract/9\">",
"     9",
"    </a>",
"    ]. Light and electron microscopic studies of this single isolate revealed that the organism is a spirochete that is morphologically similar but not identical to Borrelia burgdorferi sensu lato (",
"    <a class=\"graphic graphic_picture graphicRef77675 \" href=\"UTD.htm?0/34/544\">",
"     picture 3",
"    </a>",
"    ). B. burgdorferi sensu lato is a broad term that includes three closely related borrelial species that have been associated with Lyme disease; B. burgdorferi sensu stricto is the sole cause of Lyme disease in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link\">",
"     \"Epidemiology of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This Borrelia isolate did not react with OspA antibody specific for B. burgdorferi or give positive results using indirect fluorescent antibody testing methods used for B. burgdorferi detection. In addition, PCR amplification of DNA from this tick isolate had an essentially identical sequence to amplification products of 16S rRNA made from Lone star ticks collected in different geographic locations and from blood samples from white-tailed deer killed in several southeastern states [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26533/abstract/3-5,9,10\">",
"     3-5,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spirochetes resembling Borrelia spp have been visualized in Lone star ticks collected in Alabama, Missouri, New Jersey, North Carolina, Oklahoma, and Texas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26533/abstract/5,11\">",
"     5,11",
"    </a>",
"    ]. Molecular evidence that such spirochetes are B. lonestari has been reported by investigators studying A. americanum ticks collected from in the field, from deer, or from patients with STARI in Alabama, Missouri, Tennessee, and Texas, and from a tick from a patient who had recently been in both North Carolina and Maryland [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26533/abstract/3-5,7,10\">",
"     3-5,7,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All three stages of A. americanum feed on white-tailed deer. As a result, it is possible that these animals are one of the vertebrate reservoir hosts for B. lonestari. In addition, white-tailed deer and A. americanum have well-established interrelationships in the epidemiology of Ehrlichia chaffeensis and E. ewingii infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23525?source=see_link\">",
"     \"Biology of ehrlichiae\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, 7 of 80 samples obtained from deer killed in 17 separate sites in Arkansas, Georgia, North and South Carolina had evidence of B. lonestari infection using PCR amplification for the Borrelia flagellin gene. Furthermore, the flagellin gene sequence amplified from deer blood was identical to the DNA sequences previously amplified from ticks collected in Alabama, Missouri, Tennessee and Texas and from the single human patient with STARI who had PCR products typical of B. lonestari [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26533/abstract/3,10\">",
"     3,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, inoculation of white-tailed deer with B. lonestari resulted in spirochetemia, as assessed with blood smears. These deer showed evidence of infection by PCR within four days of inoculation and subsequent PCR tests remained positive for up to 28 days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26533/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human illness with typical clinical features of STARI have been described in patients from Missouri, Maryland, Georgia, South Carolina, and North Carolina [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26533/abstract/6,13-16\">",
"     6,13-16",
"    </a>",
"    ]. If subsequent studies confirm that B. lonestari is the cause of STARI and white-tailed deer are the intermediate host, it is likely that human disease will be found to occur in other areas where both the tick and reservoir host are common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of STARI is currently based upon the presence of an erythema migrans-like rash following a history of tick bite that occurs in areas where the vector of Lyme disease is uncommon or unknown. As a result, it is possible that the clinical spectrum of STARI is broader than currently recognized.",
"   </p>",
"   <p>",
"    The clinical spectrum of STARI was illustrated in a report of 14 patients seen over a two-year period in central North Carolina [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26533/abstract/13\">",
"     13",
"    </a>",
"    ]. All of the patients had a recent history of EM-like skin lesions after removing attached ticks, and eight remembered removing a tick from the exact site where the rash developed. The median time from tick detection to onset of rash was 12 days with a range of 2 to 21 days. In every case in which the tick was available for subsequent study, it was identified as A. americanum. The illness was mild in all cases; only one had fever and all recovered without sequelae.",
"   </p>",
"   <p>",
"    Skin lesions in patients with STARI may be single or multiple. The lesions are characteristically erythematous with irregular borders and central clearing (",
"    <a class=\"graphic graphic_picture graphicRef60256 \" href=\"UTD.htm?32/19/33086\">",
"     picture 4",
"    </a>",
"    ). Some patients have a papule in the center of their EM-like lesions, many recall removing a tick at the exact site of this papule. The skin lesions may expand centrifugally over several days. At the time of diagnosis, the circumference of such lesions has ranged from 3 to 10 cm.",
"   </p>",
"   <p>",
"    Patients with STARI often complain of headache, generalized aching, fatigue,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nausea, but these symptoms as well as the rash disappear following treatment with tetracyclines. Thus far, no long-term complications or evidence of recurrence following treatment has been recognized.",
"   </p>",
"   <p>",
"    In a prospective study, the clinical and epidemiologic features of 21 patients from Missouri with EM-like skin lesions were compared to 97 patients from New York with EM-like lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26533/abstract/17\">",
"     17",
"    </a>",
"    ]. The two groups of patients had substantial and statistically significant clinical differences. Compared to patients from New York, patients from Missouri with EM-like skin lesions were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More likely to recall a recent tick bite (86 versus 20 percent)",
"     </li>",
"     <li>",
"      Less likely to be symptomatic (19 versus 76 percent)",
"     </li>",
"     <li>",
"      Less likely to have multiple skin lesions (5 versus 27 percent)",
"     </li>",
"     <li>",
"      More likely to have smaller lesions (mean size 8.3 cm versus 16.4 cm)",
"     </li>",
"     <li>",
"      More likely to have lesions with central clearing (76 versus 22 percent)",
"     </li>",
"     <li>",
"      More likely to recover rapidly after antibiotic treatment (at three-month follow-up visit 0 versus 21 percent with persistent symptoms)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors of this report concluded that these differences were further evidence that STARI is a distinct and different illness than Lyme disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although ELISA testing is equivocal or weakly positive B. burgdorferi antibodies in some patients with STARI, Western blot patterns show profiles that are inconsistent with acute B. burgdorferi infection. In addition, patients with STARI do not develop antibodies to rickettsial or ehrlichial antigens. Thrombocytopenia and leukopenia do not occur and routine laboratory tests of renal and hepatic function are typically normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7615635\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, there is no serologic antibody test available to detect acute infection with B. lonestari. The diagnosis is a clinical one, based on compatible symptoms and physical examination findings in a person with a history of a tick bite from a known endemic area of the Lone Star tick.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no randomized controlled trials of treatment for patients with STARI. Patients described in most case series and case reports have responded promptly to therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    . Since the organism causing this disease appears to be a spirochete of the Borrelia family, some experts believe that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    in doses similar to treat erythema migrans of acute B. burgdorferi infection is also likely to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26533/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of Lyme disease\", section on 'Early disease (erythema migrans)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Suggested approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;When patients residing in or traveling to areas where Lyme disease is uncommon develop skin lesions typical of erythema migrans and when a history of a recent tick bite is either elicited or thought to be possible, a 10-day course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg orally twice daily) should be prescribed. Patients such as pregnant women or young children and those with a history of allergic reactions to doxycycline can be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    500 mg orally three times a day for 10 days.",
"   </p>",
"   <p>",
"    Follow-up serological testing for Lyme disease is not necessary in such patients since the preceding regimens are highly effective for both STARI and early Lyme disease and because early treatment of such patients may prevent antibody development, even in patients with B. burgdorferi infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     UNRESOLVED QUESTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the full clinical spectrum of STARI will await better diagnostic methodology. When such testing is available, there may be an expansion in both the spectrum of clinical features and the geographic range of illness. As an example, A. americanum and white-tailed deer are known to exist throughout the eastern United States as far north as New England [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26533/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Until there is a reliable laboratory method to diagnosis STARI, it is likely that some patients with EM-like skin lesions due to STARI will be misdiagnosed as having Lyme disease if they reside in areas where the vectors of both illnesses coexist. This phenomenon may be responsible for the remarkable increases in the reported incidence of Lyme disease in North Carolina, a state where the vector of B. burgdorferi is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26533/abstract/19\">",
"     19",
"    </a>",
"    ]. The frequency that such diagnostic confusion occurs has not yet been studied, nor has the potential clinical and financial consequences of unnecessary testing and treatment for Lyme disease in patients with STARI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7615687\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the 1980s, physicians in Missouri and the southeastern United States described a new illness characterized by the presence of a rash typical of erythema migrans (EM) and mild flu-like symptoms that was temporally associated with a bite by the Lone Star tick (Amblyomma americanum). This infection was described as the Southern Tick-associated Rash Illness or &ldquo;STARI&rdquo;. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The putative causative agent of this disease, Borrelia lonestari, has never been isolated from a human with STARI, and Koch's postulates have not yet been fulfilled in experimental studies. Nevertheless, STARI is widely presumed to be caused by B. lonestari and to be transmitted to humans by the Lone Star tick. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causative organism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Human illness with typical clinical features of STARI have been described in patients from Missouri, Maryland, Georgia, South Carolina, and North Carolina. All three stages of the A. americanum tick feed on white-tailed deer, which may serve as the reservoir for this infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      STARI is characterized as a mild illness with onset of skin lesions, which can be single or multiple. Patients often complain of headache, generalized malaise and nausea. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)The diagnosis of STARI is currently based upon the presence of an erythema migrans-like rash following a history of tick bite that occurs in areas where the vector of Lyme disease is uncommon or unknown. At present, there is no serologic antibody test available to detect acute infection with B. lonestari. (See",
"      <a class=\"local\" href=\"#H7615635\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg twice daily) in patients with suspected STARI. Among pregnant women, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (500 mg three times daily). The duration of therapy is 10 days. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/1\">",
"      Felz MW, Durden LA. Attachment sites of four tick species (Acari: Ixodidae) parasitizing humans in Georgia and South Carolina. J Med Entomol 1999; 36:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/2\">",
"      Felz MW, Durden LA, Oliver JH Jr. Ticks parasitizing humans in Georgia and South Carolina. J Parasitol 1996; 82:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/3\">",
"      James AM, Liveris D, Wormser GP, et al. Borrelia lonestari infection after a bite by an Amblyomma americanum tick. J Infect Dis 2001; 183:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/4\">",
"      Burkot TR, Mullen GR, Anderson R, et al. Borrelia lonestari DNA in adult Amblyomma americanum ticks, Alabama. Emerg Infect Dis 2001; 7:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/5\">",
"      Barbour AG, Maupin GO, Teltow GJ, et al. Identification of an uncultivable Borrelia species in the hard tick Amblyomma americanum: possible agent of a Lyme disease-like illness. J Infect Dis 1996; 173:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/6\">",
"      Armstrong PM, Rich SM, Smith RD, et al. A new Borrelia infecting Lone Star ticks. Lancet 1996; 347:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/7\">",
"      Stegall-Faulk T, Clark DC, Wright SM. Detection of Borrelia lonestari in Amblyomma americanum (Acari: Ixodidae) from Tennessee. J Med Entomol 2003; 40:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/8\">",
"      Wormser GP, Masters E, Liveris D, et al. Microbiologic evaluation of patients from Missouri with erythema migrans. Clin Infect Dis 2005; 40:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/9\">",
"      Varela AS, Luttrell MP, Howerth EW, et al. First culture isolation of Borrelia lonestari, putative agent of southern tick-associated rash illness. J Clin Microbiol 2004; 42:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/10\">",
"      Moore VA 4th, Varela AS, Yabsley MJ, et al. Detection of Borrelia lonestari, putative agent of southern tick-associated rash illness, in white-tailed deer (Odocoileus virginianus) from the southeastern United States. J Clin Microbiol 2003; 41:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/11\">",
"      Luckhart S, Mullen GR, Wright JC. Etiologic agent of Lyme disease, Borrelia burgdorferi, detected in ticks (Acari: Ixodidae) collected at a focus in Alabama. J Med Entomol 1991; 28:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/12\">",
"      Moyer PL, Varela AS, Luttrell MP, et al. White-tailed deer (Odocoileus virginianus) develop spirochetemia following experimental infection with Borrelia lonestari. Vet Microbiol 2006; 115:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/13\">",
"      Kirkland KB, Klimko TB, Meriwether RA, et al. Erythema migrans-like rash illness at a camp in North Carolina: a new tick-borne disease? Arch Intern Med 1997; 157:2635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/14\">",
"      Campbell GL, Paul WS, Schriefer ME, et al. Epidemiologic and diagnostic studies of patients with suspected early Lyme disease, Missouri, 1990-1993. J Infect Dis 1995; 172:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/15\">",
"      Felz MW, Chandler FW Jr, Oliver JH Jr, et al. Solitary erythema migrans in Georgia and South Carolina. Arch Dermatol 1999; 135:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/16\">",
"      Masters E, Granter S, Duray P, Cordes P. Physician-diagnosed erythema migrans and erythema migrans-like rashes following Lone Star tick bites. Arch Dermatol 1998; 134:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/17\">",
"      Wormser GP, Masters E, Nowakowski J, et al. Prospective clinical evaluation of patients from Missouri and New York with erythema migrans-like skin lesions. Clin Infect Dis 2005; 41:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26533/abstract/18\">",
"      Means RG, White DJ. New distribution records of Amblyomma americanum (L.) (Acari: Ixodidae) in New York State. J Vector Ecol 1997; 22:133.",
"     </a>",
"    </li>",
"    <li>",
"     Epi Note. North Carolina Department of Health and Human Service 2004; 2:1. Available at www.epi.state.nc.us/epi/ (Accessed 3/8/05).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7899 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-8AB89F2CF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_58_26533=[""].join("\n");
var outline_f25_58_26533=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7615687\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSATIVE ORGANISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7615635\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Suggested approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      UNRESOLVED QUESTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7615687\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7899\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7899|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/1/23582\" title=\"picture 1\">",
"      Lone star tick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/13/14558\" title=\"picture 2\">",
"      Ixodes scapularis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/34/544\" title=\"picture 3\">",
"      Borrelia lonestari",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/19/33086\" title=\"picture 4\">",
"      STARI rash",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23525?source=related_link\">",
"      Biology of ehrlichiae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=related_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=related_link\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_58_26534="Atrial premature beat tutorial";
var content_f25_58_26534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1046px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atrial premature beats",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 108px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The third beat is an atrial premature beat that is normally conducted. The interval between the second sinus beat and the ectopic beat is shorter than the interval between the first two sinus beats. The P wave morphology differs from that of sinus rhythm. Since the RR cycle length is shorter, there is a decrease in the rate of conduction of the ectopic beat through the atrioventricular node. The PR interval is therefore longer than that of the sinus beat. Activation of the ventricular myocardium occurs in a normal fashion; as a result, the QRS complex is unchanged from that of sinus rhythm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_58_26534=[""].join("\n");
var outline_f25_58_26534=null;
var title_f25_58_26535="Classification and diagnosis of endometrial hyperplasia";
var content_f25_58_26535=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification and diagnosis of endometrial hyperplasia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/58/26535/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26535/contributors\">",
"     Robert L Giuntoli, II, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26535/contributors\">",
"     Howard A Zacur, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/58/26535/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26535/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26535/contributors\">",
"     Rochelle L Garcia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/58/26535/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26535/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/58/26535/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial hyperplasia is characterized by a proliferation of endometrial glands that may progress to or coexist with endometrial carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/1\">",
"     1",
"    </a>",
"    ]. Endometrial hyperplasia virtually always results from chronic estrogen stimulation unopposed by the counterbalancing effects of progesterone.",
"   </p>",
"   <p>",
"    The classification, clinical manifestations, diagnosis, and evaluation of endometrial hyperplasia are reviewed here. Related topics can be found separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of endometrial hyperplasia (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37943?source=see_link\">",
"       \"Management of endometrial hyperplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other etiologies of abnormal uterine bleeding (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=see_link\">",
"       \"Initial approach to the premenopausal woman with abnormal uterine bleeding\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=see_link\">",
"       \"Postmenopausal uterine bleeding\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Endometrial cancer (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link\">",
"       \"Endometrial carcinoma: Epidemiology and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTOLOGY AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial hyperplasia is a characterized by a proliferation of endometrial glands resulting in a greater gland-to-stroma ratio than observed in normal endometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/1\">",
"     1",
"    </a>",
"    ]. The proliferating glands vary in size and shape and cells may have cytologic atypia. Endometrial hyperplasia may be non-neoplastic (most simple and some complex hyperplasias) or neoplastic (some complex and all complex atypical hyperplasias). Neoplastic hyperplasia is a non-obligate precursor to the most common form of endometrial carcinoma, endometrioid histology. This pattern of precursor and carcinoma is similar to intraepithelial neoplasms in other body sites (eg, cervical intraepithelial neoplasia, adenoma in the colon, or ductal carcinoma in situ of the breast). Unfortunately, the terminology for endometrial hyperplasia does not make the relationship to malignant potential clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H506961\">",
"    <span class=\"h2\">",
"     World Health Organization classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) classification of endometrial hyperplasia is the most widely used system [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, the WHO system correlates well with the risk of progression to endometrial carcinoma (see",
"    <a class=\"local\" href=\"#H381678\">",
"     'Risk of carcinoma'",
"    </a>",
"    below). However, a major limitation of this system is interobserver variability across pathologists reviewing the same slides [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The finding of nuclear atypia, which is the most important indicator of malignant potential, has the lowest level of interobserver agreement (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Nuclear atypia'",
"    </a>",
"    below). As an example, two studies of 100 or more endometrial biopsy slides found concordance across pathologists for a report of nuclear atypia was only 38 to 47 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H381562\">",
"    <span class=\"h3\">",
"     Categories",
"    </span>",
"    &nbsp;&mdash;&nbsp;The WHO classification of endometria hyperplasia is based upon two features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       glandular/stromal",
"      </span>",
"      architectural pattern of the endometrium, which is described as either simple or complex",
"     </li>",
"     <li>",
"      The presence or absence of nuclear atypia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This results in four possible categories of endometrial hyperplasia:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Simple hyperplasia without atypia",
"     </li>",
"     <li>",
"      Complex hyperplasia without atypia",
"     </li>",
"     <li>",
"      Simple atypical hyperplasia",
"     </li>",
"     <li>",
"      Complex atypical hyperplasia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Simple atypical hyperplasia is rare, and many reports use the term atypical hyperplasia to refer to all women with either simple or complex atypical hyperplasia.",
"   </p>",
"   <p>",
"    Women with simple hyperplasia without atypia are least likely to develop endometrial carcinoma, whereas women with complex hyperplasia with atypia are most likely to develop carcinoma. The presence of nuclear atypia is the most worrisome finding. (See",
"    <a class=\"local\" href=\"#H381678\">",
"     'Risk of carcinoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1312360\">",
"    <span class=\"h4\">",
"     Normal endometrium",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the normal menstrual cycle, proliferative endometrium is found during the follicular phase and secretory endometrium is found during the luteal phase (",
"    <a class=\"graphic graphic_figure graphicRef62189 \" href=\"UTD.htm?14/16/14601\">",
"     figure 1",
"    </a>",
"    ). Normal proliferative endometrium exhibits no crowding of glands within the stroma (&lt;50 percent ratio of glands to stroma). Normal secretory endometrium may have &gt;50 percent gland to stroma ratio. Although they exhibit crowding, these glands are organized, and cells comprising the glands are spaced and are not mitotically active. Normal proliferative and secretory endometrium is shown in the picture (",
"    <a class=\"graphic graphic_picture graphicRef67488 graphicRef76588 \" href=\"UTD.htm?35/20/36170\">",
"     picture 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h4\">",
"     Simple versus complex hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple and complex endometrial hyperplasia are characterized by the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Simple hyperplasia consists of glands that are mildly crowded. They are frequently cystically dilated with only occasional outpouching. Mitoses may or may not be present in the glandular cells (",
"      <a class=\"graphic graphic_picture graphicRef73789 \" href=\"UTD.htm?33/20/34121\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Complex hyperplasia consists of glands that are crowded (&gt;50 percent gland to stromal ratio); the gland-to-stroma ratio is higher in complex compared to simple hyperplasia. The glands appear disorganized and have luminal outpouching. Mitoses are typically present (",
"      <a class=\"graphic graphic_picture graphicRef57406 \" href=\"UTD.htm?23/53/24409\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h4\">",
"     Nuclear atypia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nuclear atypia is the presence of nuclear enlargement; the chromatin may be either evenly dispersed or clumped [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/7\">",
"     7",
"    </a>",
"    ]. Atypical endometrial hyperplasia is usually complex, although rarely there is a finding of simple atypical hyperplasia. The features of atypical endometrial hyperplasia are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complex atypical hyperplasia consists of crowding of glands lined by atypical cells (",
"      <a class=\"graphic graphic_picture graphicRef66592 \" href=\"UTD.htm?22/13/22744\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef80373 \" href=\"UTD.htm?9/34/9769\">",
"       picture 5",
"      </a>",
"      ). Rarely, extreme complexity",
"      <strong>",
"       without",
"      </strong>",
"      marked cytologic atypia warrants a diagnosis of complex atypical hyperplasia.",
"      <br/>",
"      <br/>",
"      A drawback of the WHO classification scheme is that the category of complex atypical hyperplasia includes both neoplasms bordering on invasive carcinoma and those that are clearly not invasive. Complex atypical hyperplasia is distinguished from grade 1 endometrial carcinoma by the presence of residual endometrial stroma that separates all glands. Variability is often noted across pathologists in making this distinction. As an example, in one study 289 endometrial sampling specimens with a diagnosis of complex atypical hyperplasia made at a community hospital were reviewed by pathologists using WHO criteria; 25 percent of cases were downgraded to less severe histology than complex atypical hyperplasia and 29 percent were upgraded to endometrial carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Simple atypical hyperplasia is characterized by cells with nuclear atypia that line glands that are separated by significant amounts of normal stroma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H381678\">",
"    <span class=\"h3\">",
"     Risk of carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using the WHO classification, the presence of nuclear atypia is the most important indicator of the risk of endometrial carcinoma in women with endometrial hyperplasia.",
"   </p>",
"   <p>",
"    High quality data are lacking regarding the natural history of endometrial hyperplasia. The best available data regarding the likelihood of progression from endometrial hyperplasia to carcinoma are from a classic retrospective study of 170 women who had endometrial sampling and then had a hysterectomy after an average of 13 years (range 1 to 27 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/9\">",
"     9",
"    </a>",
"    ]. This study was limited by the small overall number of events and the fact that most of these women had some intervention between initial endometrial sampling and hysterectomy. Endometrial carcinoma at hysterectomy was more than 10-fold higher in women with atypical hyperplasia than in women with no atypia (23 versus 1.6 percent). The incidence of cancer for each histologic category was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Simple hyperplasia without atypia &ndash; 1 of 93 patients (1 percent)",
"     </li>",
"     <li>",
"      Complex hyperplasia without atypia &ndash; 1 of 29 patients (3 percent)",
"     </li>",
"     <li>",
"      Simple atypical hyperplasia &ndash; 1 of 13 patients (8 percent) &nbsp;",
"     </li>",
"     <li>",
"      Complex atypical hyperplasia &ndash; 10 of 35 patients (29 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings reported in a case control study found that the cumulative risk of endometrial carcinoma at 19 years after diagnosis of endometrial hyperplasia was higher for women with atypia compared with those without atypia (28 versus 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The time course from a diagnosis of endometrial hyperplasia to carcinoma is not well established. The case control study cited above reported that the average time to diagnosis of cancer was six years in women with all types of endometrial hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many women with atypical endometrial hyperplasia have coexistent endometrial carcinoma. A literature review noted the frequency of concurrent carcinoma among patients with atypical endometrial hyperplasia ranged from 17 to 52 percent across studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, women with a finding of atypical endometrial hyperplasia on endometrial biopsy require further evaluation. (See",
"    <a class=\"local\" href=\"#H507792\">",
"     'Positive endometrial sampling'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Endometrial intraepithelial neoplasia system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endometrial intraepithelial neoplasia classification system was proposed by an international group of gynecologic pathologists in 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/11\">",
"     11",
"    </a>",
"    ]. This system has not gained widespread acceptance, but is used in some institutions. The system defines two classes of endometrial changes that are relevant to clinical management:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endometrial hyperplasia (EH) &ndash; Changes typically observed with anovulation or other etiology of prolonged exposure to estrogen. The morphology of EH varies from proliferative endometrium with a few cysts (persistent proliferative endometrium) to bulkier endometria with many dilated and contorted glands that in other systems have been designated as &ldquo;cystic glandular hyperplasia&rdquo;, &ldquo;mild hyperplasia&rdquo;, or &ldquo;simple hyperplasia&rdquo;.",
"     </li>",
"     <li>",
"      Endometrial intraepithelial neoplasia (EIN) &ndash; Endometrial precancers. Epithelial crowding in precancers displaces stroma to a point at which stromal volume is less than approximately half of total tissue volume (stroma + epithelium + gland lumen). Stromal volume can be measured using computerized morphometric analysis and assigned a D-score [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. Using this method, specimens are classified as benign (D&gt;1), indeterminate (0&lt;D&lt;1), or EIN (D&lt;0).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    EIN system categories do not correspond directly to specific categories in the WHO system, but there is some consistency. Most simple and some complex hyperplasias fall into the EH category. Many complex hyperplasia without atypia and most complex hyperplasia with atypia fall into the EIN category.",
"   </p>",
"   <p>",
"    The EIN classification system has demonstrated high interobserver reproducibility and studies have confirmed that EIN correlates with progression to endometrial carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/12\">",
"     12",
"    </a>",
"    ]. A recognized drawback of the EIN system is that it lumps findings that would receive different treatments (hormonal treatment or surgery), ostensibly because of the lack of ability to reproducibly distinguish between differing severities within the EIN category [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8943236\">",
"    <span class=\"h2\">",
"     Comparing the WHO and EIN systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have compared the diagnostic performance of the WHO and EIN systems. The available observational data suggest that the EIN system may be better able to predict which lesions will progress to invasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. As an example, a retrospective multicenter study compared the performance of the EIN and WHO classification systems for predicting progression of endometrial hyperplasia to endometrial carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/14\">",
"     14",
"    </a>",
"    ]. The EIN system was better able to distinguish between lesions likely to progress versus those not likely to progress. With the EIN system, progression rates for the two categories were: EH (2 of 359 patients [0.6 percent]) versus EIN (22 of 118 patients [19 percent]). By comparison, use of the WHO system had the following progression rates: hyperplasia without atypia (8 of 354 patients [2 percent]) versus atypical hyperplasia (16 of 123 patients [13 percent]).",
"   </p>",
"   <p>",
"    The Society of Gynecologic Oncologists recommends using a pathologic diagnosis system that utilizes criteria and terminology that distinguish between clinicopathologic entities requiring different management.&nbsp;The EIN system appears to better fulfill these objectives.&nbsp;However, the WHO classification remains more widely used [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H507038\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best available data regarding the epidemiology of endometrial hyperplasia are from a report from a large integrated health plan that included women aged 18 to 90 over an 18-year period (1985 to 2003) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/17\">",
"     17",
"    </a>",
"    ]. The overall incidence of endometrial hyperplasia was 133 per 100,000 woman-years. The diagnosis is most commonly made in woman age 50 to 54 years and rarely was found in women less than age 30. The incidence of simple and complex hyperplasia without atypia were highest in women age 50 to 54 years (142 and 213 per 100,000 woman-years, respectively), whereas the rate of atypical hyperplasia was highest in women age 60 to 64 (56 per 100,000 woman-years). Trends in incidence over the accrual period demonstrated declining incidence over time, particularly for atypical hyperplasia (1985 to 1989: 23 per 100,000 woman-years versus 2000 to 2003: 5 per 100,000 woman-years). The reason for this trend is unknown, but may be the decreasing use of unopposed estrogen therapy. &nbsp;",
"   </p>",
"   <p>",
"    In general, reliable estimates of the incidence of endometrial hyperplasia are difficult to obtain due to many factors, including changing diagnostic criteria over time, bias of studies evaluating symptomatic women (eg, abnormal uterine bleeding), trends in postmenopausal hormone therapy, assessment technique (endometrial sampling versus hysterectomy), and concomitant diagnoses of endometrial cancer with hyperplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors for endometrial hyperplasia are the same as those for endometrial carcinoma (",
"    <a class=\"graphic graphic_table graphicRef62089 \" href=\"UTD.htm?38/30/39403\">",
"     table 1",
"    </a>",
"    ). Most of these risk factors involve exposure of the endometrium to continuous estrogen unopposed by a progestin. This effect may be due to endogenous or exogenous hormone. Physiologically, estrogen stimulates endometrial proliferation during the normal menstrual cycle; this effect is buffered by progesterone, which inhibits endometrial proliferation and stimulates differentiation in preparation for implantation of an embryo.",
"   </p>",
"   <p>",
"    In addition, women with Lynch syndrome (hereditary nonpolyposis colorectal cancer) are at a greatly increased risk of endometrial hyperplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18233?source=see_link&amp;anchor=H7#H7\">",
"     \"Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Endometrial cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for endometrial neoplasia in general are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link&amp;anchor=H2#H2\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial hyperplasia typically presents with abnormal uterine bleeding and is most common in women who are postmenopausal and with increasing age in premenopausal women. Occasionally, women with no abnormal uterine bleeding present with abnormal findings on cervical cytology.",
"   </p>",
"   <p>",
"    The clinical presentation for endometrial hyperplasia is the same as for endometrial carcinoma. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=see_link&amp;anchor=H336595#H336595\">",
"     \"Endometrial carcinoma: Clinical features and diagnosis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H508097\">",
"    <span class=\"h1\">",
"     EVALUATION OF WOMEN WITH SUSPECTED ENDOMETRIAL NEOPLASIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a clinical presentation suspicious for endometrial hyperplasia are evaluated initially with physical examination. Pelvic sonography may also be performed to exclude another etiology of abnormal uterine bleeding or to assess endometrial thickness in postmenopausal women. This evaluation is the same as for women with suspected endometrial carcinoma and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=see_link&amp;anchor=H281523#H281523\">",
"     \"Endometrial carcinoma: Clinical features and diagnosis\", section on 'Evaluation of women with suspected endometrial neoplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H507663\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial hyperplasia is a histologic diagnosis made based upon the results of evaluation of an endometrial biopsy, curettage sample, or hysterectomy specimen. &nbsp;",
"   </p>",
"   <p>",
"    Diagnostic methods are the same as for endometrial carcinoma and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=see_link\">",
"     \"Endometrial carcinoma: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H507988\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of endometrial hyperplasia includes other conditions that present with abnormal uterine bleeding. Women with presumed uterine bleeding should be evaluated to confirm that the source of the blood is the uterus, and not another part of the genital tract or the anus or rectum. The etiologies of uterine bleeding and other sources of genital tract bleeding are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=see_link\">",
"     \"Overview of causes of genital tract bleeding in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, for women who present with abnormal finding on cervical cytology, the differential diagnosis includes benign endometrium and cervical neoplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40185?source=see_link&amp;anchor=H17#H17\">",
"     \"Cervical cytology: Interpretation of results\", section on 'Benign-appearing endometrial cells in a woman &ge;40 years'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9624?source=see_link&amp;anchor=H16564920#H16564920\">",
"     \"Cervical cytology: Evaluation of atypical and malignant glandular cells\", section on 'Risk of premalignant or malignant disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H507785\">",
"    <span class=\"h1\">",
"     FURTHER EVALUATION AFTER ENDOMETRIAL SAMPLING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H507868\">",
"    <span class=\"h2\">",
"     Negative endometrial sampling",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1110025\">",
"    <span class=\"h3\">",
"     Office endometrial biopsy with insufficient endometrial cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with an endometrial biopsy result that has insufficient endometrial cells should have sampling repeated with an office biopsy or dilation and curettage (D&amp;C). If two office endometrial biopsies have been unsuccessful, a D&amp;C should be performed. Cervical stenosis, a common cause of an unsuccessful biopsy, can be managed with preprocedure cervical preparation or dilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/131?source=see_link&amp;anchor=H391920#H391920\">",
"     \"Endometrial sampling procedures\", section on 'Cervical preparation and dilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1110035\">",
"    <span class=\"h3\">",
"     Persistent or recurrent bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;If bleeding persists or recurs after endometrial sampling with benign findings, further evaluation is required. In our practice, we reevaluate such cases after three to six months.",
"   </p>",
"   <p>",
"    Abnormal uterine bleeding symptoms may be due to an etiology other than endometrial neoplasia. Transvaginal ultrasound, sonohysterography, or diagnostic hysteroscopy should be performed to exclude structural lesions (leiomyomas, endometrial polyp). Any structural lesions that are found should be treated, as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32601?source=see_link\">",
"     \"Hysteroscopic myomectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=see_link&amp;anchor=H1500838#H1500838\">",
"     \"Endometrial polyps\", section on 'Choosing a management approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to evaluation for structural lesions, it is essential to repeat endometrial sampling to exclude endometrial hyperplasia or carcinoma. Reported rates of endometrial neoplasia in women evaluated for persistent or recurrent postmenopausal bleeding vary widely, from 4 to 21 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H507792\">",
"    <span class=\"h2\">",
"     Positive endometrial sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with endometrial hyperplasia should be treated, as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37943?source=see_link\">",
"     \"Management of endometrial hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H507800\">",
"    <span class=\"h3\">",
"     Office endometrial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with atypical endometrial hyperplasia on an office endometrial biopsy, if a hysterectomy is not planned, we suggest further evaluation with dilation and curettage to exclude a coexistent endometrial carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Coexistent endometrial carcinoma is present in 17 to 52 percent of women with complex hyperplasia at time of hysterectomy, as noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26535/abstract/8\">",
"     8",
"    </a>",
"    ]. Women with endometrial carcinoma should be treated, as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=see_link\">",
"     \"Overview of endometrial carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the uterine curettage results are less severe or negative, the patient should be managed based upon the results of the office endometrial biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H507808\">",
"    <span class=\"h3\">",
"     Postmenopausal women with no known estrogen source",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development of endometrial hyperplasia with or without atypia in a woman who should be estrogen-deficient requires an explanation. In the absence of other sources of estrogen (eg, estrogen therapy, obesity), such women require evaluation for an estrogen-producing tumor. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=see_link&amp;anchor=H383853#H383853\">",
"     \"Endometrial carcinoma: Clinical features and diagnosis\", section on 'Postmenopausal women not on hormone therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endometrial hyperplasia is characterized by a proliferation of endometrial glands that may progress to or coexist with endometrial carcinoma. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most commonly used classification system for endometrial hyperplasia is the World Health Organization system, which has four categories: simple without nuclear atypia, complex without atypia, simple atypical hyperplasia, and complex atypical hyperplasia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Histology and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The endometrial intraepithelial neoplasia system is another classification system. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Endometrial intraepithelial neoplasia system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of nuclear atypia is the most important indicator of the risk of endometrial carcinoma in women with endometrial hyperplasia. The risk of progression from atypical hyperplasia to carcinoma is approximately 23 to 29 percent. In addition, 17 to 52 percent of women with atypical hyperplasia are found to have coexistent endometrial carcinoma when a hysterectomy is performed. (See",
"      <a class=\"local\" href=\"#H381678\">",
"       'Risk of carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endometrial hyperplasia almost always results from excess estrogen exposure. This may be caused by obesity, anovulation, estrogen therapy without a progestin, or estrogen producing ovarian tumors (rare). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endometrial hyperplasia typically presents with abnormal uterine bleeding and is most common in women who are postmenopausal and with increasing age in premenopausal women. Occasionally, women with no abnormal uterine bleeding present with abnormal findings on cervical cytology. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endometrial hyperplasia is a histologic diagnosis made with sampling of the endometrium. Either an office endometrial biopsy or dilation and curettage may be performed. (See",
"      <a class=\"local\" href=\"#H507663\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with atypical endometrial hyperplasia on an office endometrial biopsy, if a hysterectomy is not planned, we suggest further evaluation with dilation and curettage to exclude a coexistent endometrial carcinoma. (See",
"      <a class=\"local\" href=\"#H507800\">",
"       'Office endometrial biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kurman RJ, Norris HJ. Endometrial hyperplasia and related cellular changes. In: Blaustein's Pathology of the Female Genital Tract, 4th ed, Kurman, RJ. In: Blaustein's Pathology of the Female Genital Tract, 4th, Kurman RJ (Ed), Springer Verlag, New York 1994. p.441.",
"    </li>",
"    <li>",
"     Scully RE, Bonfiglio TA, Kurman, et al. Uterine corpus. In: Histological Typing of Female Genital Tract Tumours, 2nd ed., Springer-Verlag, New York 1994. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/3\">",
"      Zaino RJ, Kauderer J, Trimble CL, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006; 106:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/4\">",
"      Kendall BS, Ronnett BM, Isacson C, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol 1998; 22:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/5\">",
"      Bergeron C, Nogales FF, Masseroli M, et al. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol 1999; 23:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/6\">",
"      Skov BG, Broholm H, Engel U, et al. Comparison of the reproducibility of the WHO classifications of 1975 and 1994 of endometrial hyperplasia. Int J Gynecol Pathol 1997; 16:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/7\">",
"      Lacey JV Jr, Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas 2009; 63:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/8\">",
"      Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006; 106:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/9\">",
"      Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of \"untreated\" hyperplasia in 170 patients. Cancer 1985; 56:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/10\">",
"      Lacey JV Jr, Sherman ME, Rush BB, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010; 28:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/11\">",
"      Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 2000; 76:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/12\">",
"      Baak JP, &Oslash;rbo A, van Diest PJ, et al. Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. Am J Surg Pathol 2001; 25:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/13\">",
"      Mutter GL, Baak JP, Crum CP, et al. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol 2000; 190:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/14\">",
"      Baak JP, Mutter GL, Robboy S, et al. The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 2005; 103:2304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/15\">",
"      Hecht JL, Ince TA, Baak JP, et al. Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol 2005; 18:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/16\">",
"      Trimble CL, Method M, Leitao M, et al. Management of endometrial precancers. Obstet Gynecol 2012; 120:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/17\">",
"      Reed SD, Newton KM, Clinton WL, et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol 2009; 200:678.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/18\">",
"      Twu NF, Chen SS. Five-year follow-up of patients with recurrent postmenopausal bleeding. Zhonghua Yi Xue Za Zhi (Taipei) 2000; 63:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/19\">",
"      Ronghe R, Gaudoin M. Women with recurrent postmenopausal bleeding should be re-investigated but are not more likely to have endometrial cancer. Menopause Int 2010; 16:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/20\">",
"      Larson DM, Johnson KK, Broste SK, et al. Comparison of D&amp;C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol 1995; 86:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26535/abstract/21\">",
"      Leitao MM Jr, Kehoe S, Barakat RR, et al. Comparison of D&amp;C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 2009; 113:105.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3217 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_58_26535=[""].join("\n");
var outline_f25_58_26535=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTOLOGY AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H506961\">",
"      World Health Organization classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H381562\">",
"      - Categories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1312360\">",
"      Normal endometrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Simple versus complex hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nuclear atypia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H381678\">",
"      - Risk of carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Endometrial intraepithelial neoplasia system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8943236\">",
"      Comparing the WHO and EIN systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H507038\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H508097\">",
"      EVALUATION OF WOMEN WITH SUSPECTED ENDOMETRIAL NEOPLASIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H507663\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H507988\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H507785\">",
"      FURTHER EVALUATION AFTER ENDOMETRIAL SAMPLING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H507868\">",
"      Negative endometrial sampling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1110025\">",
"      - Office endometrial biopsy with insufficient endometrial cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1110035\">",
"      - Persistent or recurrent bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H507792\">",
"      Positive endometrial sampling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H507800\">",
"      - Office endometrial biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H507808\">",
"      - Postmenopausal women with no known estrogen source",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3217\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3217|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/16/14601\" title=\"figure 1\">",
"      Menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3217|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/48/12041\" title=\"picture 1A\">",
"      NI proliferativ endometrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/54/5991\" title=\"picture 1B\">",
"      NI secretory endometrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/20/34121\" title=\"picture 2\">",
"      Simple endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/53/24409\" title=\"picture 3\">",
"      Complex endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/13/22744\" title=\"picture 4\">",
"      Complex atyp hyperplas endomet1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/34/9769\" title=\"picture 5\">",
"      Complex atyp hyperplas endometr",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3217|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/30/39403\" title=\"table 1\">",
"      Risk factors endometrial cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9624?source=related_link\">",
"      Cervical cytology: Evaluation of atypical and malignant glandular cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40185?source=related_link\">",
"      Cervical cytology: Interpretation of results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18233?source=related_link\">",
"      Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=related_link\">",
"      Endometrial carcinoma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=related_link\">",
"      Endometrial polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/131?source=related_link\">",
"      Endometrial sampling procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=related_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32601?source=related_link\">",
"      Hysteroscopic myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=related_link\">",
"      Initial approach to the premenopausal woman with abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37943?source=related_link\">",
"      Management of endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=related_link\">",
"      Overview of causes of genital tract bleeding in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=related_link\">",
"      Overview of endometrial carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=related_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_58_26536="Management of epistaxis in children";
var content_f25_58_26536=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of epistaxis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/58/26536/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26536/contributors\">",
"     Anna H Messner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/58/26536/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26536/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26536/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26536/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/58/26536/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26536/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/58/26536/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epistaxis is common in children. Childhood nosebleeds are rarely severe and seldom require hospital admission [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/1\">",
"     1",
"    </a>",
"    ]. Nonetheless, frequent minor nosebleeds can be both bothersome and alarming for parents and children. Most epistaxis in children is minor and is easily managed with direct compression of the nasal alae for 5 to 10 minutes. For more significant or recurrent epistaxis other techniques might include vasoconstrictor nose drops, cautery with 75 percent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/46/20194?source=see_link\">",
"     silver nitrate",
"    </a>",
"    , topical sealants or glue, nasal packing, or balloon catheters. Children with refractory epistaxis or underlying local or systemic factors (eg, nasal tumor or bleeding disorder) that predispose to epistaxis require an individualized approach to management and specialty consultation.",
"   </p>",
"   <p>",
"    The management of epistaxis in children will be reviewed here. The epidemiology, etiology, and evaluation of epistaxis in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27912?source=see_link\">",
"     \"Epidemiology and etiology of epistaxis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=see_link\">",
"     \"Evaluation of epistaxis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EMERGENCY TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with epistaxis have spontaneous anterior nasal bleeding without airway compromise or hemodynamic instability. Rapid assessment of general appearance, vital signs, airway stability, and mental status are still necessary to identify children who require airway intervention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fluid resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Airway intervention may be needed for patients who are spitting or regurgitating blood and in those with hemorrhagic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link&amp;anchor=H13#H13\">",
"     \"Hypovolemic shock in children: Initial evaluation and management\", section on 'Fluid resuscitation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with marked nasal hemorrhage, rapid assessment and stabilization is followed immediately by attempts to identify the source of bleeding and initiation of measures to control it, usually in consultation with otolaryngology [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Blood factors or platelets should be administered to patients who have bleeding disorders that can be treated with such products. The remainder of the evaluation is undertaken after the patient is stabilized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=see_link\">",
"     \"Evaluation of epistaxis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR CONSULTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most episodes of epistaxis resolve with compression of the nasal alae for 5 to 10 minutes and do not require specialty care. Referral to or consultation with an otolaryngologist or other specialist is indicated for patients with severe epistaxis, troublesome recurrent epistaxis, or local abnormalities, such as tumors (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76702 \" href=\"UTD.htm?33/3/33842\">",
"     image 1",
"    </a>",
"    ), polyps, or telangiectasias [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27912?source=see_link\">",
"     \"Epidemiology and etiology of epistaxis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=see_link\">",
"     \"Evaluation of epistaxis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, consultation with an otolaryngologist may be helpful in children who require nasal packing. The otolaryngologist can place the pack and help to determine the underlying cause of bleeding. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Emergency treatment'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Nasal packing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Referral to hematology may be warranted for patients with severe or recurrent bleeding,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a family history of bleeding disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link\">",
"     \"Approach to the child with bleeding symptoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=see_link&amp;anchor=H9#H9\">",
"     \"Evaluation of epistaxis in children\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ACUTE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the patient is stabilized, management of epistaxis in children entails control of acute hemorrhage and prevention of recurrences by controlling underlying local or systemic disease processes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Active bleeding usually responds to simple compression, but may require cautery, application of a hemostatic agent, nasal packing, or more aggressive measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Direct compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active bleeding usually responds to simple compression, which involves compressing the nasal alae together to apply pressure to the Kiesselbach plexus (",
"    <a class=\"graphic graphic_picture graphicRef50603 \" href=\"UTD.htm?25/20/25920\">",
"     picture 1",
"    </a>",
"    ). Pressure should be applied for a minimum of five minutes before checking to see if the bleeding is controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/4\">",
"     4",
"    </a>",
"    ]. If the patient is too young to reliably pinch his or her nose closed the parents or clinical personnel can perform the compression maneuver. Young children typically do best with parental compression. During simple compression the child should be sitting up and bent forward at the waist to minimize bleeding into the oral cavity and hypopharynx. This position avoids possible aspiration or swallowing of the blood [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/5\">",
"     5",
"    </a>",
"    ]. Efforts to calm the child (eg, distraction, reassuring statements, and positive imagery) and reduce crying are complementary to direct compression. Control of bleeding is usually achieved within 5 to 10 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If direct compression does not readily stop epistaxis, topical vasoconstriction may be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Because",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/46/41696?source=see_link\">",
"     phenylephrine",
"    </a>",
"    has been associated with significant morbidity and even mortality when used topically in children in the operative setting, we prefer",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/22/35168?source=see_link\">",
"     oxymetazoline",
"    </a>",
"    (eg, one to two squirts into the bleeding side of the nose with 0.05 percent oxymetazoline hydrochloride) although the amount of either vasoconstrictor is less in the emergency setting than in operative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/22/35168?source=see_link\">",
"     oxymetazoline",
"    </a>",
"    is not available, the minimum dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/46/41696?source=see_link\">",
"     phenylephrine",
"    </a>",
"    needed to obtain vasoconstriction is recommended, and in children weighing up to 25 kg, the initial dose should not exceed 20",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/7\">",
"     7",
"    </a>",
"    ]. The lowest concentration of phenylephrine should be used for small children (eg, phenylephrine 0.25 percent diluted with an equal volume of sterile saline to 0.125 percent; phenylephrine 0.25 percent contains 2500",
"    <span class=\"nowrap\">",
"     mcg/mL;",
"    </span>",
"    phenylephrine 0.125 percent contains 1250",
"    <span class=\"nowrap\">",
"     mcg/mL).",
"    </span>",
"    The dose for small children should be carefully measured in a 1 or 0.5 mL oral type dosing syringe labeled for topical use only.",
"   </p>",
"   <p>",
"    The vasoconstrictor can be applied using a squirt bottle or a small piece of",
"    <span class=\"nowrap\">",
"     cotton/gauze",
"    </span>",
"    pledget gently placed in the nose adjacent to the septum. After the vasoconstrictor is placed, direct pressure is applied at the sides of the nose for five minutes, after which any pledgets can be removed for reinspection of the bleeding site [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other techniques",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Cautery",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anterior septal bleed unresponsive to the above measures may benefit from cautery, either chemically or electrically (thermally) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/9\">",
"     9",
"    </a>",
"    ]. Cauterization is also commonly used for children with recurrent benign epistaxis who are seen in the otolaryngology clinic. The procedure is well tolerated by most children in spite of minor pain, even though topical anesthesia with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    is routinely used [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For cauterization to be successful, the patient must be cooperative or sedated. Chemical cautery is usually accomplished with 75 percent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/46/20194?source=see_link\">",
"     silver nitrate",
"    </a>",
"    sticks. The applicator tip is applied to a small area surrounding the bleeding site with care to avoid intact skin, starting proximally (",
"    <a class=\"graphic graphic_picture graphicRef61123 \" href=\"UTD.htm?40/23/41343\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef72922 \" href=\"UTD.htm?38/40/39553\">",
"     picture 3",
"    </a>",
"    ). The agent will work only on a relatively dry surface; the bleeding point itself cannot be cauterized until hemostasis is achieved either through cautery of the adjacent area, vasoconstrictive agents,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    direct pressure. Electrical cautery works equally well, but again the surface needs to be relatively dry. Both types of cautery may cause rhinorrhea and crusting. Overzealous and simultaneous bilateral cautery of the septum should be avoided because septal ulceration and perforation may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]. Some clinicians choose to use a nasal speculum to guide cautery, although it is not typically required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Matrix sealant",
"    </span>",
"    &nbsp;&mdash;&nbsp;A matrix hemostatic sealant composed of collagen-derived particles and topical bovine-derived thrombin, has been used to control acute epistaxis (eg, Floseal, Surgiflo) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/12\">",
"     12",
"    </a>",
"    ]. The matrix sealant is applied via a syringe and is hydrophilic, so it conforms well to irregular bleeding surfaces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Fibrin glue",
"    </span>",
"    &nbsp;&mdash;&nbsp;The application of fibrin glue is another method of treatment of epistaxis unresponsive to local pressure. Fibrin glue provides rapid hemostasis without nasal packing and is relatively painless compared to cauterization or nasal packing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/13\">",
"     13",
"    </a>",
"    ]. This technique is particularly useful for patients with coagulopathy or hereditary hemorrhagic telangiectasia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Fibrin glue is used less commonly now that matrix sealants are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link\">",
"     \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Nasal packing",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the bleeding is severe or if local compression and vasoconstriction are unsuccessful, the next step in management is nasal packing to tamponade local bleeding. If nasal packing is required, otolaryngology consultation is usually warranted. The otolaryngologist can place the pack and help determine the underlying cause of the bleeding. In addition, hospital admission may be required, since the need for nasal packing is suggestive of an underlying disorder that may require further attention. Nasal packing should be avoided in infants younger than one year of age because of the risk of aspiration. However, serious epistaxis warranting nasal packing in this age group is rare.",
"   </p>",
"   <p>",
"    Nasal packing is rarely needed for children, but if it is, rapid placement is critical to its success. Nasal packing may be preceded by the application of topical anesthesia (eg, 2 percent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    mixed 50:50 with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/22/35168?source=see_link\">",
"     oxymetazoline",
"    </a>",
"    , 0.1",
"    <span class=\"nowrap\">",
"     mL/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/4\">",
"     4",
"    </a>",
"    ]. However, if the bleeding is brisk, this may not be possible. Nasal packing is most easily accomplished with a pediatric nasal sponge (eg, Merocel, Rhinocell) The pack is inserted directly along the floor of the nasal cavity and is expanded with 10 to 20 mL of saline. The open-cell polymer pack will need to be removed in one to five days.",
"   </p>",
"   <p>",
"    Alternative absorbable nasal packs are made of gelatin (Gelfoam), which liquefies in the nose in two to five days; oxidized, regenerated cellulose (Surgicel), which dissolves in approximately seven days; or microfibrillar collagen (Avitene).",
"   </p>",
"   <p>",
"    These absorbable agents are preferred in patients in whom minimal pressure is needed for bleeding control [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/17\">",
"     17",
"    </a>",
"    ], or in whom standard nasal packing might promote more bleeding by destroying the nasal mucosa (eg, patients with bleeding disorders and immune deficiencies, and those requiring renal dialysis) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A less technology-intensive but more technique-dependent approach to nasal packing is to use Vaseline or Xeroform gauze dispensed in 72-inch lengths. The procedure is performed by laying the gauze in an accordion fashion throughout the nasal cavity. Gauze packing provides a tight pack, but requires removal, is uncomfortable, and may create additional mucosal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, it is an acceptable method but the alternatives above are preferred, if available.",
"   </p>",
"   <p>",
"    Nonabsorbable packs are typically left in place for one to five days and then removed by the otolaryngologist. The practitioner and patient should be prepared for possible additional bleeding at the time of pack removal. While the pack is in place, and even after its removal, there is a small risk of staphylococcal toxic shock syndrome. Neither prophylactic systemic antibiotics nor impregnation of nasal packing with antibiotic ointment eradicate nasal carriage or reliably prevent toxic shock syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/20-24\">",
"     20-24",
"    </a>",
"    ]. Thus, antibiotics are not routinely recommended. However, antibiotics may be prescribed if there is evidence of an underlying sinus infection (",
"    <a class=\"graphic graphic_table graphicRef83454 \" href=\"UTD.htm?31/10/31917\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42921?source=see_link&amp;anchor=H3#H3\">",
"     \"Acute bacterial rhinosinusitis in children: Microbiology and treatment\", section on 'Empiric antibiotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After anterior nasal packing is placed, the oropharynx must be examined to confirm adequate hemostasis. Posterior bleeding may be present if patients report swallowing blood after anterior nasal packing has been placed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/3\">",
"     3",
"    </a>",
"    ]. Evaluation for posterior bleeding requires consultation with an otolaryngologist, and possibly placement of posterior nasal packing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Advanced techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the extremely rare case where bleeding cannot be controlled by one of the methods described above, more aggressive therapeutic procedures may be necessary as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Nasal balloon catheters",
"      </strong>",
"      &ndash; Placement of nasal balloon catheters is relatively straight forward and can be accomplished emergently by any trained clinician. A single or double balloon catheter (eg, a Foley catheter, Rapid Rhino, Epistat, Epi-Max, Post-stat, or Post-stop) can be inserted. The technique for insertion is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1690?source=see_link&amp;anchor=H29#H29\">",
"       \"Approach to the adult with epistaxis\", section on 'Balloon catheters'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1690?source=see_link&amp;anchor=H30#H30\">",
"       \"Approach to the adult with epistaxis\", section on 'Foley catheter'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Embolization of the internal maxillary artery",
"      </strong>",
"      &ndash; Embolization of the internal maxillary artery has been reported to be successful in cases of intractable epistaxis unresponsive to other treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/25\">",
"       25",
"      </a>",
"      ]. An otolaryngologist with pediatric expertise should guide the decision to perform embolization versus operative control.",
"      <br/>",
"      <br/>",
"      Embolization also has been useful in controlling bleeding in patients with hereditary hemorrhagic telangiectasia, juvenile angiofibromas, hemangiomas, arterial-venous malformations, and traumatic arterial lacerations [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/18\">",
"       18",
"      </a>",
"      ]. In general, morbidity is low when embolization is performed by an experienced radiologist. However, most studies report a slightly increased rate of major complications, usually stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Operative control",
"      </strong>",
"      &ndash; Surgery (transnasal endoscopy and direct cautery or arterial ligation) is necessary in some cases, particularly those in which the bleeding is of posterior or superior origin and should be performed by an otolaryngologist with pediatric expertise [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Additional evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with refractory or prolonged (&gt;30 minutes) epistaxis, the cause and source of the bleeding must be reconsidered. Additional studies that may be helpful in patients with refractory or prolonged epistaxis include (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=see_link\">",
"     \"Evaluation of epistaxis in children\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Otolaryngology consultation for evaluation and management of severe bleeding or persistent bleeding",
"     </li>",
"     <li>",
"      Evaluation for a bleeding disorder including measurement of platelet count, prothrombin time, and activated partial thromboplastin time. Consultation with a pediatric hematologist is also suggested for patients with refractory epistaxis.",
"     </li>",
"     <li>",
"      Computed tomography with contrast or magnetic resonance imaging if a mass lesion is suspected",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Special cases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with underlying local or systemic factors that predispose to epistaxis often require an individualized approach to management",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    specialty consultation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4043810\">",
"    <span class=\"h3\">",
"     Coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with von Willebrand disease (VWD) and epistaxis may be packed with gelatin or regenerated cellulose that has been soaked in",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/62/2020?source=see_link\">",
"     topical thrombin",
"    </a>",
"    . If bleeding persists, consultation with a hematologist is advised to determine the best therapy. Options include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"     desmopressin",
"    </a>",
"    (dDAVP), von Willebrand factor replacement,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/18/44324?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    , or intravenous IgG (IVIG) depending upon whether the patient is known to respond to dDAVP or has inherited or acquired VWD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of von Willebrand disease\", section on 'General considerations of therapy'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    In addition to local measures for prolonged bleeding, blood factors or platelets should be administered to patients who have other bleeding disorders that can be treated with such products, such as nonimmune thrombocytopenia and hemophilia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=see_link\">",
"     \"Treatment of hemophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with immune thrombocytopenia often respond to local measures if platelet counts are &gt;20,000. Life-threatening epistaxis warrants emergent consultation with a hematologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/53/37721?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in children\", section on 'Life-threatening bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4043818\">",
"    <span class=\"h3\">",
"     Anticoagulated patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    cessation and reversal of anticoagulation are controversial in epistaxis situations. Patients who are in the therapeutic range for their specific indication and in whom hemostasis is achieved may be safely maintained on their warfarin regimen. The specialty physician who ordered the anticoagulant medications should be consulted before reversal of anticoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4043826\">",
"    <span class=\"h3\">",
"     Hereditary hemorrhagic telangiectasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epistaxis can be difficult to control in patients with hereditary hemorrhagic telangiectasia (HHT). The friable lesions in these patients appear to bleed more with treatment than without. Cautery should be avoided, and when packing is necessary, absorbable packing is preferable to gauze packing. Fibrin glue has been reported to be successful in these patients. Treatment with the potassium titanyl phosphate (KTP) laser and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/44/20166?source=see_link\">",
"     bevacizumab",
"    </a>",
"    have been reported to be effective in adults with HHT, but the safety and efficacy in children have not been established. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Fibrin glue'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link&amp;anchor=H21#H21\">",
"     \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\", section on 'Localized bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4043834\">",
"    <span class=\"h3\">",
"     Juvenile nasopharyngeal angiofibroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Juvenile nasopharyngeal angiofibroma is treated with surgery or radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/17\">",
"     17",
"    </a>",
"    ]. Preoperative embolization is frequently performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Discharge instructions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discharge instructions for children with epistaxis should include education regarding home management, indications for reevaluation, and prevention of recurrent episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with nasal packing in place should follow-up with an otolaryngologist within one to five days for packing removal and reexamination. Children who have undergone cauterization of the nasal septum only need to follow-up with their primary care physician or otolaryngologist if the epistaxis recurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Home management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple compression may be used to control nosebleeds at home. Parents and patients may require explicit instructions and frequent review of the proper technique, as described above. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Direct compression'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Prevention of recurrent benign epistaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Application of pressure to the Kiesselbach plexus is crucial, since this site is the source of most nosebleeds in children. Some patients and parents believe that they should compress the nasal bones between the eyes, but compression between the eyes does not affect the source of bleeding. Some families also believe that ice should be applied to the neck, forehead, or nasal bones, but at this time there is no evidence that this helps (on the other hand, it probably does not hurt) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Families may also try to induce vasoconstriction with over-the-counter decongestants (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/22/35168?source=see_link\">",
"     oxymetazoline",
"    </a>",
"    ), but the family should be warned that oxymetazoline should be used sparingly and for a maximum of three days to avoid rebound hyperemia with recurrent epistaxis.",
"   </p>",
"   <p>",
"    If simple compression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vasoconstriction are not successful in controlling bleeding, then further measures must be taken, usually in an emergency department setting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PREVENTION OF RECURRENT BENIGN EPISTAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, recurrent episodes of benign epistaxis are more common than epistaxis that cannot be controlled. Recurrence of epistaxis can be prevented only if the many causes are considered and appropriate preventive measures are instituted. To ensure that recurrent epistaxis is benign, children with recurrent epistaxis should be examined closely for a foreign body or nasal mass; bleeding disorders should be excluded in the appropriate clinical setting and the suggested laboratory evaluation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=see_link&amp;anchor=H5#H5\">",
"     \"Evaluation of epistaxis in children\", section on 'Examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=see_link&amp;anchor=H9#H9\">",
"     \"Evaluation of epistaxis in children\", section on 'Laboratory evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27912?source=see_link\">",
"     \"Epidemiology and etiology of epistaxis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest humidification of the nasal mucosa and prevention of local trauma as first-line therapies for prevention of recurrent benign epistaxis in children. Running a warm or cold humidifier containing water without additives in the child's bedroom during the night can be helpful, but may be contraindicated in the child with severe allergies or pulmonary problems. Alternatively, saline nose spray, commonly available over-the-counter in most drug stores, can be applied to the nose two to four times a day. In addition, prevention of local trauma by discouraging nose picking, keeping fingernails closely trimmed, and use of protective face-gear, as indicated, during sports participation is appropriate for all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional measures vary, depending upon the suspected underlying cause of epistaxis, and include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cautery",
"      </strong>",
"      &ndash; Cauterization of the septum with 75 percent",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/46/20194?source=see_link\">",
"       silver nitrate",
"      </a>",
"      , as described above, may be a temporizing measure if prominent vessels are seen in the Kiesselbach plexus. We avoid the use of 95 percent silver nitrate for cautery. In one trial of 101 children that compared 75 versus 95 percent silver nitrate, application of 75 percent silver nitrate was clinically significantly more effective at two weeks than 95 percent silver nitrate (88 versus 65 percent complete resolution of bleeding, respectively) and was also significantly less painful [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cautery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Topical therapy",
"      </strong>",
"      &ndash; Various topical treatments (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/9/44180?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      -",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/42/29348?source=see_link\">",
"       neomycin",
"      </a>",
"      cream or triple antibiotic ointment) have been advocated to reduce chronic inflammation caused by",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      which may play a role in recurrent epistaxis. These agents may be applied to the mucosa of the nasal septum, potentially decreasing the propensity to bleed. Application is typically recommended one to two times per day. Care must be taken that the applicator (often a cotton swab) does not traumatize the mucosa of the nose. However, the indications and duration of this therapy are unclear and long-term benefit has",
"      <strong>",
"       not",
"      </strong>",
"      been established [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/29\">",
"       29",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Petroleum jelly has been recommended in the past, but has no benefit over simple observation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Patients with allergic rhinitis",
"      </strong>",
"      &ndash; In patients with allergic rhinitis, nasal corticosteroids should be discontinued. However, because allergic rhinitis can contribute to epistaxis independent of topical corticosteroid therapy, alternative therapy should be provided (eg, oral antihistamines). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"       \"Pharmacotherapy of allergic rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Patients with upper respiratory tract infection",
"      </strong>",
"      &ndash; Recurrent epistaxis during an acute upper respiratory tract infection or an exacerbation of allergic rhinitis occasionally may be prevented by using anti-histamine decongestant preparations in patients older than two years of age, although care must be taken to avoid excessive drying of the nasal mucosa [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The best treatment for recurrent epistaxis in children is not known. Limited evidence suggests that cautery with topical therapy or topical therapy alone may be helpful in the short-term but may not provide improved long-term resolution of recurrent epistaxis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of five small trials evaluated the short term effectiveness of various interventions for recurrent idiopathic epistaxis in 468 children [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/31\">",
"       31",
"      </a>",
"      ]. Interventions included",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/46/20194?source=see_link\">",
"       silver nitrate",
"      </a>",
"      cautery, application of antiseptic cream containing 0.5 percent",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/42/29348?source=see_link\">",
"       neomycin",
"      </a>",
"      and 0.1 percent",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/9/44180?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      (eg, Naseptin), and application of petroleum jelly. Resolution of epistaxis at four to eight weeks in children undergoing cautery, topical therapy, or both varied from approximately 50 to 98 percent compared with 29 to 44 percent in two studies with a total of 94 control patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/30,32\">",
"       30,32",
"      </a>",
"      ]. The highest reported success (98 percent) occurred in 49 children with visible anterior nasal vessels who received cautery with 75 percent silver nitrate followed by application of chlorhexidine-neomycin cream (0.5 percent neomycin and 0.1 percent chlorhexidine) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/28,31\">",
"       28,31",
"      </a>",
"      ]. Application of petroleum jelly in a prospective trial of 105 children was not significantly different from control [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one trial that was included in the systematic review and compared the frequency of recurrent epistaxis in 93 children with visible septal blood vessels who received either cautery with 75 percent",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/46/20194?source=see_link\">",
"       silver nitrate",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/9/44180?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      -",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/42/29348?source=see_link\">",
"       neomycin",
"      </a>",
"      cream or chlorhexidine-neomycin cream alone, more patients treated with cautery plus antiseptic cream had clinically significantly reduced frequency and severity of bleeding at four weeks than those using cream alone (91 versus 70 percent, respectively), but complete resolution of recurrent epistaxis at eight weeks was not statistically different (46 versus 30 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a five-year follow-up study of 60 of 88 children who initially underwent treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/9/44180?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      -",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/42/29348?source=see_link\">",
"       neomycin",
"      </a>",
"      cream or chlorhexidine-neomycin cream and cautery, 65 percent were found to still have problems with epistaxis and children who had undergone cautery had the highest frequency of recurrent epistaxis (77 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the optimal approach for long-term prevention of bleeding in children with recurrent idiopathic epistaxis is unclear and further research is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most episodes of nose bleeding in children resolve spontaneously or with compression of the nasal alae as described above. Recurrent idiopathic epistaxis appears to resolve with time and is uncommon in children older than 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26536/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/50/1826?source=see_link\">",
"       \"Patient information: Nosebleeds (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/10/19617?source=see_link\">",
"       \"Patient information: Nosebleeds (epistaxis) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid assessment of general appearance, vital signs, airway stability, and mental status are necessary to identify children with epistaxis who have respiratory or hemodynamic instability and require airway intervention",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fluid resuscitation. Identification of the source of bleeding and initiation of bleeding control measures follow immediately. Patients with an acute or past medical history of bleeding disorders may warrant special therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Emergency treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Special cases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most episodes of epistaxis in children respond to simple compression and do not require specialty referral. Consultation with otolaryngologist or other specialist is indicated for patients with local abnormalities, suspected posterior bleeding or occult nasal lesions, severe epistaxis, or frequent recurrence. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications for consultation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of epistaxis entails control of acute hemorrhage and prevention of recurrences by controlling underlying local or systemic disease processes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Acute management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Active bleeding usually responds to simple compression",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      topical application of a vasoconstricting agent. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Direct compression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Active bleeding that does not respond to compression may require cautery, application of a hemostatic agent, or more aggressive measures. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Other techniques'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Advanced techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with prolonged or refractory bleeding, the cause and source of the bleeding must be carefully evaluated. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Additional evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal management for long-term control of bleeding in children with recurrent benign epistaxis is unknown. We suggest humidification of the nasal mucosa and prevention of local trauma as first-line therapies for prevention of recurrent benign epistaxis in children (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Other treatment options include cautery in children with prominent anterior nasal septal blood vessels and topical therapies; however, the long-term efficacy of such approaches is not established. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Prevention of recurrent benign epistaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Discharge instructions for children with epistaxis should include education regarding home management, indications for reevaluation, and prevention of recurrent episodes. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Discharge instructions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/1\">",
"      Brown NJ, Berkowitz RG. Epistaxis in healthy children requiring hospital admission. Int J Pediatr Otorhinolaryngol 2004; 68:1181.",
"     </a>",
"    </li>",
"    <li>",
"     Nadel F, Henretig FM. Epistaxis. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippicott Williams &amp; Wilkins, Philadelphia 2006. p.263.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/3\">",
"      Alvi A, Joyner-Triplett N. Acute epistaxis. How to spot the source and stop the flow. Postgrad Med 1996; 99:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/4\">",
"      Bernius M, Perlin D. Pediatric ear, nose, and throat emergencies. Pediatr Clin North Am 2006; 53:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/5\">",
"      Guarisco JL, Graham HD 3rd. Epistaxis in children: causes, diagnosis, and treatment. Ear Nose Throat J 1989; 68:522, 528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/6\">",
"      Higgins TS, Hwang PH, Kingdom TT, et al. Systematic review of topical vasoconstrictors in endoscopic sinus surgery. Laryngoscope 2011; 121:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/7\">",
"      Groudine SB, Hollinger I, Jones J, DeBouno BA. New York State guidelines on the topical use of phenylephrine in the operating room. The Phenylephrine Advisory Committee. Anesthesiology 2000; 92:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/8\">",
"      Kucik CJ, Clenney T. Management of epistaxis. Am Fam Physician 2005; 71:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/9\">",
"      Calder N, Kang S, Fraser L, et al. A double-blind randomized controlled trial of management of recurrent nosebleeds in children. Otolaryngol Head Neck Surg 2009; 140:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/10\">",
"      Makura ZG, Porter GC, McCormick MS. Paediatric epistaxis: Alder Hey experience. J Laryngol Otol 2002; 116:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/11\">",
"      McGarry G. Nosebleeds in children. Clin Evid 2005; :399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/12\">",
"      Douglas R, Wormald PJ. Update on epistaxis. Curr Opin Otolaryngol Head Neck Surg 2007; 15:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/13\">",
"      Vaiman M, Segal S, Eviatar E. Fibrin glue treatment for epistaxis. Rhinology 2002; 40:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/14\">",
"      Farnan TB, Gallagher G, Scally CM. A novel treatment for patients with hereditary haemorrhagic telangiectasia. J Laryngol Otol 2002; 116:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/15\">",
"      Vaiman M, Martinovich U, Eviatar E, et al. Fibrin glue in initial treatment of epistaxis in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease). Blood Coagul Fibrinolysis 2004; 15:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/16\">",
"      Walshe P. The use of fibrin glue to arrest epistaxis in the presence of a coagulopathy. Laryngoscope 2002; 112:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/17\">",
"      Mulbury PE. Recurrent epistaxis. Pediatr Rev 1991; 12:213.",
"     </a>",
"    </li>",
"    <li>",
"     Edelstein DR, Khabie N. Epistaxis. In: Primary Pediatric Care, 4th, Hoekelman RA (Ed), Mosby, St. Louis 2001. p.1058.",
"    </li>",
"    <li>",
"     Manning SC, Culbertson MC. Epistaxis. In: Pediatric Otolaryngology, 4th, Bluestone CD, Casselbrant ML, Stool SE, et al (Eds), Saunders, Philadelphia 2002. p.925.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/20\">",
"      Weber R, Keerl R, Hochapfel F, et al. Packing in endonasal surgery. Am J Otolaryngol 2001; 22:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/21\">",
"      Abram AC, Bellian KT, Giles WJ, Gross CW. Toxic shock syndrome after functional endonasal sinus surgery: an all or none phenomenon? Laryngoscope 1994; 104:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/22\">",
"      de Vries N, van der Baan S. Toxic shock syndrome after nasal surgery: is prevention possible? A case report and review of the literature. Rhinology 1989; 27:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/23\">",
"      Jacobson JA, Stevens MH, Kasworm EM. Evaluation of single-dose cefazolin prophylaxis for toxic shock syndrome. Arch Otolaryngol Head Neck Surg 1988; 114:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/24\">",
"      Graham DR, O'Brien M, Hayes JM, Raab MG. Postoperative toxic shock syndrome. Clin Infect Dis 1995; 20:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/25\">",
"      Goldman JL, Winstead W, Ganzel TM. Embolization as the definitive treatment of epistaxis in the pediatric patient. Ear Nose Throat J 1995; 74:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/26\">",
"      Christensen NP, Smith DS, Barnwell SL, Wax MK. Arterial embolization in the management of posterior epistaxis. Otolaryngol Head Neck Surg 2005; 133:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/27\">",
"      Teymoortash A, Sesterhenn A, Kress R, et al. Efficacy of ice packs in the management of epistaxis. Clin Otolaryngol Allied Sci 2003; 28:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/28\">",
"      Glynn F, Amin M, Sheahan P, Mc Shane D. Prospective double blind randomized clinical trial comparing 75% versus 95% silver nitrate cauterization in the management of idiopathic childhood epistaxis. Int J Pediatr Otorhinolaryngol 2011; 75:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/29\">",
"      Robertson S, Kubba H. Long-term effectiveness of antiseptic cream for recurrent epistaxis in childhood: five-year follow up of a randomised, controlled trial. J Laryngol Otol 2008; 122:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/30\">",
"      Loughran S, Spinou E, Clement WA, et al. A prospective, single-blind, randomized controlled trial of petroleum jelly/Vaseline for recurrent paediatric epistaxis. Clin Otolaryngol Allied Sci 2004; 29:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/31\">",
"      Qureishi A, Burton MJ. Interventions for recurrent idiopathic epistaxis (nosebleeds) in children. Cochrane Database Syst Rev 2012; 9:CD004461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26536/abstract/32\">",
"      Kubba H, MacAndie C, Botma M, et al. A prospective, single-blind, randomized controlled trial of antiseptic cream for recurrent epistaxis in childhood. Clin Otolaryngol Allied Sci 2001; 26:465.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6484 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_58_26536=[""].join("\n");
var outline_f25_58_26536=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EMERGENCY TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS FOR CONSULTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ACUTE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Direct compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Cautery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Matrix sealant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Fibrin glue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Nasal packing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Advanced techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Additional evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Special cases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4043810\">",
"      - Coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4043818\">",
"      - Anticoagulated patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4043826\">",
"      - Hereditary hemorrhagic telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4043834\">",
"      - Juvenile nasopharyngeal angiofibroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Discharge instructions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Home management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PREVENTION OF RECURRENT BENIGN EPISTAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6484\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6484|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/3/33842\" title=\"diagnostic image 1\">",
"      Juvenile angiofibroma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6484|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/20/25920\" title=\"picture 1\">",
"      Epistaxis control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/23/41343\" title=\"picture 2\">",
"      Cautery of epistaxis with a silver nitrate stick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/40/39553\" title=\"picture 3\">",
"      Silver nitrate cautery of anterior epistaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6484|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/10/31917\" title=\"table 1\">",
"      Antimicrobial regimens sinusitis children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42921?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Microbiology and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1690?source=related_link\">",
"      Approach to the adult with epistaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27912?source=related_link\">",
"      Epidemiology and etiology of epistaxis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=related_link\">",
"      Evaluation of epistaxis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=related_link\">",
"      Hypovolemic shock in children: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/50/1826?source=related_link\">",
"      Patient information: Nosebleeds (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/10/19617?source=related_link\">",
"      Patient information: Nosebleeds (epistaxis) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/53/37721?source=related_link\">",
"      Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=related_link\">",
"      Treatment of hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=related_link\">",
"      Treatment of von Willebrand disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_58_26537="Microbiology and antibiotic management of chronic rhinosinusitis";
var content_f25_58_26537=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology and antibiotic management of chronic rhinosinusitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/58/26537/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26537/contributors\">",
"     Itzhak Brook, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/58/26537/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26537/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26537/contributors\">",
"     Jonathan Corren, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/58/26537/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26537/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/58/26537/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic rhinosinusitis (CRS) is defined as a complex inflammatory condition involving the paranasal sinuses and linings of the nasal passages that lasts 12 weeks or longer, despite attempts at medical management. The diagnostic criteria for CRS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link&amp;anchor=H39#H39\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factors that may contribute to the development of CRS include exposure to allergens and irritants, defects in mucociliary function, immunodeficiency, and infections with bacteria, viruses, and fungi. The common endpoint is local inflammation and swelling of the sinonasal mucosa and impairment of normal sinus drainage. The recognition that CRS represents a multifactorial inflammatory disorder, rather than simply a persistent bacterial infection, has led to the reexamination of the role of antimicrobials in CRS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The medical management of CRS is now focused upon controlling the inflammation that predisposes patients to obstruction, thus minimizing the incidence of infections. Despite this, all forms of CRS are associated with poor sinus drainage and secondary bacterial infections. Most patients require antibiotics to clear infections at the outset of therapy, and intermittently thereafter to treat acute exacerbations of CRS. However, the role of these agents beyond these two indications remains an area of investigation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CRS can be divided into three distinct clinical syndromes, since the underlying causes and contributing factors, as well as the response to medical or surgical management, are different:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CRS with nasal polyposis",
"     </li>",
"     <li>",
"      Allergic fungal rhinosinusitis",
"     </li>",
"     <li>",
"      CRS without nasal polyposis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goals of medical therapy for CRS are to reduce mucosal edema, promote sinus drainage, and eradicate infections that may be present. This often requires a combination of topical or oral glucocorticoids, antibiotics, and nasal irrigation. When these measures fail, the patient should be referred to an otolaryngologist for consideration of sinus surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evolution of the upper respiratory flora in rhinosinusitis and the microbiology and antibiotic management of chronic rhinosinusitis will be reviewed here. The clinical manifestations, diagnosis, classification, and treatment (other than antimicrobial therapy) of CRS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute rhinosinusitis, allergic rhinitis, and fungal sinusitis are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link\">",
"     \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6775?source=see_link\">",
"     \"Pathogenesis of allergic rhinitis (rhinosinusitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8775?source=see_link\">",
"     \"Fungal rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Evolution of bacterial flora",
"    </span>",
"    &nbsp;&mdash;&nbsp;The microbiology of rhinosinusitis evolves through several phases. The early phase (acute rhinosinusitis) is usually caused by a viral infection (most commonly rhinovirus, adenovirus, influenza, or parainfluenza) that generally lasts up to 10 days; complete recovery occurs in 99 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/1\">",
"     1",
"    </a>",
"    ]. In occasional patients, a secondary acute bacterial infection develops. The most common bacterial causes of acute rhinosinusitis are aerobes such as Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If resolution from acute rhinosinusitis does not occur, colonizing anaerobic oropharyngeal flora and aerobes, such as Staphylococcus aureus, become predominant over time [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/2-11\">",
"     2-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Anaerobes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prominence of anaerobes in CRS has been demonstrated in both children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/4,12,13\">",
"     4,12,13",
"    </a>",
"    ] and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/5-8,10,11,14-20\">",
"     5-8,10,11,14-20",
"    </a>",
"    ]. In a series of repeated endoscopic aspirations of sinus secretions from five patients with acute maxillary rhinosinusitis who did not respond to therapy, growth of resistant anaerobes occurred over time, including Fusobacterium nucleatum, pigmented Prevotella spp, Porphyromonas spp, and Peptostreptococcus spp [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several factors may contribute to the emergence of anaerobes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Selective pressure of antimicrobial agents that enable resistant organisms to survive.",
"     </li>",
"     <li>",
"      Mucosal inflammation and edema decrease the blood supply to the sinuses, which leads to reduced oxygen tension [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Aerobic bacteria consume oxygen and decrease the pH of the sinuses, which promotes the growth of anaerobes [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Expression of some anaerobic virulence factors, such as a capsule, is slow [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Aerobes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aerobic gram-negative bacilli and Staphylococcus aureus (including methicillin-resistant S. aureus) have also been implicated in CRS. Polymicrobial infection is common and may be synergistic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aerobes (in the absence of anaerobes) have been implicated in the pathogenesis of CRS. Most studies in which only aerobes were cultured from CRS patients did not use sufficiently careful techniques for the recovery of anaerobes; however, even carefully performed studies sometimes fail to identify anaerobes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, it is possible that some patients with CRS have a predominance of aerobes, or a mixture of aerobes and anaerobes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gram-negative bacilli &mdash; Aerobic gram-negative bacilli, such as Pseudomonas aeruginosa, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter spp, and Escherichia coli, have been implicated as etiologic agents of CRS, especially in patients with underlying conditions such as cystic fibrosis (in the case of Pseudomonas) or diabetes, and in immunocompromised hosts (eg, stem cell transplant recipients, neutropenics, or HIV patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/26-30\">",
"       26-30",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Since these organisms are rarely found in cultures of the middle meatus obtained from normal individuals, their isolation from symptomatic patients suggests a pathogenic role. However, their presence could also be due to selection pressure following administration of antimicrobial therapy. In one study, aerobic gram-negative rods were recovered more often in patients who had had previous surgery or sinus irrigation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/27\">",
"       27",
"      </a>",
"      ]. P. aeruginosa was also more common in patients receiving systemic steroids. Other studies have also noted this shift toward gram-negative organisms in patients who have been extensively and repeatedly treated with antibiotics or have undergone sinus surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/28,31,32\">",
"       28,31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Staphylococcus aureus &mdash; S. aureus, including methicillin-resistant S. aureus (MRSA), colonizes the nasal mucosa of a small percentage of normal individuals, and is found more frequently in individuals with rhinosinusitis, especially in those with CRS [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. The incidence of MRSA is increasing not only as a colonizer of the sinuses, but also as a cause of both acute and chronic rhinosinusitis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/35\">",
"       35",
"      </a>",
"      ]. S. aureus is also found more frequently in diabetics with CRS [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=see_link\">",
"       \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=see_link\">",
"       \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Staphylococcus epidermidis &mdash; The pathogenicity of low-virulence organisms, such as S. epidermidis (coagulase-negative staphylococci), a colonizer of the nasal cavity, is questionable [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Specific clinical settings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Nasal polyposis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the microbiology of infections in patients with CRS with nasal polyposis suggest that the organisms involved are similar to those in CRS without nasal polyposis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. CRS with and without nasal polyposis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Acute exacerbation of chronic rhinosinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute exacerbation of CRS (AECRS) represents a sudden worsening of the baseline manifestations of CRS, which may involve new symptoms or an accentuation of existing symptoms. The acute, but not the chronic, symptoms typically resolve completely between occurrences. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The microbiology of maxillary AECRS was investigated by performing serial endoscopic aspirations in seven patients who had &ge;3 episodes of maxillary AECRS per year, each lasting &ge;10 days, with complete resolution of their acute symptoms between episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/40\">",
"     40",
"    </a>",
"    ]. The patients were followed over a period of 125 to 242 days.",
"   </p>",
"   <p>",
"    Two to four bacterial isolates were recovered from each sample. The aerobes isolated were H. influenzae, S. pneumoniae, M. catarrhalis, S. aureus, and K. pneumoniae, while the anaerobes included pigmented Prevotella spp, Porphyromonas spp, Peptostreptococcus spp, Fusobacterium spp, and Propionibacterium acnes. A change in the species isolated from individual patients was noted in all sequential cultures and an increase in antimicrobial resistance over time was noted in six subjects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Odontogenic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Odontogenic sinusitis is a well-recognized entity and accounts for approximately 10 to 12 percent of cases of maxillary sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/41\">",
"     41",
"    </a>",
"    ] and may be either acute or chronic. The microorganisms recovered from odontogenic infections generally reflect the oral flora. The association between periapical abscesses and rhinosinusitis was established in a study of pus aspirates from five periapical abscesses of the upper jaw and their corresponding maxillary sinuses [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16873?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections\", section on 'Anatomic considerations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A polymicrobial flora was found in all instances, and the number of isolates grown from each specimen ranged from two to five. Anaerobes were recovered from all specimens. The predominant anaerobes grown were Prevotella spp, Porphyromonas spp, Peptostreptococcus spp, and Fusobacterium nucleatum. Concordance in the microbiological findings between periapical abscess and the maxillary sinus flora was found in all instances, suggesting contiguous spread.",
"   </p>",
"   <p>",
"    Another study evaluated the microbiology of 20 patients with acute rhinosinusitis and 28 patients with chronic maxillary sinusitis associated with odontogenic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/29\">",
"     29",
"    </a>",
"    ]. Polymicrobial infection was common, with an average of 3.4 isolates recovered per specimen. A total of 98 isolates were recovered from the 28 cases of CRS: 21 aerobic and facultative and 77 anaerobic. Aerobes alone were recovered in 3 (11 percent), anaerobes only in 11 (39 percent), and mixed aerobic and anaerobic bacteria in 14 (50 percent). The predominant anaerobes in both acute and chronic infection were Peptostreptococcus spp, Fusobacterium spp, and pigmented Prevotella and Porphyromonas spp, all members of the oropharyngeal flora that predominate in periodontal and endodontal infection. The most commonly isolated aerobes were alpha-hemolytic streptococci, microaerophilic streptococci, and S. aureus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Concurrent chronic otitis media in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study correlated the microbiology of concurrent chronic otitis media with effusion and maxillary sinusitis in 32 children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/12\">",
"     12",
"    </a>",
"    ]. Two-thirds of the patients had a bacterial etiology. The most common isolates were H. influenzae (9 isolates), S. pneumoniae (7 isolates), Prevotella spp (8 isolates), and Peptostreptococcus spp (6 isolates). Microbiologic concordance between the ear and sinus was found in 22 (69 percent) culture-positive patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhinosinusitis occurs in a range of immunocompromised hosts including those with neutropenia, diabetes mellitus, critical illness, or HIV, and may be either acute or chronic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fungi and Pseudomonas aeruginosa are the most common causes of rhinosinusitis in neutropenic patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/30,43\">",
"       30,43",
"      </a>",
"      ]. When fungal rhinosinusitis is present, Aspergillus spp is frequently the causative organism, although zygomycetes (eg, Mucor, Rhizopus), Alternaria, and other molds have been implicated [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/43\">",
"       43",
"      </a>",
"      ]. Fungal rhinosinusitis is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8775?source=see_link\">",
"       \"Fungal rhinosinusitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with diabetes mellitus, fungi and S. aureus, streptococci and gram-negative enteric bacteria are the most common isolates [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with cystic fibrosis, P. aeruginosa often causes rhinosinusitis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Common causative organisms of rhinosinusitis in patients with HIV include P. aeruginosa, S. aureus, streptococci, anaerobes, and fungi (Aspergillus, Cryptococcus, and Rhizopus) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/30,45\">",
"       30,45",
"      </a>",
"      ]. Rare causes of rhinosinusitis in AIDS patients include cytomegalovirus; non-tuberculous mycobacteria, such as Mycobacterium kansasii; and parasites, such as Microsporidium, Cryptosporidium and Acanthamoeba [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/30,46,47\">",
"       30,46,47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of CRS, such as periorbital cellulitis, brain abscess, subdural empyema, and epidural abscess are often polymicrobial and include both aerobes and anaerobes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/9,48,49\">",
"     9,48,49",
"    </a>",
"    ]. These infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link\">",
"     \"Orbital cellulitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of brain abscess\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32438?source=see_link\">",
"     \"Treatment and prognosis of brain abscess\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=see_link\">",
"     \"Epidural abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Fungi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungi may cause allergic fungal rhinosinusitis, fungal colonization, or invasive fungal sinusitis. Allergic fungal rhinosinusitis (AFRS) refers to CRS that is accompanied by sinus opacification with \"allergic mucin,\" or thick, inspissated mucus containing degranulating eosinophils and fungal hyphae. Fungal colonization may also cause similar symptoms as are seen in CRS. In contrast, invasive fungal sinusitis typically occurs in immunocompromised hosts and can be rapidly progressive or indolent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'Allergic fungal rhinosinusitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8775?source=see_link\">",
"     \"Fungal rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of medical therapy for CRS is to promote sinus drainage, reduce chronic inflammation, and eradicate infecting pathogens. This often requires a combination of topical or oral glucocorticoids, antibiotics, and nasal irrigation. When these measures fail, the patient should be referred to an otolaryngologist for consideration of sinus surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Efficacy of antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence that antibiotics, as a single therapy, are beneficial in the treatment of CRS. Instead, a comprehensive approach to medical management, which includes antimicrobials combined with topical or systemic glucocorticoids, and sometimes other agents, is now encouraged. Studies examining the effects of comprehensive medical therapy are lacking, although most experts believe that antimicrobials are an important component of therapy for this disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One placebo-controlled trial in 64 patients with CRS evaluated monotherapy with the macrolide roxithromycin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/50\">",
"     50",
"    </a>",
"    ]. After 12 weeks of therapy, patients reported small but statistically significant benefits compared with placebo on the primary outcome measure of the patient's subjective perception of improvement or worsening. A potential concern is that macrolides have antiinflammatory effects; thus, the benefits with roxithromycin may have been unrelated to its antimicrobial effects. In addition, the duration of therapy was substantially longer than the usually recommended period of three weeks. A 2011 systematic review identified only this single trial as being of adequate quality for assessing the efficacy of antibiotics for CRS without nasal polyposis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other randomized trials have compared different antibiotics and generally found similar cure rates between antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. Although observational studies have suggested that antibiotics with anaerobic coverage might provide greater efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/10,56\">",
"     10,56",
"    </a>",
"    ], this was not seen in randomized trials. However, in one of the randomized trials of more than 200 adults with CRS, the relapse rate was significantly higher in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    group compared with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    group (7 percent versus 0 percent), suggesting that including anaerobic coverage may be important for preventing relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial compared medical therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    , nasal irrigation, nasal glucocorticoids) with surgical management in 90 patients with CRS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/57\">",
"     57",
"    </a>",
"    ]. The results were similar in the two groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, antibiotic therapy is commonly prescribed for patients who meet the diagnostic criteria for CRS, and we suggest such therapy, even though the level of evidence remains low. For most patients, antimicrobials represent one component of comprehensive medical management. It is important to note that antibiotics should be used",
"    <strong>",
"     only",
"    </strong>",
"    in patients who meet the diagnostic criteria for CRS. The diagnostic criteria for CRS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link&amp;anchor=H39#H39\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Empiric regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic regimens for CRS are generally oral since this is primarily an outpatient disease. Antibiotic selection depends upon several factors, including history of drug allergies, cost of therapy, and the incidence of",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    risk factors for beta-lactamase producing organisms and methicillin-resistant S. aureus. In addition, if antibiotics have been given over the past three months, a different class of antibiotics should be used.",
"   </p>",
"   <p>",
"    Initial selection of the appropriate antimicrobial(s) is usually empiric. Sinus cultures are generally not necessary for community-acquired infections unless a patient fails to respond to empiric therapy. The agent(s) chosen should be effective against the most likely bacterial etiologies, including both aerobic (Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis) and anaerobic pathogens (Fusobacterium nucleatum, pigmented Prevotella spp, Porphyromonas spp, and Peptostreptococcus spp). If there are risk factors for methicillin-resistant Staphylococcus aureus, then coverage for this should be included.",
"   </p>",
"   <p>",
"    Bacterial resistance to the antibiotics used for the treatment of rhinosinusitis has increased in recent years. Production of the enzyme beta-lactamase is one of the most important mechanisms of penicillin and cephalosporin resistance in the organisms that cause CRS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/5-8,58\">",
"     5-8,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26663?source=see_link&amp;anchor=H6#H6\">",
"     \"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects\", section on 'Inactivation by a bacterial enzyme'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    as the first-line regimen for most patients who meet the diagnostic criteria for CRS. For penicillin-allergic patients and those in whom methicillin-resistant Staphylococcus aureus is suspected, we suggest monotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    . There are numerous other possible regimens, as described below.",
"   </p>",
"   <p>",
"    These three regimens cover aerobic and anaerobic organisms with a single preparation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       Amoxicillin-clavulanate",
"      </a>",
"      (in children: 45",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided every 12 hours; in adults: 500 mg three times daily OR 875 mg twice daily OR two 1000 mg extended-release tablets twice daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      (in children: 20 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day orally divided every 6 to 8 hours; in adults: 300 mg four times daily or 450 mg three times daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       Moxifloxacin",
"      </a>",
"      (400 mg once daily) generally in adults only",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The two-drug regimens below include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    for coverage of anaerobes in addition to an agent with aerobic coverage. These regimens are more cumbersome and are usually reserved for refractory cases, in which the patient has been evaluated by an otolaryngologist and cultures have been obtained to guide therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      PLUS one of the following:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"       cefuroxime",
"      </a>",
"      axetil,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/21/5461?source=see_link\">",
"       cefdinir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"       cefpodoxime",
"      </a>",
"      proxetil,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      (generally in adults only),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     MRSA coverage",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is concern for MRSA, because of recovery of this organism from the involved sinus or other sites,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (see previous section for dosing) is usually the preferred initial therapy because it is also effective against anaerobes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/59\">",
"     59",
"    </a>",
"    ]. Alternatives include TMP-SMX and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    , which should be added to one of the above regimens that covers anaerobes.",
"   </p>",
"   <p>",
"    Parenteral antimicrobials effective against methicillin-resistant S. aureus (MRSA) include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Initial treatment failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The treatment of invasive MRSA infections is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Specific settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with concurrent odontogenic infections should be evaluated and treated by a dentist. Antimicrobial therapy is only an adjuvant to dental management directed at resolving the odontogenic source.",
"   </p>",
"   <p>",
"    Children with concurrent otitis media should receive one of the regimens described above. In those requiring myringotomy, culture can be performed at the time of the procedure.",
"   </p>",
"   <p>",
"    Immunocompromised hosts (eg, stem cell transplant recipients, neutropenics, HIV patients) and those with cystic fibrosis or diabetes should be treated with agents that cover Pseudomonas spp. Cultures should be obtained in these patients to guide the ultimate choice of therapy.",
"   </p>",
"   <p>",
"    The possible role of antifungal therapy for patients with allergic fungal rhinosinusitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link&amp;anchor=H31#H31\">",
"     \"Management of chronic rhinosinusitis\", section on 'Controversial treatments'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, there is only limited evidence that antibiotics are effective in the treatment of CRS. In addition, the duration of therapy has not been studied prospectively. Therapy is typically given for at least three weeks and may be extended for up to ten weeks in refractory cases. Patients who might benefit from the longer duration of ten weeks include those who have severe symptoms, long duration of illness, failure of prior courses of antibiotics, or extensive surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Initial treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture obtained directly from the sinus cavity, usually by an otolaryngology specialist, should be obtained in patients who fail to have significant improvement within five to seven days or who demonstrate signs of deterioration despite therapy. Endoscopic culture is a commonly used alternative approach to sinus puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/60\">",
"     60",
"    </a>",
"    ]. However, specimens obtained by endoscopy can become contaminated with nasal flora.",
"   </p>",
"   <p>",
"    We use the culture results to ensure that antibiotic coverage is adequate for organisms resistant to the empiric regimen. We generally suggest not narrowing the regimen to cover only the organism cultured because certain bacteria, such as anaerobes, may be difficult to isolate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Parenteral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of patients require parenteral therapy for CRS. Parenteral antimicrobials are indicated in patients who are seriously ill, undergoing surgery, or in whom compliance is questionable. Sinus cultures should be obtained from patients requiring parenteral therapy.",
"   </p>",
"   <p>",
"    Parenteral antibiotics effective against both anaerobes and aerobes include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"     ticarcillin-clavulanate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , the carbapenems (imipenem,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"     ertapenem",
"    </a>",
"    ), and the second-generation cephalosporins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17269?source=see_link\">",
"     cefotetan",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    If Pseudomonas aeruginosa is suspected, the preferred antibiotics include a fluoroquinolone (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ); a third- or fourth-generation cephalosporin with antipseudomonal activity (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ); an aminoglycoside; or the carbapenems, imipenem or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    (but not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"     ertapenem",
"    </a>",
"    , which lacks activity against Pseudomonas). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=see_link\">",
"     \"Treatment of Pseudomonas aeruginosa infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    may also be given parenterally to cover anaerobes in combination with an agent with aerobic activity. The absorption of oral metronidazole and the fluoroquinolones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ) are excellent, so these should only be given parenterally if the patient is unable to take oral medications.",
"   </p>",
"   <p>",
"    Parenteral antimicrobials effective against methicillin-resistant S. aureus (MRSA) include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    . The use of these and other agents for the treatment of invasive MRSA infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nebulized antimicrobials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nebulized antibacterial and antifungal agents are being used with increasing frequency in patients with rhinosinusitis, although they are not licensed for this indication and there are few published data to support this practice.",
"   </p>",
"   <p>",
"    Nebulized delivery may offer potential benefits over nasal sprays in the management of CRS patients, as nebulization allows for small particles to be distributed over a wider area of sinonasal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. There is inadequate evidence to support the use of antimicrobial nasal sprays for the treatment of CRS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of nebulized antimicrobials is most often applied to post-surgical patients, in whom there are wider than usual openings into the sinus cavities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/64\">",
"     64",
"    </a>",
"    ]. Some reserve nebulization for patients who have failed other therapies and are approaching either a course of intravenous antibiotics or revision surgery. Further studies are needed to define the role of nebulized (and other topical) antimicrobials in the management of CRS.",
"   </p>",
"   <p>",
"    Nebulized medications include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    , betadine, and mixed agents used for other sites such as ophthalmic solutions and preparations for genitourinary irrigation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A nonrandomized, unblinded study showed that three to six weeks of nebulized antibiotics were safe and effective in 34 of 41 (83 percent) of patients with chronic and recurrent acute infections after previous surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another nonrandomized, unblinded study of 42 patients with CRS, previous sinus surgery, and an acute infection were offered either nebulized antibiotics or standard therapy with systemic antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26537/abstract/67\">",
"     67",
"    </a>",
"    ]. A longer infection-free period (average, 17 weeks) was observed in those who received nebulized therapy as compared with standard therapy (average, 6 weeks).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/37/14930?source=see_link\">",
"       \"Patient information: Chronic sinusitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/58/42915?source=see_link\">",
"       \"Patient information: Chronic rhinosinusitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic rhinosinusitis (CRS) is defined as an inflammatory condition involving the paranasal sinuses and linings of the nasal passages that lasts 12 weeks or longer, despite attempts at medical management. The diagnostic criteria for CRS are discussed separately. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link&amp;anchor=H39#H39\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The microbiology evolves through several phases. The early phase (acute rhinosinusitis) is usually caused by a viral infection, but may be followed by an aerobic bacterial infection in a minority of patients. Colonizing anaerobic oropharyngeal flora and aerobes such as S. aureus become predominant over time. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evolution of bacterial flora'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fungi may cause allergic fungal rhinosinusitis, colonization of the sinuses, and invasive fungal sinusitis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Fungi'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'Allergic fungal rhinosinusitis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8775?source=see_link\">",
"       \"Fungal rhinosinusitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest treating patients who meet the diagnostic criteria for CRS with antimicrobial therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, antimicrobials are just one component of comprehensive medical and surgical management for this disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"       \"Management of chronic rhinosinusitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A number of antimicrobial regimens are available to treat CRS. Given that most of these infections are polymicrobial and many include anaerobes, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      as the first-line regimen for most patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For penicillin-allergic patients, we suggest monotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If there is concern for MRSA,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      is usually the preferred initial therapy because it is also effective against anaerobes. Alternatives include TMP-SMX and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      in combination with an empiric regimen that includes anaerobic coverage. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'MRSA coverage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy is given for at least 21 days and may be extended for up to 10 weeks in refractory cases. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A culture should be obtained in patients who fail to have significant improvement or who demonstrate signs of deterioration despite therapy, preferably directly from the sinus cavity. We use the culture results to ensure that coverage is adequate for organisms resistant to the empiric regimen. We generally suggest NOT narrowing the regimen to cover only the organisms cultured because certain bacteria, such as anaerobes, may be difficult to isolate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Initial treatment failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/1\">",
"      Sande MA, Gwaltney JM. Acute community-acquired bacterial sinusitis: continuing challenges and current management. Clin Infect Dis 2004; 39 Suppl 3:S151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/2\">",
"      Brook I. Acute and chronic bacterial sinusitis. Infect Dis Clin North Am 2007; 21:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/3\">",
"      Bhattacharyya N. The role of infection in chronic rhinosinusitis. Curr Allergy Asthma Rep 2002; 2:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/4\">",
"      Brook I. Bacteriologic features of chronic sinusitis in children. JAMA 1981; 246:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/5\">",
"      Brook I. Bacteriology of chronic maxillary sinusitis in adults. Ann Otol Rhinol Laryngol 1989; 98:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/6\">",
"      Brook I. Bacteriology of acute and chronic frontal sinusitis. Arch Otolaryngol Head Neck Surg 2002; 128:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/7\">",
"      Brook I. Bacteriology of acute and chronic sphenoid sinusitis. Ann Otol Rhinol Laryngol 2002; 111:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/8\">",
"      Brook I. Bacteriology of acute and chronic ethmoid sinusitis. J Clin Microbiol 2005; 43:3479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/9\">",
"      Nord CE. The role of anaerobic bacteria in recurrent episodes of sinusitis and tonsillitis. Clin Infect Dis 1995; 20:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/10\">",
"      Brook I, Thompson DH, Frazier EH. Microbiology and management of chronic maxillary sinusitis. Arch Otolaryngol Head Neck Surg 1994; 120:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/11\">",
"      Finegold SM, Flynn MJ, Rose FV, et al. Bacteriologic findings associated with chronic bacterial maxillary sinusitis in adults. Clin Infect Dis 2002; 35:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/12\">",
"      Brook I, Yocum P, Shah K. Aerobic and anaerobic bacteriology of concurrent chronic otitis media with effusion and chronic sinusitis in children. Arch Otolaryngol Head Neck Surg 2000; 126:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/13\">",
"      Erkan M, Ozcan M, Arslan S, et al. Bacteriology of antrum in children with chronic maxillary sinusitis. Scand J Infect Dis 1996; 28:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/14\">",
"      Frederick J, Braude AI. Anaerobic infection of the paranasal sinuses. N Engl J Med 1974; 290:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/15\">",
"      Van Cauwenberge P, Verschraegen G, Van Renterghem L. Bacteriological findings in sinusitis (1963-1975). Scand J Infect Dis Suppl 1976; :72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/16\">",
"      Karma P, Jokipii L, Sipil&auml; P, et al. Bacteria in chronic maxillary sinusitis. Arch Otolaryngol 1979; 105:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/17\">",
"      Berg O, Carenfelt C, Kronvall G. Bacteriology of maxillary sinusitis in relation to character of inflammation and prior treatment. Scand J Infect Dis 1988; 20:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/18\">",
"      Erkan M, Aslan T, Ozcan M, Ko&ccedil; N. Bacteriology of antrum in adults with chronic maxillary sinusitis. Laryngoscope 1994; 104:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/19\">",
"      Klossek JM, Dubreuil L, Richet H, et al. Bacteriology of chronic purulent secretions in chronic rhinosinusitis. J Laryngol Otol 1998; 112:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/20\">",
"      Brook I, Frazier EH, Foote PA. Microbiology of the transition from acute to chronic maxillary sinusitis. J Med Microbiol 1996; 45:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/21\">",
"      Aust R, Drettner B. Oxygen tension in the human maxillary sinus under normal and pathological conditions. Acta Otolaryngol 1974; 78:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/22\">",
"      Carenfelt C, Lundberg C. Purulent and non-purulent maxillary sinus secretions with respect to pO2, pCO2 and pH. Acta Otolaryngol 1977; 84:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/23\">",
"      Brook I, Myhal LA, Dorsey CH. Encapsulation and pilus formation of Bacteroides spp. in normal flora abscesses and blood. J Infect 1992; 25:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/24\">",
"      Brook I. Role of encapsulated anaerobic bacteria in synergistic infections. Crit Rev Microbiol 1987; 14:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/25\">",
"      Doyle PW, Woodham JD. Evaluation of the microbiology of chronic ethmoid sinusitis. J Clin Microbiol 1991; 29:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/26\">",
"      Shapiro ED, Milmoe GJ, Wald ER, et al. Bacteriology of the maxillary sinuses in patients with cystic fibrosis. J Infect Dis 1982; 146:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/27\">",
"      Nadel DM, Lanza DC, Kennedy DW. Endoscopically guided cultures in chronic sinusitis. Am J Rhinol 1998; 12:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/28\">",
"      Bhattacharyya N, Kepnes LJ. The microbiology of recurrent rhinosinusitis after endoscopic sinus surgery. Arch Otolaryngol Head Neck Surg 1999; 125:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/29\">",
"      Brook I. Microbiology of acute and chronic maxillary sinusitis associated with an odontogenic origin. Laryngoscope 2005; 115:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/30\">",
"      Decker CF. Sinusitis in the Immunocompromised Host. Curr Infect Dis Rep 1999; 1:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/31\">",
"      Hsu J, Lanza DC, Kennedy DW. Antimicrobial resistance in bacterial chronic sinusitis. Am J Rhinol 1998; 12:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/32\">",
"      Brook I, Frazier EH. Correlation between microbiology and previous sinus surgery in patients with chronic maxillary sinusitis. Ann Otol Rhinol Laryngol 2001; 110:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/33\">",
"      Huang WH, Hung PK. Methicillin-resistant Staphylococcus aureus infections in acute rhinosinusitis. Laryngoscope 2006; 116:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/34\">",
"      Manarey CR, Anand VK, Huang C. Incidence of methicillin-resistant Staphylococcus aureus causing chronic rhinosinusitis. Laryngoscope 2004; 114:939.",
"     </a>",
"    </li>",
"    <li>",
"     Brook, I, Foote, PA, Hausfeld, JN. Changes in the frequency of recovery of methicillin-resistant Staphylococcus aureus in acute and chronic maxillary sinusitis. Submitted for publication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/36\">",
"      Jiang RS, Hsu CY, Jang JW. Bacteriology of the maxillary and ethmoid sinuses in chronic sinusitis. J Laryngol Otol 1998; 112:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/37\">",
"      Brook I, Frazier EH. Bacteriology of chronic maxillary sinusitis associated with nasal polyposis. J Med Microbiol 2005; 54:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/38\">",
"      Kim HJ, Lee K, Yoo JB, et al. Bacteriological findings and antimicrobial susceptibility in chronic sinusitis with nasal polyp. Acta Otolaryngol 2006; 126:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/39\">",
"      Niederfuhr A, Kirsche H, Riechelmann H, Wellinghausen N. The bacteriology of chronic rhinosinusitis with and without nasal polyps. Arch Otolaryngol Head Neck Surg 2009; 135:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/40\">",
"      Brook I, Foote PA, Frazier EH. Microbiology of acute exacerbation of chronic sinusitis. Ann Otol Rhinol Laryngol 2005; 114:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/41\">",
"      Mehra P, Jeong D. Maxillary sinusitis of odontogenic origin. Curr Infect Dis Rep 2008; 10:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/42\">",
"      Brook I, Frazier EH, Gher ME Jr. Microbiology of periapical abscesses and associated maxillary sinusitis. J Periodontol 1996; 67:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/43\">",
"      Gillespie MB, O'Malley BW Jr, Francis HW. An approach to fulminant invasive fungal rhinosinusitis in the immunocompromised host. Arch Otolaryngol Head Neck Surg 1998; 124:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/44\">",
"      Jackson RM, Rice DH. Acute bacterial sinusitis and diabetes mellitus. Otolaryngol Head Neck Surg 1987; 97:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/45\">",
"      Godofsky EW, Zinreich J, Armstrong M, et al. Sinusitis in HIV-infected patients: a clinical and radiographic review. Am J Med 1992; 93:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/46\">",
"      Del Borgo C, Del Forno A, Ottaviani F, Fantoni M. Sinusitis in HIV-infected patients. J Chemother 1997; 9:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/47\">",
"      Dunand VA, Hammer SM, Rossi R, et al. Parasitic sinusitis and otitis in patients infected with human immunodeficiency virus: report of five cases and review. Clin Infect Dis 1997; 25:267.",
"     </a>",
"    </li>",
"    <li>",
"     Finegold SM. Anaerobic bacteria in human disease, Academic Press Inc, Orlando, FL 1977.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/49\">",
"      Brook I. Microbiology of intracranial abscesses and their associated sinusitis. Arch Otolaryngol Head Neck Surg 2005; 131:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/50\">",
"      Wallwork B, Coman W, Mackay-Sim A, et al. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope 2006; 116:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/51\">",
"      Piromchai P, Thanaviratananich S, Laopaiboon M. Systemic antibiotics for chronic rhinosinusitis without nasal polyps in adults. Cochrane Database Syst Rev 2011; :CD008233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/52\">",
"      Namyslowski G, Misiolek M, Czecior E, et al. Comparison of the efficacy and tolerability of amoxycillin/clavulanic acid 875 mg b.i.d. with cefuroxime 500 mg b.i.d. in the treatment of chronic and acute exacerbation of chronic sinusitis in adults. J Chemother 2002; 14:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/53\">",
"      Legent F, Bordure P, Beauvillain C, Berche P. A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis. Chemotherapy 1994; 40 Suppl 1:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/54\">",
"      Husfeldt P, Egede F, Nielsen PB. Antibiotic treatment of sinusitis in general practice. A double-blind study comparing ofloxacin and erythromycin. Eur Arch Otorhinolaryngol 1993; 250 Suppl 1:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/55\">",
"      Dubin MG, Kuhn FA, Melroy CT. Radiographic resolution of chronic rhinosinusitis without polyposis after 6 weeks vs 3 weeks of oral antibiotics. Ann Allergy Asthma Immunol 2007; 98:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/56\">",
"      Brook I, Yocum P. Antimicrobial management of chronic sinusitis in children. J Laryngol Otol 1995; 109:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/57\">",
"      Ragab SM, Lund VJ, Scadding G. Evaluation of the medical and surgical treatment of chronic rhinosinusitis: a prospective, randomised, controlled trial. Laryngoscope 2004; 114:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/58\">",
"      Brook I. The role of beta-lactamase-producing bacteria in the persistence of streptococcal tonsillar infection. Rev Infect Dis 1984; 6:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/59\">",
"      Brook I. Role of methicillin-resistant Staphylococcus aureus in head and neck infections. J Laryngol Otol 2009; 123:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/60\">",
"      Brook I. Beta-lactamase-producing bacteria in head and neck infection. Laryngoscope 1988; 98:428.",
"     </a>",
"    </li>",
"    <li>",
"     Suman JD, Laube BL, Dalby R. Nasal nebulizers versus aqueous nasal spray pumps: A comparison of deposition patterns in human volunteers. In: Respiratory Drug Delivery VI, Dalby RN, Byron PR, Farr SJ (Eds), Interpharm Press, Buffalo Grove, IL 1998. p.211.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/62\">",
"      Durand M, Rusch P, Granjon D, et al. Preliminary study of the deposition of aerosol in the maxillary sinuses using a plastinated model. J Aerosol Med 2001; 14:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/63\">",
"      Lim M, Citardi MJ, Leong JL. Topical antimicrobials in the management of chronic rhinosinusitis: a systematic review. Am J Rhinol 2008; 22:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/64\">",
"      Leonard DW, Bolger WE. Topical antibiotic therapy for recalcitrant sinusitis. Laryngoscope 1999; 109:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/65\">",
"      Goh YH, Goode RL. Current status of topical nasal antimicrobial agents. Laryngoscope 2000; 110:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/66\">",
"      Scheinberg PA, Otsuji A. Nebulized antibiotics for the treatment of acute exacerbations of chronic rhinosinusitis. Ear Nose Throat J 2002; 81:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26537/abstract/67\">",
"      Vaughan WC, Carvalho G. Use of nebulized antibiotics for acute infections in chronic sinusitis. Otolaryngol Head Neck Surg 2002; 127:558.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3412 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-FD0A04FE88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_58_26537=[""].join("\n");
var outline_f25_58_26537=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Evolution of bacterial flora",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Anaerobes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Aerobes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Specific clinical settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Nasal polyposis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Acute exacerbation of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Odontogenic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Concurrent chronic otitis media in children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Fungi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ANTIMICROBIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Efficacy of antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Empiric regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - MRSA coverage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Specific settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Initial treatment failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Parenteral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nebulized antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39688?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26663?source=related_link\">",
"      Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16873?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=related_link\">",
"      Epidural abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8775?source=related_link\">",
"      Fungal rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=related_link\">",
"      Orbital cellulitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6775?source=related_link\">",
"      Pathogenesis of allergic rhinitis (rhinosinusitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of brain abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/58/42915?source=related_link\">",
"      Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/37/14930?source=related_link\">",
"      Patient information: Chronic sinusitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32438?source=related_link\">",
"      Treatment and prognosis of brain abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=related_link\">",
"      Treatment of Pseudomonas aeruginosa infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_58_26538="Prevention, presentation, and management of saphenous vein graft stenosis";
var content_f25_58_26538=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention, presentation, and management of saphenous vein graft stenosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/58/26538/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26538/contributors\">",
"     Thomas Levin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26538/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/58/26538/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26538/contributors\">",
"     Stephan Windecker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/58/26538/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/58/26538/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/58/26538/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term freedom from angina and ischemic events after coronary artery bypass graft (CABG) surgery using saphenous vein grafts (SVGs) is limited by the development of graft stenosis (",
"    <a class=\"graphic graphic_movie graphicRef61140 \" href=\"UTD.htm?11/2/11310\">",
"     movie 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Graft stenosis results from intimal hyperplasia, mostly within the first year, followed by atherosclerotic plaque build-up and graft remodeling in subsequent years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result of these processes, only about 80 percent of SVGs remain patent five years after surgery and about 60 percent at 7 to 10 years. SVG stenosis has become a less common problem because of the preferential use of internal mammary artery grafts in patients who undergo CABG. A detailed discussion of the frequency and underlying pathology of vein graft occlusion is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link&amp;anchor=H3#H3\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\", section on 'Saphenous vein graft'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to the prevention, clinical presentation, and management of SVG stenosis will be reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive secondary preventive interventions, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and statin use, achieving blood pressure goal, avoidance of smoking, and the control of serum glucose in patients with diabetes, are recommended in all patients with CHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both antiplatelet and statin therapy improve cardiovascular outcomes in patients who have undergone CABG. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link&amp;anchor=H29#H29\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\", section on 'General medical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, these two therapies are of proven efficacy for the prevention of SVG stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet activation and vein graft thrombosis are thought to be early steps in the process of stenosis and occlusion and forms the rationale for using antiplatelet therapy for prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link&amp;anchor=H5#H5\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\", section on 'Intermediate phase occlusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    therapy given early in the postoperative period improves cardiovascular outcomes after CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/2\">",
"     2",
"    </a>",
"    ] and reduces the incidence of SVG stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In a meta-analysis from the Antiplatelet Trialists' Collaboration, low-dose aspirin was associated with improved graft patency, as assessed by coronary angiography, at an average of one year after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/5\">",
"     5",
"    </a>",
"    ]. The pooled odds reduction for SVG closure was 41 percent (8 percent absolute risk reduction) with low-dose aspirin (75 to 325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    compared to placebo or control therapy. The benefit was similar to that seen with higher and more gastrotoxic doses of aspirin.",
"   </p>",
"   <p>",
"    We recommend that, among patients not treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    before CABG, aspirin (75 to 162",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    be started as soon after surgery as possible and continued indefinitely. For patients who are allergic to aspirin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (300 mg loading six hours after surgery, followed by a maintenance dose of 75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is recommended. Oral anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is recommended only if such therapy is indicated for other reasons. These recommendations are generally in agreement with the 2008 American College of Chest Physicians (ACCP) guideline on the primary and secondary prevention of coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two small studies have yielded conflicting results regarding the efficacy of",
"    <strong>",
"     dual",
"    </strong>",
"    antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    to prevent vein graft disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 249 patients who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or to aspirin alone prior to CABG, the rate of vein graft patency at three months, as assessed by multislice computed tomography angiography, was significantly higher in those treated with dual antiplatelet therapy (92 versus 86 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial of 113 CABG patients who were randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      162 mg plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      75 mg daily or aspirin 162 mg daily, there was no significant difference in the rate of SVG hyperplasia as determined by intravascular ultrasound at one year [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Issues related to the preoperative use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and platelet P2Y12 receptor blocker therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40360?source=see_link&amp;anchor=H3#H3\">",
"     \"Medical therapy to prevent complications after coronary artery bypass graft surgery\", section on 'Preoperative aspirin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40360?source=see_link&amp;anchor=H6#H6\">",
"     \"Medical therapy to prevent complications after coronary artery bypass graft surgery\", section on 'Platelet P2Y12 receptor blocker therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive lipid lowering with a statin is warranted in all patients with coronary heart disease. Based upon the available evidence, we recommend a target LDL-C concentration substantially less than 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in patients with established CHD. In addition, the modified ATP III guidelines published in July 2004 recommended an optional goal LDL below 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for \"very high risk\" patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to improvements in mortality and cardiovascular outcomes, lipid-lowering also may protect against SVG stenosis. This was illustrated in the Post Coronary Artery Bypass Graft Trial, which evaluated 1351 patients with serum LDL cholesterol concentrations between 130 and 175",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4 to 4.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and at least one patent vein graft documented on angiography performed one to 11 years after CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Patients were randomly assigned to receive aggressive therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    and, if needed,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    to reduce LDL cholesterol to less than 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or to moderate therapy which resulted in levels of approximately 134",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.5",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Angiography was repeated an average of 4.3 years.",
"   </p>",
"   <p>",
"    The following significant benefits were noted with aggressive compared to moderate therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lower percentage of grafts showing progression of atherosclerosis (27 versus 39 percent) (",
"      <a class=\"graphic graphic_figure graphicRef72758 \" href=\"UTD.htm?19/19/19774\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A lower rate of revascularization (CABG or PTCA) (6.5 versus 9.2 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The delay in progression of atherosclerosis was seen in both men and women, in all age groups, and in patients with or without risk factors for coronary heart disease, including smoking, hypertension, diabetes, or elevated serum triglyceride concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/11\">",
"     11",
"    </a>",
"    ]. In a separate randomization, low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    had no effect on disease progression.",
"   </p>",
"   <p>",
"    Clinical outcomes were evaluated after a follow-up of 7.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/12\">",
"     12",
"    </a>",
"    ]. Compared to moderate therapy, aggressive therapy was associated with a 30 percent reduction in revascularization procedures and a 24 percent reduction in the composite end point of cardiovascular death, MI, stroke, CABG, or angioplasty (",
"    <a class=\"graphic graphic_figure graphicRef74401 \" href=\"UTD.htm?21/39/22142\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Isolated low serum HDL is a risk factor for the development of coronary artery disease and also may contribute to the development of SVG disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=see_link\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential benefit of therapy aimed at elevating serum HDL was illustrated in Lopid Coronary Angiography Trial (LOCAT) in which 395 post-CABG patients with serum LDL cholesterol &le;175",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and serum HDL cholesterol concentration &le;42",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    were randomly assigned to therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    (1200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/14\">",
"     14",
"    </a>",
"    ]. After an average of 32 months, patients receiving gemfibrozil had less progression of native coronary artery atherosclerosis and a lower incidence of new lesions in their SVG grafts (2 versus 14 percent of patients) compared to the control group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521217436\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fish oil is of unproven benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Attempting to diminish neointimal hyperplasia and prevent SVG failure via ex vivo treatment of the graft with the E2F transcription factor decoy edifoligide was no more effective than ex vivo treatment with placebo in the randomized PREVENT IV trial [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Saphenous vein graft stenosis often presents with recurrent angina. However, the cause of angina depends in part upon the time after surgery when symptoms are first noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent angina during the postoperative period is usually due to a technical problem with a graft or with early graft closure. It is therefore an indication for prompt catheterization with catheter revascularization if feasible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link\">",
"       \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recurrent angina after the first few months is caused by either graft stenosis or progression of atherosclerosis in non-bypassed vessels. The older the saphenous vein graft, the higher the likelihood that symptoms are the result of a culprit lesion within the graft (",
"      <a class=\"graphic graphic_figure graphicRef50106 \" href=\"UTD.htm?1/58/1966\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24536?source=see_link\">",
"       \"Late recurrent angina pectoris after coronary artery bypass graft surgery\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is especially important that graft problems be investigated early, since stenoses in these vessels can progress rapidly to total thrombotic occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/18\">",
"     18",
"    </a>",
"    ]. A heavy thrombus burden in an SVG markedly increases the difficulty in obtaining a satisfactory result using a catheter technique.",
"   </p>",
"   <p>",
"    The reported incidence of reoperation for recurrent angina after saphenous vein grafting ranges from 3 to 17 percent in the first five years, but rises to 30 percent at 15 years in those who have survived. One study, for example, monitored 3480 patients who had undergone a first saphenous vein graft between 1978 and 1981 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/19\">",
"     19",
"    </a>",
"    ]. The 5, 10 and 12 year incidence of either reoperative CABG or PTCA was 4, 19, and 31 percent. Younger patients had much a higher incidence of repeat procedures.",
"   </p>",
"   <p>",
"    Less often, patients with saphenous vein graft stenosis present with an acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     THERAPEUTIC OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most patients with recurrent angina due to SVG stenosis can be managed medically, catheterization should be performed at the earliest signs of recurrent ischemia to detect critical graft lesions that can be treated before irreversible loss of the graft.",
"   </p>",
"   <p>",
"    The optimal management of SVG stenosis that requires revascularization may involve repeat surgery or, more often percutaneous coronary intervention (PCI) with stent placement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repeat CABG is not optimal since many patients who develop graft disease are poor candidates for surgery because they are older, more likely to have comorbid illnesses, and are at risk for increased morbidity and mortality compared to their first bypass surgery. Furthermore, reoperation is generally associated with less complete revascularization and control of symptoms when compared to the first procedure.",
"     </li>",
"     <li>",
"      Balloon angioplasty for vein graft disease is also not optimal, since it is associated with high rates of restenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/22\">",
"       22",
"      </a>",
"      ]. Restenosis is less likely with coronary artery stenting as illustrated in the SAVED trial [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Comparison to PTCA'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For these reasons, intracoronary stents are being increasingly used for the treatment of SVG stenosis. The 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Society",
"    </span>",
"    for Cardiovascular Angiography and Interventions",
"    <span class=\"nowrap\">",
"     (ACC/AHA/SCAI)",
"    </span>",
"    guidelines on percutaneous coronary intervention published recommendations on the use of PCI in patients with a prior CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/24\">",
"     24",
"    </a>",
"    ]. These recommendations were not changed in the 2007 focused update [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     REPEAT CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reoperation is associated with increased perioperative mortality and with less complete revascularization and control of symptoms when compared to the first procedure. Repeat CABG is also associated with an increase in in-hospital mortality compared to PCI (6 to 9 versus &le;0.5 percent overall and 11.2 versus 1.6 percent in diabetics). On the other hand, the requirement for subsequent revascularization is greater with PCI and no difference has been detected in long-term survival with the two approaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24536?source=see_link\">",
"     \"Late recurrent angina pectoris after coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PERCUTANEOUS CORONARY INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of PCI for SVG stenosis, including the different modalities that may be used, will be reviewed here. The choice between repeat CABG and PCI in these patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24536?source=see_link\">",
"     \"Late recurrent angina pectoris after coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since SVGs lack side branches, distal occlusion results in stasis and thrombus formation throughout the graft, which makes PCI more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/26\">",
"     26",
"    </a>",
"    ]. Thus, as with bypass surgery, outcomes after PCI for SVG stenosis are worse than in native vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/26\">",
"     26",
"    </a>",
"    ]. This was illustrated in a pooled analysis of five randomized glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor trials in which PCI for SVG stenosis was associated with significant increases in mortality at both 30 days (2.1 versus 1.0 percent compared to PCI in native vessels) and six months (4.7 versus 2.0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/27\">",
"     27",
"    </a>",
"    ]. There was no demonstrable benefit from GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy in patients undergoing SVG intervention.",
"   </p>",
"   <p>",
"    Initial studies evaluated percutaneous transluminal coronary angioplasty (PTCA) alone but, as noted above, stenting is now performed in most procedures. Atherectomy also may be useful in selected patients.",
"   </p>",
"   <p>",
"    In a large observational series evaluating the outcomes with these procedures, the in-hospital incidence of and risk factors for a major cardiac event after any PCI were evaluated in 1062 patients with SVG stenosis who were followed for three years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/22\">",
"     22",
"    </a>",
"    ]. The patients were treated with PTCA alone (42 percent), laser or atherectomy (16 percent), or stenting (42 percent). The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of in-hospital major adverse cardiac events was 13 percent; death occurred in 8 percent, MI in 2 percent, and bypass surgery was performed in 3 percent. Predictors of an in-hospital event were a restenotic lesion, unstable angina, and heart failure.",
"     </li>",
"     <li>",
"      Late major coronary events occurred in 54 percent of patients and included death in 9 percent, MI in 9 percent, and target vessel revascularization (TVR) in 36 percent.",
"     </li>",
"     <li>",
"      Angiographic restenosis occurred significantly less often in stented grafts (29 versus 43 percent in nonstented grafts). However, there was no event-free or survival benefit with stenting, due at least in part to progressive disease at nonstented sites.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the increase in risk with PCI of a totally occluded SVG, it has been suggested that attention be paid to the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio in such patients and that, if possible, an attempt should be made to recanalize the underlying native coronary artery rather than the vein graft [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/26\">",
"     26",
"    </a>",
"    ]. If this is not possible, medical therapy rather than PCI should initially be tried unless the patient has symptoms that interfere with the quality of life or a large amount of myocardium at risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Angioplasty",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTCA has been performed for SVG disease in three clinical settings: recurrent angina due to subtotal or chronic total occlusion or, infrequently, acute infarction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PTCA of a graft with subtotal occlusion has an initial success rate of approximately 90 percent with low rates of mortality and periprocedural MI (1 and 4 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/28\">",
"       28",
"      </a>",
"      ]. The average restenosis rate is 40 to 45 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/22,28\">",
"       22,28",
"      </a>",
"      ], but certain groups can be identified with a lower success rate and higher risk (eg, those with a totally occluded graft).",
"     </li>",
"     <li>",
"      PTCA of chronic total occlusion of an SVG is associated with a lower initial success rate and higher complication rate than seen with subtotal occlusion or native coronary arteries [",
"      <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/26,28-30\">",
"       26,28-30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PTCA has largely been replaced by PCI with stenting, because of better outcomes with the latter approach. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Intracoronary stents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The periprocedural complications of PTCA are discussed in detail elsewhere. Similar complications can occur with PTCA for SVG stenosis but the data are much more limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Coronary embolization of atherothrombotic debris, resulting in elevated cardiac enzymes and an ST elevation or non-ST elevation MI during catheter intervention, is a more common problem after PTCA in saphenous vein grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/26\">",
"     26",
"    </a>",
"    ]. A possible explanation is that atherosclerotic plaques in saphenous grafts are softer, and more friable, and more commonly associated with thrombus and platelet activation compared to plaques in native coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/31\">",
"     31",
"    </a>",
"    ]. Plaque debris can be retrieved and distal embolization minimized after PCI with an embolic protection device, leading to a reduction in both MI and no-reflow (microvascular dysfunction). (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Distal devices'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The likelihood of developing an elevation in serum CK-MB and its clinical significance were evaluated in a report of 1056 patients with successful dilation of an SVG lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/32\">",
"     32",
"    </a>",
"    ]. A major increase in CK-MB (&gt;5 times the upper limit of normal) occurred in 15 percent of patients. There was no difference in major clinical events at 30 days among those with and without CK-MB elevations; however, mortality at one year was significantly greater in patients with a major increase in serum CK-MB compared to those with no increase or only a minor elevation (10.7 versus 4.8 and 6.5 percent). On multivariate analysis, major CK-MB elevation was the strongest independent predictor of late mortality, followed by diabetes mellitus (odds ratio 3.3 and 2, 6, respectively).",
"   </p>",
"   <p>",
"    These findings are similar to those following PTCA in native arteries, although the association with mortality is much stronger with SVG PTCA. Patients with serum CK-MB more &ge;3 times the upper limit of normal should be treated as having an MI, especially if there has been a technical complication of the procedure. The significance of elevations of less than three times normal is more uncertain in the absence of clinical instability [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intracoronary stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elective stent placement for vein graft disease may reduce the long-term incidence of restenosis, as it does in native coronary arteries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, adverse events and durability after PCI for SVG stenosis are worse than in native vessels. A pooled analysis of five randomized GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor trials found that PCI for SVG stenosis was associated with significantly higher mortality compared with PCI for native disease at both 30 days (2.1 versus 1.0 percent) and six months (4.7 versus 2.0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/27\">",
"     27",
"    </a>",
"    ]. In an observational study of 175 patients, poorer overall and event-free survival persisted in patients with SVG disease at five years (",
"    <a class=\"graphic graphic_figure graphicRef69447 \" href=\"UTD.htm?20/6/20590\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/34\">",
"     34",
"    </a>",
"    ]. The increased need for repeat revascularization was primarily due to progression of disease at other sites (",
"    <a class=\"graphic graphic_figure graphicRef78527 \" href=\"UTD.htm?18/11/18622\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As will be described below, restenosis remains an important problem even though it is less frequent than with angioplasty alone. Brachytherapy with gamma radiation appears to minimize recurrence of in-stent restenosis in SVGs, but this modality is no longer available at most institutions. It is anticipated that drug-eluting stents will result in a lower rate of restenosis, although data on native vessels predominates in trials to date. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25560?source=see_link&amp;anchor=H8#H8\">",
"     \"Use of intracoronary radiation to prevent restenosis\", section on 'Saphenous vein grafts'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial observational studies found a 17 to 30 percent restenosis rate for stented vein grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]; these values were lower than the 40 to 45 percent seen in historical controls treated by other means such as balloon angioplasty and atherectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/28,37\">",
"     28,37",
"    </a>",
"    ]. The subacute thrombosis rate is very low (about 1 to 2 percent), a reflection of the usually larger luminal diameters in vein grafts than in native coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of stenting for SVG disease was illustrated in a report from the Palmaz-Schatz Stent Study Group [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/36\">",
"     36",
"    </a>",
"    ]. The procedural success rate in 589 symptomatic patients who received a stent for SVG stenosis was 97 percent; 2.9 percent had an in-hospital complication. At 12 months, the restenosis rate was 30 percent and the actuarial event-free survival was 76 percent. Predictors for restenosis included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A restenotic lesion",
"     </li>",
"     <li>",
"      Smaller reference vessel size",
"     </li>",
"     <li>",
"      Higher percent post-stent diameter stenosis",
"     </li>",
"     <li>",
"      History of diabetes mellitus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other predictors for restenosis include use of a long stent or multiple stents and stenosis at the coronary or aortic anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=see_link\">",
"     \"Intracoronary stent restenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second observational series with longer follow-up consisted of 186 patients, 90 percent of whom presented with an acute MI or unstable angina; the initial success rate was 97 percent with a 3 percent incidence of an in-hospital major complication (death, infarction, bypass surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/20\">",
"     20",
"    </a>",
"    ]. The Kaplan-Meier estimated overall and event-free survival at four years were 79 and 29 percent, respectively, with one-half of the cardiac events occurring during the first year (",
"    <a class=\"graphic graphic_figure graphicRef53319 \" href=\"UTD.htm?15/24/15758\">",
"     figure 6",
"    </a>",
"    ). Revascularization was required in 35 percent, one-quarter of which were for nontarget lesions. Among the survivors, 36 percent were free of angina and 69 percent were in functional class I or II.",
"   </p>",
"   <p>",
"    The outcome of SVG stenting is worse in diabetics, who have higher rates of in-hospital mortality and target lesion revascularization at one year, and a lower rate of overall cardiac event-free survival at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Comparison to PTCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only controlled comparative data comes from the relatively small Saphenous Vein De Novo (SAVED) Trial, which randomly assigned 220 patients with new SVG lesions to placement of a Palmaz-Schatz stent or standard balloon PTCA [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/23\">",
"     23",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to PTCA alone, patients receiving a stent had a higher procedural success rate, defined as a reduction in stenosis to less than 50 percent of the vessel diameter without a major complication (92 versus 69 percent).",
"     </li>",
"     <li>",
"      At 240 days, patients who underwent stenting had a significantly lower incidence of the composite end point of death, MI, repeat bypass surgery, or revascularization of the target lesion (27 versus 42 percent).",
"     </li>",
"     <li>",
"      Despite the stent group having a greater luminal diameter immediately after the procedure and at six months, the binary angiographic restenosis rate was not significantly reduced (37 versus 46 percent with PTCA alone).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Larger observational studies also suggested benefit from stenting compared to PTCA alone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/22,37\">",
"     22,37",
"    </a>",
"    ]. A report described above evaluated 1062 patients with SVG stenosis who were then followed for three years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/22\">",
"     22",
"    </a>",
"    ]. The patients were treated with PTCA alone (42 percent), laser or atherectomy (16 percent), or stenting (42 percent). Angiographic restenosis occurred significantly less often in stented grafts (29 versus 43 percent in nonstented grafts). However, there was no event-free or survival benefit with stenting, due at least in part to progressive disease at nonstented sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Drug-eluting stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-eluting stents are being utilized with increasing frequency in preference to bare metal stents whenever feasible in coronary arterial lesions because they are associated with a marked reduction in the incidence of restenosis and target vessel revascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonrandomized studies suggested that drug-eluting stents (DES) have a similar benefit compared with bare metal stents (BMS) in diseased SVGs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Two small randomized trials have demonstrated lower rates of in-stent restenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The RRISC trial compared sirolimus-eluting stents (SES) and (BMS) in 75 patients with 96 de novo SVG lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/43\">",
"     43",
"    </a>",
"    ]. At six-month follow-up, the primary end point of in-stent late lumen loss was significantly reduced with SES (0.38 versus 0.79 mm). The study was not powered to evaluate clinical end points. However, longer-term evaluation of the patients in the RRISC trial suggested no advantage, and possible harm, to the use of SES in patients with diseased SVG [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/45\">",
"     45",
"    </a>",
"    ]. After a median follow-up of 32 months death occurred in 11 patients after SES and 0 patients after BMS.",
"   </p>",
"   <p>",
"    In the Stenting of Saphenous Vein Grafts (SOS) trial, 80 patients with 112 lesions in 88 SVGs were randomly assigned to either BMS or paclitaxel-eluting stents (PES) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/44\">",
"     44",
"    </a>",
"    ]. At 12 month angiographic follow-up, restenosis occurred significantly more often with BMS (51 versus 9 percent; relative risk 0.18, 95% CI 0.07-0.48). At a median clinical follow-up of 1.5 years, PES (compared to BMS) use, was associated with significantly less target lesion (5 versus 28 percent) and a trend toward less target vessel (22 versus 46 percent) revascularization, while mortality was similar (12 versus 5 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Primary PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary PCI is usually the preferred therapy in patients with an ST elevation MI. There are limited data on the efficacy of this modality in patients with saphenous vein graft (SVG) lesions. In one study of 370 patients who underwent primary or rescue PTCA, 21 (5.7 percent) were performed on SVGs, with a stent implanted in 14 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/21\">",
"     21",
"    </a>",
"    ]. Flow was established in 86 percent of patients, but TIMI grade 3 was restored in only 48 percent. Distal embolization and no-reflow occurred in 57 and 71 percent, respectively. The in-hospital mortality was 19 percent and, at six months, the rate of survival free of death, repeat target vessel revascularization, or MI was 55 percent. These results were worse when compared to a parallel group of patients undergoing primary PCI of a native coronary artery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Diffusely degenerated graft",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment strategy for diffusely degenerated SVGs is uncertain. Stents are effective as treatment for focal lesions, and endoluminal reconstruction with stent implantation has been proposed as a treatment for diffuse lesions. The latter approach was evaluated in a series of 126 patients with diffusely degenerated stenosed or occluded saphenous grafts treated with less-shortening Wallstents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/46\">",
"     46",
"    </a>",
"    ]. Before hospital discharge, 10 percent of patients had at least one major cardiovascular event, including death, MI, or repeat target vessel revascularization. At 22 month follow-up in survivors, 11 percent died, 9.4 percent had a MI, and 35 percent required repeat revascularization. Three year survival free of death, infarction, or revascularization was only 43 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Stenosis at distal anastomosis site",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions at the distal anastomosis site of an SVG have been successfully treated with PTCA. Although data are limited, the rate of restenosis at this site appears to be lower than those at the aorto-ostial site or the shaft portion of the vein graft. In a review of 182 such patients who underwent either PTCA or stenting, the in-hospital outcome was the same for both procedures, and the procedural success rate was 98 percent with major ischemic complications occurring in 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/47\">",
"     47",
"    </a>",
"    ]. After an average follow-up of 17 months, the mortality and ST elevation infarction rates were the same with both procedures (12 versus 13 percent and 1 versus 0 percent); however, there was a trend toward a higher rate of target lesion revascularization with PTCA (25 versus 14 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Multivessel stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have involved stenting of a single SVG. In one report, 70 patients who had two or three SVGs were compared to 649 patients with single vessel stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/48\">",
"     48",
"    </a>",
"    ]. The overall success (97 percent) and the incidence of procedural complications (2.8 versus 2.7 percent for single vessel stenting) were the same, but the rate of non-ST elevation infarction was higher with multivessel stenting (28 versus 16 percent). During an 18 month follow-up, there was no difference in target lesion revascularization, death, or ST elevation MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Covered stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;It was hoped that stents covered with a polymer membrane would serve as a barrier to isolate the graft lumen from the degenerated SVG wall, and thereby reduce the incidence of both 30-day major adverse cardiac events and late restenosis. The RECOVERS trial comparing the JoMed PTFE covered stent to the similar bare metal stent in the treatment of SVG stenosis found no reduction in restenosis rate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/49\">",
"     49",
"    </a>",
"    ]. There was also a higher incidence of nonfatal MI, possibly due to delayed reendothelialization of the stent and subsequent thrombotic occlusion. Similar lack of benefit was seen in the randomized STING trial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/50\">",
"     50",
"    </a>",
"    ]. The larger BARRICADE trial and from studies of the Symbiot covered stent found no benefit from covered stents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Possible role of GP IIb/IIIa inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thrombus is present in up to 70 percent of occluded SVGs, and is associated with an increased rate of failure and complications such as abrupt closure, distal embolization, and no reflow. The potential role of platelets in mediating distal embolization and MI has led to interest in the role of antiplatelet agents for preventing these complications.",
"   </p>",
"   <p>",
"    A pooled analysis of five randomized trials evaluating the efficacy of intravenous GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors during percutaneous coronary intervention included 627 patients who underwent PCI for SVG stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/27\">",
"     27",
"    </a>",
"    ]. There was",
"    <strong>",
"     no evidence of benefit",
"    </strong>",
"    as GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy was associated with nonsignificant trends toward an increase in the triple end point of death, MI, or revascularization at 30 days (16.5 versus 12.6 percent) and at six months (39.4 versus 32.7 percent).",
"   </p>",
"   <p>",
"    This lack of benefit, which has also been noted in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/53-55\">",
"     53-55",
"    </a>",
"    ], is in marked contrast to the clear benefit from GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy during PCI for native vessel disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate issue is whether a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor might be beneficial if given in conjunction with a distal embolic protection device. In the FIRE trial described below, GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor use was at the discretion of the investigator, and these patients were at higher baseline risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/56\">",
"     56",
"    </a>",
"    ]. It was concluded that, in high-risk patients, GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors may improve procedural outcomes (less abrupt closure, no reflow, or distal embolization) in patients treated with the FilterWire EX device, but not the GuardWire device. These nonrandomized observations need to be confirmed. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Distal devices'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Atherectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been thought that rotational, directional, or extraction atherectomy might be beneficial in some patients with SVG stenosis, especially when the lesions are densely calcified, aorto-ostial, or at the distal anastomosis site. However, removing graft atheroma using catheter-based techniques has",
"    <strong>",
"     not",
"    </strong>",
"    demonstrated durable value and these procedures are rarely used [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/57-61\">",
"     57-61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41142?source=see_link\">",
"     \"Specialized revascularization devices in the management of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Thrombolysis and thrombectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As atheromas in SVGs are often associated with thrombus, thrombolysis and thrombectomy have been studied as adjunctive therapy for SVG stenosis or occlusion. We do not recommend using thrombolytic therapy to treat SVG thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/62\">",
"     62",
"    </a>",
"    ]. Catheter-based treatment is an alternative to pharmacologic thrombolysis. None of the devices that can mechanically aspirate thrombus have been shown to improve clinically important outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/61-66\">",
"     61-66",
"    </a>",
"    ]. These devices should rarely be used in this setting. For example, we occasionally use the AngioJet device for cases with extremely large clot burden.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Embolic protection devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embolic protection devices (EPD) trap blood and suspended debris in the body of the saphenous vein graft during stenting, allowing their evacuation before normal flow is restored [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/67\">",
"     67",
"    </a>",
"    ]. Studies with these devices have shown that large quantities of atheroembolic debris are liberated during PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. The aspirate also contains vasoactive substances that can contribute to impaired microvascular perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Distal devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of a distal protection device was evaluated in the SAFER trial in which 801 patients with SVG stenosis were randomly assigned to stent placement over the shaft of a protective device (PercuSurge GuardWire) or a conventional angioplasty guidewire [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/72\">",
"     72",
"    </a>",
"    ]. Use of the embolic protection device, with or without the concomitant administration of a glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor, significantly reduced the incidence of myocardial infarction (8.6 versus 14.7 percent) and the no-reflow phenomenon (ie, microvascular dysfunction) (3 versus 9 percent).",
"   </p>",
"   <p>",
"    The PercuSurge GuardWire provided important but not complete protection from atheroembolization. This device has been approved for use by the FDA. Interestingly, this device did not improve outcomes compared to PCI alone in the EMERALD trial of patients undergoing primary PCI for acute ST segment elevation myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9994?source=see_link&amp;anchor=H4#H4\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on 'No-reflow phenomenon'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A review of early results with the FilterWire EX system highlighted the importance of anatomic, device-specific, and operator related factors (eg, lack of optimal filter apposition against the saphenous vein graft wall and an excessively distal lesion resulting in incomplete filter opening or unprotected native side branches) in the attainment of maximal efficacy. Operator attention to these factors reduced the 30-day incidence of adverse events, primarily periprocedural myocardial infarction, from 21.3 to 11.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The FIRE trial compared the PercuSurge GuardWire and the FilterWire EX system in 651 patients undergoing SVG stenting. Initial procedural success was excellent for both devices (97 and 96 percent, respectively). At 30 days, the composite end point of death, myocardial infarction, or target vessel revascularization was comparable for the GuardWire and the FilterWire (11.6 and 9.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/74\">",
"     74",
"    </a>",
"    ]. The outcomes in terms of the composite end point remained comparable at six months but an additional 10 percent of patients had a new event (21.9 versus 19.3 percent overall) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/75\">",
"     75",
"    </a>",
"    ]. Target vessel revascularization was required in 9.1 percent.",
"   </p>",
"   <p>",
"    Based upon the 30-day results, the FilterWire was approved for use by the FDA. It has become the preferred distal protection device in most laboratories due to advantages of the filter type systems noted above and protection that is equivalent to the GuardWire.",
"   </p>",
"   <p>",
"    Another trial (PRIDE) compared the TriActiv System, a balloon-protection flush and extraction device, to both the PercuSurge GuardWire and the FilterWire EX system [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/76\">",
"     76",
"    </a>",
"    ]. In terms of major adverse cardiac events, the TriActiv System was not inferior to the other devices but may be associated with a higher rate of bleeding complications.",
"   </p>",
"   <p>",
"    A separate issue is the efficacy of distal embolic protection devices in patients with in-stent restenosis in SVGs. The lesion in this setting primarily consists of neointimal proliferation and might be expected to have a lower embolic potential. Observations in 54 consecutive patients who underwent PCI for in-stent restenosis in SVGs without a distal embolic protection device are consistent with this hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/77\">",
"     77",
"    </a>",
"    ]. There were no episodes of no-reflow or slow flow during the procedure and no procedure-related myocardial infarctions. More data are needed to determine the generalizability of these findings.",
"   </p>",
"   <p>",
"    Taken together, the above trials have demonstrated the utility of distal embolic protection devices to minimize the adverse effect of downstream debris and thereby improve outcomes in PCI for SVG stenosis. Although these devices have become the standard of care in many laboratories, they are currently underutilized in SVG interventions, in part due to their recognized limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/70,78\">",
"     70,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limitations of distal protection devices include passage of the device across a stenotic lesion before distal protection is in place, occlusion of distal filters with debris, failure to prevent the movement of toxic soluble mediators into the distal myocardium, and inability to use the device in distal lesions. These limitations and others have led to the development of a variety of other distal embolic protection devices, proximal occlusion devices, and local plaque trapping devices [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/70,78,79\">",
"     70,78,79",
"    </a>",
"    ]. Clinical trials of these newer devices have required demonstration of equivalent levels of protection to those achieved with the PercuSurge GuardWire.",
"   </p>",
"   <p>",
"    Despite these limitations, distal protection devices are underutilized, even after excluding patients who are not ideal candidates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Proximal devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PROXIMAL trial evaluated the use of the Proxis embolic protection system, comprised of a proximal sealing balloon and subsequent aspiration of stagnated blood after PCI, in 594 patients undergoing stenting of 639 saphenous vein grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/70\">",
"     70",
"    </a>",
"    ]. The patients were randomly assigned to treatment with either current care (distal embolic protection device whenever possible, and no embolic protection when not) or a test arm (proximal protection device whenever possible and distal embolic protection when proximal protection was not feasible).",
"   </p>",
"   <p>",
"    Using a noninferiority study design, there was no significant difference in the primary end point of death, MI, or TVR at 30 days between patients in the current care or test arms (10.0 versus 9.2 percent, respectively). This observation suggests that there is now a suitable alternative for cases in which a distal device cannot be employed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Registry findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the success of embolic protection devices (EPD) in clinical trials, clinical adoption has been poor at many centers. In a report from the American College of Cardiology - National Cardiovascular Data Registry, the following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/80\">",
"     80",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EPD use was associated with significant reduction in no-reflow (OR 0.68, CI 0.48-0.97)",
"     </li>",
"     <li>",
"      EPD use was not associated with lower mortality at 30 days (1.0 versus 0.9 percent)",
"     </li>",
"     <li>",
"      EPDs were never used in 19 percent of centers and used in &lt;10 percent of cases at 41 percent of centers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our current practice is to use EPDs routinely for all appropriate SVG lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Intracoronary vasodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some operators recommend prophylactic use of intracoronary vasodilators as an alternative to EPDs. The evidence to do so is limited.",
"   </p>",
"   <p>",
"    In one study, 83 SVG PCI procedures (average graft age 12 years) were performed in 69 patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    (200 to 300 micrograms) delivered via the SVG immediately prior to direct stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/81\">",
"     81",
"    </a>",
"    ]. MI, defined as CK-MB &gt;3 times normal, occurred in three (4.4 percent) patients. These results have to be interpreted with caution given the small nonrandomized sample size at a single center.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA/SCAI",
"    </span>",
"    guideline update for percutaneous coronary intervention included recommendations (which were not changed in the 2009 focused update) for its use in patients with prior CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/25\">",
"     25",
"    </a>",
"    ], while the 2004 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on coronary artery bypass graft surgery made recommendations for repeat CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. The choice between PCI and repeat CABG is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24536?source=see_link&amp;anchor=H703120015#H703120015\">",
"     \"Late recurrent angina pectoris after coronary artery bypass graft surgery\", section on 'Indications for repeat revascularization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The PCI guidelines concluded that there was general agreement that distal embolic protection devices be used, if technically feasible, in patients with SVG disease.",
"   </p>",
"   <p>",
"    There are insufficient data upon which firm recommendations regarding the choice between bare-metal and drug-eluting stents (DES) for saphenous vein graft stenosis can be made. DES should be considered when the risk for restenosis outweighs other risks and the patient is able to be compliant with a longer period of dual antiplatelet therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More than one-half of subsequent ischemic events occur more than 30 days after PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/58/26538/abstract/27\">",
"     27",
"    </a>",
"    ]. Thus, secondary preventive measures, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , lipid lowering, and blood pressure control, are likely to be important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21156?source=see_link\">",
"       \"Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/16/23813?source=see_link\">",
"       \"Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284174286\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aggressive secondary preventative interventions, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and statin use, achieving blood pressure goal, avoidance of smoking, and the control of serum glucose in patients with diabetes, are recommended in all patients with coronary heart disease to improve cardiovascular outcomes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Saphenous vein graft (SVG) stenosis often presents with recurrent angina. However, the cause of angina depends in part upon the time after surgery when symptoms are first noted. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although most patients with recurrent angina due to SVG stenosis can be managed medically, coronary arteriography should be performed at the earliest signs of recurrent ischemia to detect critical graft lesions that can be treated before irreversible loss of the graft. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Therapeutic options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Percutaneous coronary intervention (PCI) is preferred to repeat coronary artery bypass graft surgery in many patients with recurrent angina, in part due to the increased risks associated with the latter. Factors that might allow for consideration of coronary artery bypass graft surgery include",
"      <strong>",
"      </strong>",
"      low anticipated success rate of PCI, quality of the distal vessels, and whether the graft to the proximal LAD is involved. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Intracoronary stents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Repeat CABG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of distal embolic protection devices should be considered to minimize the adverse effect of downstream debris and thereby improve outcomes in PCI for SVG stenosis. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Embolic protection devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drug-eluting stents should be chosen in preference to bare-metal stent when the risk for restenosis outweighs other risks and the patient is able to be compliant with a longer period of dual antiplatelet therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"       \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H15\">",
"       'Drug-eluting stents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When approaching a patient with recurrent ischemia due to disease in a bypass graft for whom PCI is indicated, an attempt should be made to revascularize the native vessels(s) if technically feasible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22034650\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. David O. Williams for his contributions as a Section Editor to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/1\">",
"      Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998; 97:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/2\">",
"      Mangano DT, Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/3\">",
"      Sanz G, Pajar&oacute;n A, Alegr&iacute;a E, et al. Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Grupo Espa&ntilde;ol para el Seguimiento del Injerto Coronario (GESIC). Circulation 1990; 82:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/4\">",
"      Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation 1991; 83:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/5\">",
"      Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ 1994; 308:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/6\">",
"      Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:776S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/7\">",
"      Gao G, Zheng Z, Pi Y, et al. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. J Am Coll Cardiol 2010; 56:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/8\">",
"      Kulik A, Le May MR, Voisine P, et al. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. Circulation 2010; 122:2680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/9\">",
"      Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/10\">",
"      The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 1997; 336:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/11\">",
"      Campeau L, Hunninghake DB, Knatterud GL, et al. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators. Circulation 1999; 99:3241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/12\">",
"      Knatterud GL, Rosenberg Y, Campeau L, et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation 2000; 102:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/13\">",
"      Skinner JS, Farrer M, Albers CJ, et al. High apolipoprotein AI concentrations are associated with lower mortality and myocardial infarction five years after coronary artery bypass graft surgery. Heart 1999; 81:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/14\">",
"      Frick MH, Syv&auml;nne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997; 96:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/15\">",
"      Eritsland J, Arnesen H, Gr&oslash;nseth K, et al. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 1996; 77:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/16\">",
"      Boerboom LE, Olinger GN, Almassi GH, Skrinska VA. Both dietary fish-oil supplementation and aspirin fail to inhibit atherosclerosis in long-term vein bypass grafts in moderately hypercholesterolemic nonhuman primates. Circulation 1997; 96:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/17\">",
"      Alexander JH, Hafley G, Harrington RA, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 2005; 294:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/18\">",
"      Chen L, Th&eacute;roux P, Lesp&eacute;rance J, et al. Angiographic features of vein grafts versus ungrafted coronary arteries in patients with unstable angina and previous bypass surgery. J Am Coll Cardiol 1996; 28:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/19\">",
"      Weintraub WS, Jones EL, Craver JM, Guyton RA. Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery using saphenous venous grafts. Am J Cardiol 1994; 73:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/20\">",
"      Frimerman A, Rechavia E, Eigler N, et al. Long-term follow-up of a high risk cohort after stent implantation in saphenous vein grafts. J Am Coll Cardiol 1997; 30:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/21\">",
"      Watson PS, Hadjipetrou P, Cox SV, et al. Angiographic and clinical outcomes following acute infarct angioplasty on saphenous vein grafts. Am J Cardiol 1999; 83:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/22\">",
"      Keeley EC, Velez CA, O'Neill WW, Safian RD. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol 2001; 38:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/23\">",
"      Savage MP, Douglas JS Jr, Fischman DL, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997; 337:740.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007) www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/25\">",
"      Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/26\">",
"      Stone GW, Reifart NJ, Moussa I, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. Circulation 2005; 112:2530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/27\">",
"      Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation 2002; 106:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/28\">",
"      de Feyter PJ, van Suylen RJ, de Jaegere PP, et al. Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. J Am Coll Cardiol 1993; 21:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/29\">",
"      Kahn JK, Rutherford BD, McConahay DR, et al. Initial and long-term outcome of 83 patients after balloon angioplasty of totally occluded bypass grafts. J Am Coll Cardiol 1994; 23:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/30\">",
"      Berger PB, Bell MR, Grill DE, et al. Influence of procedural success on immediate and long-term clinical outcome of patients undergoing percutaneous revascularization of occluded coronary artery bypass vein grafts. J Am Coll Cardiol 1996; 28:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/31\">",
"      Mautner SL, Mautner GC, Hunsberger SA, Roberts WC. Comparison of composition of atherosclerotic plaques in saphenous veins used as aortocoronary bypass conduits with plaques in native coronary arteries in the same men. Am J Cardiol 1992; 70:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/32\">",
"      Hong MK, Mehran R, Dangas G, et al. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation 1999; 100:2400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/33\">",
"      Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998; 31:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/34\">",
"      Laham RJ, Carrozza JP, Berger C, et al. Long-term (4- to 6-year) outcome of Palmaz-Schatz stenting: paucity of late clinical stent-related problems. J Am Coll Cardiol 1996; 28:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/35\">",
"      Piana RN, Moscucci M, Cohen DJ, et al. Palmaz-Schatz stenting for treatment of focal vein graft stenosis: immediate results and long-term outcome. J Am Coll Cardiol 1994; 23:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/36\">",
"      Wong SC, Baim DS, Schatz RA, et al. Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the multicenter U.S. Palmaz-Schatz stent experience. The Palmaz-Schatz Stent Study Group. J Am Coll Cardiol 1995; 26:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/37\">",
"      Brener SJ, Ellis SG, Apperson-Hansen C, et al. Comparison of stenting and balloon angioplasty for narrowings in aortocoronary saphenous vein conduits in place for more than five years. Am J Cardiol 1997; 79:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/38\">",
"      Heidland UE, Heintzen MP, Michel CJ, Strauer BE. Risk factors for the development of restenosis following stent implantation of venous bypass grafts. Heart 2001; 85:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/39\">",
"      Ahmed JM, Hong MK, Mehran R, et al. Influence of diabetes mellitus on early and late clinical outcomes in saphenous vein graft stenting. J Am Coll Cardiol 2000; 36:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/40\">",
"      Ge L, Iakovou I, Sangiorgi GM, et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol 2005; 45:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/41\">",
"      Tsuchida K, Ong AT, Aoki J, et al. Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents. Am J Cardiol 2005; 96:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/42\">",
"      Brilakis ES, Berger PB. Should bare metal or drug-eluting stents be used during PCI of saphenous vein graft lesions: waiting for Godot? Catheter Cardiovasc Interv 2008; 72:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/43\">",
"      Vermeersch P, Agostoni P, Verheye S, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 2006; 48:2423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/44\">",
"      Brilakis ES, Lichtenwalter C, de Lemos JA, et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol 2009; 53:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/45\">",
"      Vermeersch P, Agostoni P, Verheye S, et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol 2007; 50:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/46\">",
"      Choussat R, Black AJ, Bossi I, et al. Long-term clinical outcome after endoluminal reconstruction of diffusely degenerated saphenous vein grafts with less-shortening wallstents. J Am Coll Cardiol 2000; 36:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/47\">",
"      Gruberg L, Hong MK, Mehran R, et al. In-hospital and long-term results of stent deployment compared with balloon angioplasty for treatment of narrowing at the saphenous vein graft distal anastomosis site. Am J Cardiol 1999; 84:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/48\">",
"      Bhargava B, Kornowski R, Mehran R, et al. Procedural results and intermediate clinical outcomes after multiple saphenous vein graft stenting. J Am Coll Cardiol 2000; 35:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/49\">",
"      Stankovic G, Colombo A, Presbitero P, et al. Randomized evaluation of polytetrafluoroethylene-covered stent in saphenous vein grafts: the Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) Trial. Circulation 2003; 108:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/50\">",
"      Sch&auml;chinger V, Hamm CW, M&uuml;nzel T, et al. A randomized trial of polytetrafluoroethylene-membrane-covered stents compared with conventional stents in aortocoronary saphenous vein grafts. J Am Coll Cardiol 2003; 42:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/51\">",
"      Stone GW, Goldberg S, O'Shaughnessy C, et al. 5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial. JACC Cardiovasc Interv 2011; 4:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/52\">",
"      Blackman DJ, Choudhury RP, Banning AP, Channon KM. Failure of the Symbiot PTFE-covered stent to reduce distal embolization during percutaneous coronary intervention in saphenous vein grafts. J Invasive Cardiol 2005; 17:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/53\">",
"      Ellis SG, Lincoff AM, Miller D, et al. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade. J Am Coll Cardiol 1998; 32:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/54\">",
"      Mathew V, Grill DE, Scott CG, et al. The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions. J Am Coll Cardiol 1999; 34:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/55\">",
"      Cura FA, Bhatt DL, Lincoff AM, et al. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. Circulation 2000; 102:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/56\">",
"      Jonas M, Stone GW, Mehran R, et al. Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. Eur Heart J 2006; 27:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/57\">",
"      Holmes DR Jr, Topol EJ, Califf RM, et al. A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators. Circulation 1995; 91:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/58\">",
"      Waksman R, Weintraub WS, Ghazzal Z, et al. Short- and long-term outcome of narrowed saphenous vein bypass graft: a comparison of Palmaz-Schatz stent, directional coronary atherectomy, and balloon angioplasty. Am Heart J 1997; 134:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/59\">",
"      Thomas WJ, Cowley MJ, Vetrovec GW, et al. Effectiveness of rotational atherectomy in aortocoronary saphenous vein grafts. Am J Cardiol 2000; 86:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/60\">",
"      Ahmed JM, Hong MK, Mehran R, et al. Comparison of debulking followed by stenting versus stenting alone for saphenous vein graft aortoostial lesions: immediate and one-year clinical outcomes. J Am Coll Cardiol 2000; 35:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/61\">",
"      Stone GW, Cox DA, Babb J, et al. Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries. J Am Coll Cardiol 2003; 42:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/62\">",
"      Teirstein PS, Mann JT 3rd, Cundey PE Jr, et al. Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion. Am J Cardiol 1999; 83:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/63\">",
"      Safian RD, Grines CL, May MA, et al. Clinical and angiographic results of transluminal extraction coronary atherectomy in saphenous vein bypass grafts. Circulation 1994; 89:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/64\">",
"      Meany TB, Leon MB, Kramer BL, et al. Transluminal extraction catheter for the treatment of diseased saphenous vein grafts: a multicenter experience. Cathet Cardiovasc Diagn 1995; 34:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/65\">",
"      Kuntz RE, Baim DS, Cohen DJ, et al. A trial comparing rheolytic thrombectomy with intracoronary urokinase for coronary and vein graft thrombus (the Vein Graft AngioJet Study [VeGAS 2]). Am J Cardiol 2002; 89:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/66\">",
"      Cohen DJ, Ramee S, Baim DS, et al. Economic assessment of rheolytic thrombectomy versus intracoronary urokinase for treatment of extensive intracoronary thrombus: Results from a randomized clinical trial. Am Heart J 2001; 142:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/67\">",
"      Grube E, Gerckens U, Yeung AC, et al. Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. Circulation 2001; 104:2436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/68\">",
"      Webb JG, Carere RG, Virmani R, et al. Retrieval and analysis of particulate debris after saphenous vein graft intervention. J Am Coll Cardiol 1999; 34:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/69\">",
"      Grube E, Schofer J J&uuml;, Webb J, et al. Evaluation of a balloon occlusion and aspiration system for protection from distal embolization during stenting in saphenous vein grafts. Am J Cardiol 2002; 89:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/70\">",
"      Mauri L, Cox D, Hermiller J, et al. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. J Am Coll Cardiol 2007; 50:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/71\">",
"      Leineweber K, B&ouml;se D, Vogelsang M, et al. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. J Am Coll Cardiol 2006; 47:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/72\">",
"      Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002; 105:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/73\">",
"      Stone GW, Rogers C, Ramee S, et al. Distal filter protection during saphenous vein graft stenting: technical and clinical correlates of efficacy. J Am Coll Cardiol 2002; 40:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/74\">",
"      Stone GW, Rogers C, Hermiller J, et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 2003; 108:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/75\">",
"      Halkin A, Masud AZ, Rogers C, et al. Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial. Am Heart J 2006; 151:915.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/76\">",
"      Carrozza JP Jr, Mumma M, Breall JA, et al. Randomized evaluation of the TriActiv balloon-protection flush and extraction system for the treatment of saphenous vein graft disease. J Am Coll Cardiol 2005; 46:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/77\">",
"      Ashby DT, Dangas G, Aymong EA, et al. Effect of percutaneous coronary interventions for in-stent restenosis in degenerated saphenous vein grafts without distal embolic protection. J Am Coll Cardiol 2003; 41:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/78\">",
"      Mauri L, Rogers C, Baim DS. Devices for distal protection during percutaneous coronary revascularization. Circulation 2006; 113:2651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/79\">",
"      Gorog DA, Foale RA, Malik I. Distal myocardial protection during percutaneous coronary intervention: when and where? J Am Coll Cardiol 2005; 46:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/80\">",
"      Mehta SK, Frutkin AD, Milford-Beland S, et al. Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19,546 patients in the American College of Cardiology-National Cardiovascular Data Registry). Am J Cardiol 2007; 100:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/81\">",
"      Fischell TA, Subraya RG, Ashraf K, et al. \"Pharmacologic\" distal protection using prophylactic, intragraft nicardipine to prevent no-reflow and non-Q-wave myocardial infarction during elective saphenous vein graft intervention. J Invasive Cardiol 2007; 19:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/82\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/58/26538/abstract/83\">",
"      Taus L, Gerzov&aacute; J. Personality of semen donors and their social behaviour. Czech Med 1991; 14:173.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1565 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-118.195.65.248-47B75F185E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_58_26538=[""].join("\n");
var outline_f25_58_26538=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H284174286\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H521217436\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      THERAPEUTIC OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      REPEAT CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PERCUTANEOUS CORONARY INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Angioplasty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Comparison to PTCA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Drug-eluting stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Primary PCI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Diffusely degenerated graft",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Stenosis at distal anastomosis site",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Multivessel stenting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Covered stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Possible role of GP IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Atherectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Thrombolysis and thrombectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Embolic protection devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Distal devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Proximal devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Registry findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Intracoronary vasodilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H284174286\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22034650\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1565\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1565|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/19/19774\" title=\"figure 1\">",
"      Control of lipids decreases the progression of SVG disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/39/22142\" title=\"figure 2\">",
"      Lipid lowering improves outcome after CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/58/1966\" title=\"figure 3\">",
"      Culprit lesion after CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/6/20590\" title=\"figure 4\">",
"      Survival saphenous vein stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/11/18622\" title=\"figure 5\">",
"      Outcome saphenous vein stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/24/15758\" title=\"figure 6\">",
"      Stents saphenous grafts outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1565|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?11/2/11310\" title=\"movie 1\">",
"      Restenosis within a saphenous vein graft",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=related_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=related_link\">",
"      Intracoronary stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24536?source=related_link\">",
"      Late recurrent angina pectoris after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40360?source=related_link\">",
"      Medical therapy to prevent complications after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/16/23813?source=related_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21156?source=related_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=related_link\">",
"      Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41142?source=related_link\">",
"      Specialized revascularization devices in the management of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9994?source=related_link\">",
"      Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25560?source=related_link\">",
"      Use of intracoronary radiation to prevent restenosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_58_26539="Treatment for mild lead intoxication - lead levels 20 to 44";
var content_f25_58_26539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment strategies for asymptomatic patients with venous lead level 20 mcg/dL (0.96 micromol/L)  to 44 mcg/dL (2.12 micromol/L)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1.&nbsp;",
"       </td>",
"       <td>",
"        Report to appropriate health authorities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2.",
"       </td>",
"       <td>",
"        Perform history, physical, and laboratory examinations (complete blood count, urinalysis, serum electrolytes, glucose, blood urea nitrogen, creatinine, aspartate aminotransferase, alanine aminotransferase).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3.",
"       </td>",
"       <td>",
"        Chelation is not suggested for children with lead levels below 45 mcg/dL (2.17 micromol/L).*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4.",
"       </td>",
"       <td>",
"        Provide parents with educational and nutritional counseling.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5.",
"       </td>",
"       <td>",
"        Monitor lead level every&nbsp;two weeks x 3, then repeat every&nbsp;one month x 3-4, then every&nbsp;three to four&nbsp;months for one year. Continue to check lead levels until &lt;30 mcg/dL (1.45 micromol/L).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    *Although not suggested by many experts, we choosed to&nbsp;treat some children with blood lead levels in this range with DMSA (succimer).&nbsp;We&nbsp;repeat chelation&nbsp;if the blood lead&nbsp;level rebounds to &gt;80 percent of the original level and is greater than 30 to 35 &micro;g/dL (1.45 micromol/l to 1.69 micromol/L).",
"    <br>",
"     <br>",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_58_26539=[""].join("\n");
var outline_f25_58_26539=null;
var title_f25_58_26540="Types of cold agglutinins";
var content_f25_58_26540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Reactions of the cold agglutinins and their occurrence in clinical settings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Specificity",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Antigen",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        Reaction to:",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Antibody",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Clinical presentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Adult RBC",
"       </td>",
"       <td class=\"subtitle2\">",
"        Fetal RBC",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pro-T RBC",
"       </td>",
"       <td class=\"subtitle2\">",
"        Sial-T RBC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Anti-I",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Branched aminyllactose polymers",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        ++++",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        +",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        ++++",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        ++++",
"       </td>",
"       <td>",
"        IgM mono",
"       </td>",
"       <td>",
"        Benign chronic cold agglutin, non-aggressive lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgM oligo",
"       </td>",
"       <td>",
"        M. pneneumoniae infection, other viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Anti-i",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Linear aminyllactose polymers",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        +",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        ++++",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        ++++",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        +++++",
"       </td>",
"       <td>",
"        IgM mono",
"       </td>",
"       <td>",
"        Aggressive lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgM oligo",
"       </td>",
"       <td>",
"        Infectious mononucleosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-Pr",
"       </td>",
"       <td>",
"        Polysaccharides on glycoproteins",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        ++++",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0 to ++++",
"       </td>",
"       <td>",
"        IgM mono",
"       </td>",
"       <td>",
"        Benign or malignant lymphocytic proliferation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Various",
"       </td>",
"       <td>",
"        Polysaccharides containing sialic acid",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td colspan=\"1\">",
"        +++",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        IgM mono",
"       </td>",
"       <td>",
"        Benign or malignant lymphocytic proliferation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Pro-T: protease-treated; Sial-T: sialidase-treated; mono: monoclonal; oligo: oligoclonal.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_58_26540=[""].join("\n");
var outline_f25_58_26540=null;
var title_f25_58_26541="OSA treatment algorithm";
var content_f25_58_26541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Treatment of obstructive sleep apnea algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 343px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_58_26541=[""].join("\n");
var outline_f25_58_26541=null;
var title_f25_58_26542="Contents: Pediatric urology";
var content_f25_58_26542=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric urology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric urology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Circumcision",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/18/11559\">",
"           Care of the uncircumcised penis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Congenital anomalies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/24/24966\">",
"           Clinical manifestations and initial management of infants with bladder exstrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/0/11271\">",
"           Clinical presentation and diagnosis of posterior urethral valves",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/3/26680\">",
"           Congenital ureteropelvic junction obstruction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/3/39989\">",
"           Ectopic ureter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/30/32231\">",
"           Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/59/24506\">",
"           Evaluation of the infant with ambiguous genitalia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/42/26280\">",
"           Hypospadias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/41/36502\">",
"           Management of posterior urethral valves",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/47/35577\">",
"           Management of the infant with ambiguous genitalia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/52/42824\">",
"           Overview of antenatal hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/60/22472\">",
"           Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/58/16296\">",
"           Prenatal diagnosis of renal agenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/28/1479\">",
"           Primary megaureter in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/52/28487\">",
"           Renal ectopic and fusion anomalies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/36/11849\">",
"           Surgical management and postoperative outcome of children with bladder exstrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/44/17098\">",
"           Undescended testes (cryptorchidism) in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/8/41093\">",
"           Ureterocele",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/59/15288\">",
"           Urinary tract complications of myelomeningocele (spina bifida)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Male urologic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/23/24953\">",
"           Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33654\">",
"           Balanoposthitis in children: Epidemiology and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/47/43766\">",
"           Causes of painless scrotal swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/39/32376\">",
"           Causes of scrotal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/50/4903\">",
"           Complications of circumcision",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/38/2663\">",
"           Evaluation of scrotal pain or swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/44/712\">",
"           Neonatal testicular torsion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/48/33543\">",
"           Paraphimosis reduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/39/29302\">",
"           Paraphimosis: Definition, pathophysiology, and clinical features",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nephrolithiasis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/41/38552\">",
"           Acute management of nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/19/13623\">",
"           Clinical features and diagnosis of nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/60/6090\">",
"           Epidemiology of and risk factors for nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/62/19432\">",
"           Prevention of recurrent nephrolithiasis in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ureteral disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/62/41961\">",
"           Management of vesicoureteral reflux",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/10/3242\">",
"           Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary incontinence",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/7/28793\">",
"           Etiology and clinical features of bladder dysfunction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/21/40281\">",
"           Etiology and evaluation of nocturnal enuresis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/50/25384\">",
"           Evaluation and diagnosis of bladder dysfunction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/51/41785\">",
"           Management of bladder dysfunction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/0/7178\">",
"           Management of nocturnal enuresis in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urine abnormalities",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/6/1127\">",
"           Evaluation of gross hematuria in children",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-3B5E4146D4-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f25_58_26542=[""].join("\n");
var outline_f25_58_26542=null;
var title_f25_58_26543="Contents: Gynecologic surgery";
var content_f25_58_26543=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/48/5902\">",
"       General Surgery",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Gynecologic surgery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Gynecologic surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cervical surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/19/44343\">",
"           Cervical intraepithelial neoplasia: Ablative therapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/17/33048\">",
"           Cervical intraepithelial neoplasia: Procedures for cervical conization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/51/11062\">",
"           Cervical pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/3/27701\">",
"           Trachelectomy following supracervical hysterectomy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cliinical anatomy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/27/41400\">",
"           Surgical female pelvic anatomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/41/16026\">",
"           Surgical female urogenital anatomy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Clinical anatomy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/18/17703\">",
"           Anatomy of the abdominal wall",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fistula repair",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32951\">",
"           Rectovaginal, anovaginal, and colovesical fistulas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/47/44792\">",
"           Urogenital tract fistulas in women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/39/21113\">",
"           Abdominal surgical incisions: Prevention and treatment of complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/25/32151\">",
"           Basic principles of medical lasers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/37/31321\">",
"           Classification, clinical features and diagnosis of inguinal and femoral hernias in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/3/24631\">",
"           Complications of gynecologic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/57/29592\">",
"           Diagnostic cystourethroscopy for gynecologic conditions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/60/31689\">",
"           Exenteration for gynecologic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/18/43305\">",
"           Management of hemorrhage in gynecologic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/57/27546\">",
"           Management of postoperative pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/7/15482\">",
"           Management of pregnant women undergoing nonobstetric surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/3/3129\">",
"           Nerve injury associated with pelvic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/59/17334\">",
"           Overview of conventional gynecologic laparoscopic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/54/37737\">",
"           Overview of electrosurgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/55/39800\">",
"           Overview of preoperative evaluation and preparation for gynecologic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/1/20499\">",
"           Pelvic examination under anesthesia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/33/2586\">",
"           Postoperative ileus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/47/26359\">",
"           Preventing postoperative peritoneal adhesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/24/10633\">",
"           Principles of abdominal wall closure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/35/30265\">",
"           Principles of abdominal wall incisions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/34/38440\">",
"           Surgical instruments for gynecologic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/27/7609\">",
"           Urinary tract injury in gynecologic surgery: Evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/46/14056\">",
"           Urinary tract injury in gynecologic surgery: Prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/19/4408\">",
"           Uterine perforation during gynecologic procedures",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Laparoscopic surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/15/7415\">",
"           Complications of gynecologic laparoscopic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/56/12168\">",
"           Gynecologic laparoscopy: Non-umbilical entry sites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/52/9029\">",
"           Laparoendoscopic single-site (single port) surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/22/14698\">",
"           Laparoscopic approach to hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24583\">",
"           Laparoscopic surgery for ovulation induction in polycystic ovary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/59/17334\">",
"           Overview of conventional gynecologic laparoscopic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/63/21495\">",
"           Overview of laparoscopy in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24858\">",
"           Rectovaginal or bowel endometriosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/18/9513\">",
"           Reproductive surgery for female infertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/34/27176\">",
"           Robot-assisted laparoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/60/1993\">",
"           Urinary tract endometriosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ovarian surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/46/5863\">",
"           Diagnosis and management of ovarian endometriomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/48/36618\">",
"           Epithelial ovarian cancer: Initial surgical management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/15/25847\">",
"           Epithelial ovarian cancer: Second look surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/40/9863\">",
"           Evaluation and management of ruptured ovarian cyst",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/6/12393\">",
"           Oophorectomy and ovarian cystectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/8/23690\">",
"           Ovarian and fallopian tube torsion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/47/6902\">",
"           Ovarian transposition before pelvic radiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/26/28070\">",
"           Surgery for recurrent epithelial ovarian cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/24/33162\">",
"           Treatment of malignant germ cell tumors of the ovary",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pregnancy termination",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/45/1750\">",
"           Induced fetal demise",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/38/33386\">",
"           Mifepristone for the medical termination of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/42/28330\">",
"           Misoprostol as a single agent for medical termination of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/9/39065\">",
"           Multifetal pregnancy reduction and selective termination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/2/19498\">",
"           Overview of pregnancy termination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/47/6905\">",
"           Psychological aspects of pregnancy termination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/29/39384\">",
"           Retained products of conception",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/22/4453\">",
"           Surgical termination of pregnancy: First trimester",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/47/28409\">",
"           Termination of pregnancy: Second trimester",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/14/41191\">",
"           Unsafe abortion",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rectovaginal surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/29/34263\">",
"           Delayed surgical management of the disrupted anal sphincter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32951\">",
"           Rectovaginal, anovaginal, and colovesical fistulas",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sterilization",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/23/12665\">",
"           Hysteroscopic sterilization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/42/15018\">",
"           Surgical sterilization of women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tubal surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/47/26359\">",
"           Preventing postoperative peritoneal adhesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/18/9513\">",
"           Reproductive surgery for female infertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/53/5976\">",
"           Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Uterine surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/46/32490\">",
"           Abdominal hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/3/12346\">",
"           Abdominal myomectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/7/31866\">",
"           An overview of endometrial ablation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/41/35480\">",
"           Dilation and curettage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/21/15706\">",
"           Elective oophorectomy or ovarian conservation at the time of hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/42/44708\">",
"           Endometrial ablation or resection: Resectoscopic techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/24/393\">",
"           Endometrial ablation: Non-resectoscopic techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/8/131\">",
"           Endometrial sampling procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/41/8858\">",
"           Hyponatremia following transurethral resection or hysteroscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/53/32601\">",
"           Hysteroscopic myomectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/26/22951\">",
"           Hysteroscopy: Managing fluid and gas distending media",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/31/26101\">",
"           Intrauterine adhesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/22/14698\">",
"           Laparoscopic approach to hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/48/8970\">",
"           Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/19/12602\">",
"           Overview of hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/17/9498\">",
"           Overview of hysteroscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/24/16775\">",
"           Prolapsed uterine leiomyoma (fibroid)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/24/14730\">",
"           Radical hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/21/29014\">",
"           Surgical management of congenital uterine anomalies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/54/10088\">",
"           Techniques to reduce blood loss during abdominal or laparoscopic myomectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/60/22473\">",
"           Uterine leiomyoma (fibroid) embolization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/0/41990\">",
"           Vaginal cuff dehiscence after hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/36/35401\">",
"           Vaginal hysterectomy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vulvovaginal surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/21/34133\">",
"           Female genital cutting (circumcision)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/10/37028\">",
"           Labia minora hypertrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/52/4936\">",
"           Radical vulvectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/46/6885\">",
"           Vaginectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/40/22147\">",
"           Vaginoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/46/31464\">",
"           Vulvar abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/12/14535\">",
"           Vulvar wide local excision, simple vulvectomy, and skinning vulvectomy",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-8BDD7E4ADB-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f25_58_26543=[""].join("\n");
var outline_f25_58_26543=null;
